{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The autoreload extension is already loaded. To reload it, use:\n",
      "  %reload_ext autoreload\n"
     ]
    }
   ],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "\n",
    "import pickle\n",
    "import pandas as pd\n",
    "import os\n",
    "import openai\n",
    "import numpy as np\n",
    "import ipdb\n",
    "import re\n",
    "from tqdm import tqdm\n",
    "\n",
    "from transformers import GPT2Tokenizer\n",
    "tokenizer = GPT2Tokenizer.from_pretrained(\"gpt2\")\n",
    "import spacy\n",
    "import scipy\n",
    "\n",
    "nlp = spacy.load(\"en_core_web_sm\")\n",
    "openai.api_key= os.environ['OPENAI_KEY']\n",
    "pd.set_option('max_rows',500,'max_colwidth',1000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_name = 'bc5cdr_disease'\n",
    "seed = 42\n",
    "few_shot_num = 5\n",
    "number_of_test_samples = 50\n",
    "selection_strategy = 'random'\n",
    "sep = ', '\n",
    "engine='davinci'\n",
    "\n",
    "prompt_filename = '../data/{}_test_prompts_{}_{}.{}.{}.{}'.format(data_name, selection_strategy,seed,few_shot_num,number_of_test_samples,sep)\n",
    "filename_root = prompt_filename.split('/')[-1]\n",
    "test_ready_prompt_dataset = pickle.load(open(prompt_filename,'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "ename": "FileNotFoundError",
     "evalue": "[Errno 2] No such file or directory: '../data/ddi_test_prompts_random_42.5.50.perm_0.'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mFileNotFoundError\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-27-67fe8f6bc64b>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     11\u001b[0m \u001b[0mprompt_filename\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m'../data/{}_test_prompts_{}_{}.{}.{}.perm_{}.{}'\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdata_name\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mselection_strategy\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mseed\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mfew_shot_num\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mnumber_of_test_samples\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mpermutation\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mverbalizer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     12\u001b[0m \u001b[0mfilename_root\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mprompt_filename\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msplit\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'/'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m-\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 13\u001b[0;31m \u001b[0mtest_ready_prompt_dataset\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpickle\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mload\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mopen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mprompt_filename\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m'rb'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mFileNotFoundError\u001b[0m: [Errno 2] No such file or directory: '../data/ddi_test_prompts_random_42.5.50.perm_0.'"
     ]
    }
   ],
   "source": [
    "data_name = 'ddi'\n",
    "seed = 42\n",
    "few_shot_num = 5\n",
    "number_of_test_samples = 50\n",
    "selection_strategy = 'random'\n",
    "sep=None\n",
    "engine='davinci'\n",
    "permutation = 0\n",
    "verbalizer = ''\n",
    "\n",
    "prompt_filename = '../data/{}_test_prompts_{}_{}.{}.{}.perm_{}.{}'.format(data_name, selection_strategy,seed,few_shot_num,number_of_test_samples,permutation,verbalizer)\n",
    "filename_root = prompt_filename.split('/')[-1]\n",
    "test_ready_prompt_dataset = pickle.load(open(prompt_filename,'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_filename = '../data/ddi_test_prompts_random_42.5.50.perm_4.KNN'\n",
    "test_ready_prompt_dataset = pickle.load(open(prompt_filename,'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "test_ready_prompt_dataframe = test_ready_prompt_dataset['test_df']\n",
    "prompts = test_ready_prompt_dataframe.test_ready_prompt.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'../data/ddi_test_prompts_random_42.5.50.perm_4.KNN'"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "prompt_filename"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>index</th>\n",
       "      <th>sentence</th>\n",
       "      <th>label</th>\n",
       "      <th>doc</th>\n",
       "      <th>split</th>\n",
       "      <th>entity1</th>\n",
       "      <th>entity2</th>\n",
       "      <th>prompts</th>\n",
       "      <th>empty_prompts</th>\n",
       "      <th>labels</th>\n",
       "      <th>unique_labels</th>\n",
       "      <th>test_ready_prompt</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1065</th>\n",
       "      <td>4386</td>\n",
       "      <td>DDI-DrugBank.d48.s12.p2</td>\n",
       "      <td>The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.</td>\n",
       "      <td>DDI-advise</td>\n",
       "      <td>DDI-DrugBank.d48</td>\n",
       "      <td>dev</td>\n",
       "      <td>proton pump inhibitors</td>\n",
       "      <td>SPRYCEL</td>\n",
       "      <td>Sentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\\nDrug 1: proton pump inhibitors\\nDrug 2: SPRYCEL\\nInteraction: advice</td>\n",
       "      <td>Sentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\\nDrug1: proton pump inhibitors\\nDrug2: SPRYCEL\\nInteraction:</td>\n",
       "      <td>advice</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: antacids\\nDrug 2: H2 blockers\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: antacids\\nDrug 2: proton pump inhibitors\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: antacids\\nDrug 2: SPRYCEL\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: H2 blockers\\nDrug 2: proton pump inhibitors\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: H2 blockers\\nDrug 2: S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1157</th>\n",
       "      <td>17780</td>\n",
       "      <td>DDI-DrugBank.d31.s0.p0</td>\n",
       "      <td>MAO inhibitors should be used with caution in patients receiving hydralazine.</td>\n",
       "      <td>DDI-advise</td>\n",
       "      <td>DDI-DrugBank.d31</td>\n",
       "      <td>dev</td>\n",
       "      <td>MAO inhibitors</td>\n",
       "      <td>hydralazine</td>\n",
       "      <td>Sentence: MAO inhibitors should be used with caution in patients receiving hydralazine.\\nDrug 1: MAO inhibitors\\nDrug 2: hydralazine\\nInteraction: advice</td>\n",
       "      <td>Sentence: MAO inhibitors should be used with caution in patients receiving hydralazine.\\nDrug1: MAO inhibitors\\nDrug2: hydralazine\\nInteraction:</td>\n",
       "      <td>advice</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.\\nDrug 1: Cevimeline\\nDrug 2: beta adrenergic antagonists\\nInteraction: advice\\n\\nSentence: All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.\\nDrug 1: vasopressors\\nDrug 2: monoamine oxidase (MAO) inhibitors\\nInteraction: advice\\n\\nSentence: DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.\\nDrug 1: DISULFIRAM\\nDrug 2: PHENYTOIN\\nInteraction: advice\\n\\nSentence: NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.\\nDrug 1: NSAIDs\\nDrug 2: cyclosporine\\nInteraction: advice\\n\\nSentence: NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.\\nDrug 1: NSAIDs\\nDrug 2: cyclosporine\\nInteraction: advice\\n\\nSentence...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>9530</td>\n",
       "      <td>DDI-DrugBank.d165.s16.p2</td>\n",
       "      <td>Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.</td>\n",
       "      <td>DDI-advise</td>\n",
       "      <td>DDI-DrugBank.d165</td>\n",
       "      <td>dev</td>\n",
       "      <td>Cyclosporine</td>\n",
       "      <td>Itraconazole</td>\n",
       "      <td>Sentence: Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.\\nDrug 1: Cyclosporine\\nDrug 2: Itraconazole\\nInteraction: advice</td>\n",
       "      <td>Sentence: Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.\\nDrug1: Cyclosporine\\nDrug2: Itraconazole\\nInteraction:</td>\n",
       "      <td>advice</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.\\nDrug 1: tacrolimus\\nDrug 2: tacrolimus\\nInteraction: none\\n\\nSentence: The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.\\nDrug 1: itraconazole\\nDrug 2: Itraconazole\\nInteraction: none\\n\\nSentence: Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.\\nDrug 1: cyclosporine\\nDrug 2: cyclosporine\\nInteraction: none\\n\\nSentence: Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.\\nDrug 1: cyclosporine\\nDrug 2: cyclosporine\\nInteraction: none\\n\\nSentence: Coadministration of Itraconazole and cyclospori...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1164</th>\n",
       "      <td>19325</td>\n",
       "      <td>DDI-DrugBank.d297.s5.p0</td>\n",
       "      <td>There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.</td>\n",
       "      <td>DDI-advise</td>\n",
       "      <td>DDI-DrugBank.d297</td>\n",
       "      <td>dev</td>\n",
       "      <td>ORENCIA</td>\n",
       "      <td>anakinra</td>\n",
       "      <td>Sentence: There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.\\nDrug 1: ORENCIA\\nDrug 2: anakinra\\nInteraction: advice</td>\n",
       "      <td>Sentence: There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.\\nDrug1: ORENCIA\\nDrug2: anakinra\\nInteraction:</td>\n",
       "      <td>advice</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.\\nDrug 1: lidocaine\\nDrug 2: Bretylium Tosylate\\nInteraction: none\\n\\nSentence: The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.\\nDrug 1: anakinra\\nDrug 2: HUMIRA\\nInteraction: none\\n\\nSentence: Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.\\nDrug 1: Aspirin\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.\\nDrug 1: Aspirin\\nDrug 2: Ponstel\\nInteraction: none\\n\\nSentence: Aspirin: As with other NSAIDs, concomi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1133</th>\n",
       "      <td>14414</td>\n",
       "      <td>DDI-DrugBank.d364.s10.p1</td>\n",
       "      <td>Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.</td>\n",
       "      <td>DDI-advise</td>\n",
       "      <td>DDI-DrugBank.d364</td>\n",
       "      <td>dev</td>\n",
       "      <td>alosetron</td>\n",
       "      <td>telithromycin</td>\n",
       "      <td>Sentence: Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.\\nDrug 1: alosetron\\nDrug 2: telithromycin\\nInteraction: advice</td>\n",
       "      <td>Sentence: Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.\\nDrug1: alosetron\\nDrug2: telithromycin\\nInteraction:</td>\n",
       "      <td>advice</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.\\nDrug 1: alosetron\\nDrug 2: quinolone antibiotics\\nInteraction: advice\\n\\nSentence: Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.\\nDrug 1: alosetron\\nDrug 2: cimetidine\\nInteraction: advice\\n\\nSentence: Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.\\nDrug 1: quinolone antibiotics\\nDrug 2: cimetidine\\nInteraction: none\\n\\nSentence: Consequently, concom...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>930</td>\n",
       "      <td>DDI-DrugBank.d246.s0.p4</td>\n",
       "      <td>Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d246</td>\n",
       "      <td>dev</td>\n",
       "      <td>butorphanol</td>\n",
       "      <td>antihistamines</td>\n",
       "      <td>Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug 1: butorphanol\\nDrug 2: antihistamines\\nInteraction: effect</td>\n",
       "      <td>Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: antihistamines\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: alcohol\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: CNS depressants\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: hypnotics\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: sedatives\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>299</th>\n",
       "      <td>19162</td>\n",
       "      <td>DDI-DrugBank.d222.s0.p0</td>\n",
       "      <td>When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d222</td>\n",
       "      <td>dev</td>\n",
       "      <td>atropine</td>\n",
       "      <td>pralidoxime</td>\n",
       "      <td>Sentence: When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.\\nDrug 1: atropine\\nDrug 2: pralidoxime\\nInteraction: effect</td>\n",
       "      <td>Sentence: When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.\\nDrug1: atropine\\nDrug2: pralidoxime\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.\\nDrug 1: ROMAZICON\\nDrug 2: cyclic antidepressants\\nInteraction: effect\\n\\nSentence: Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.\\nDrug 1: ROMAZICON\\nDrug 2: benzodiazepine\\nInteraction: none\\n\\nSentence: Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>177</th>\n",
       "      <td>10039</td>\n",
       "      <td>DDI-DrugBank.d176.s6.p9</td>\n",
       "      <td>Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d176</td>\n",
       "      <td>dev</td>\n",
       "      <td>ACE inhibitors</td>\n",
       "      <td>lithium</td>\n",
       "      <td>Sentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: ACE inhibitors\\nDrug 2: lithium\\nInteraction: effect</td>\n",
       "      <td>Sentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug1: ACE inhibitors\\nDrug2: lithium\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: ACE inhibitors\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>204</th>\n",
       "      <td>12858</td>\n",
       "      <td>DDI-DrugBank.d335.s3.p4</td>\n",
       "      <td>The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d335</td>\n",
       "      <td>dev</td>\n",
       "      <td>benzodiazepines</td>\n",
       "      <td>antidepressants</td>\n",
       "      <td>Sentence: The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.\\nDrug 1: benzodiazepines\\nDrug 2: antidepressants\\nInteraction: effect</td>\n",
       "      <td>Sentence: The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.\\nDrug1: benzodiazepines\\nDrug2: antidepressants\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: benzodiazepines\\nDrug 2: anticonvulsants\\nInteraction: effect\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: benzodiazepines\\nDrug 2: antihistamines\\nInteraction: effect\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: benzodiazepines\\nDrug 2: alcohol\\nInteraction: effect\\n\\nSentence: The action of the benzodia...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>354</th>\n",
       "      <td>21838</td>\n",
       "      <td>DDI-DrugBank.d558.s8.p0</td>\n",
       "      <td>In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d558</td>\n",
       "      <td>dev</td>\n",
       "      <td>verapamil</td>\n",
       "      <td>dofetilide</td>\n",
       "      <td>Sentence: In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug 1: verapamil\\nDrug 2: dofetilide\\nInteraction: effect</td>\n",
       "      <td>Sentence: In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug1: verapamil\\nDrug2: dofetilide\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug 1: digoxin\\nDrug 2: dofetilide\\nInteraction: effect\\n\\nSentence: In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.\\nDrug 1: Angiomax\\nDrug 2: heparin\\nInteraction: effect\\n\\nSentence: In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.\\nDrug 1: Angiomax\\nDrug 2: warfarin\\nInteraction: effect\\n\\nSentence: In clinical trials in patients undergoing PTCA/PCI, co-administration of Ang...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>265</th>\n",
       "      <td>17981</td>\n",
       "      <td>DDI-DrugBank.d396.s0.p18</td>\n",
       "      <td>Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d396</td>\n",
       "      <td>dev</td>\n",
       "      <td>alcohol</td>\n",
       "      <td>hydrocodone</td>\n",
       "      <td>Sentence: Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.\\nDrug 1: alcohol\\nDrug 2: hydrocodone\\nInteraction: effect</td>\n",
       "      <td>Sentence: Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.\\nDrug1: alcohol\\nDrug2: hydrocodone\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: anesthetics\\nInteraction: none\\n\\nSentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: phenothiazines\\nInteraction: none\\n\\nSentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: tranquilizers...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>2563</td>\n",
       "      <td>DDI-DrugBank.d132.s14.p0</td>\n",
       "      <td>Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d132</td>\n",
       "      <td>dev</td>\n",
       "      <td>diflunisal</td>\n",
       "      <td>acetaminophen</td>\n",
       "      <td>Sentence: Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.\\nDrug 1: diflunisal\\nDrug 2: acetaminophen\\nInteraction: effect</td>\n",
       "      <td>Sentence: Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.\\nDrug1: diflunisal\\nDrug2: acetaminophen\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.\\nDrug 1: Diclofenac\\nDrug 2: Starlix\\nInteraction: none\\n\\nSentence: Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.\\nDrug 1: Diclofenac\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.\\nDrug 1: Starlix\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>643</td>\n",
       "      <td>DDI-DrugBank.d238.s4.p0</td>\n",
       "      <td>Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d238</td>\n",
       "      <td>dev</td>\n",
       "      <td>tricyclic antidepressants</td>\n",
       "      <td>guanethidine</td>\n",
       "      <td>Sentence: Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.\\nDrug 1: tricyclic antidepressants\\nDrug 2: guanethidine\\nInteraction: effect</td>\n",
       "      <td>Sentence: Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.\\nDrug1: tricyclic antidepressants\\nDrug2: guanethidine\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.\\nDrug 1: Tricyclic antidepressants\\nDrug 2: clonidine\\nInteraction: effect\\n\\nSentence: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.\\nDrug 1: Tricyclic antidepressants\\nDrug 2: ALPHAGAN P\\nInteraction: none\\n\\nSentence: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.\\nDrug 1: clonidine\\nDrug 2: ALPHAGAN P\\nInteraction: none\\n\\nSen...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>3227</td>\n",
       "      <td>DDI-DrugBank.d564.s0.p7</td>\n",
       "      <td>The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d564</td>\n",
       "      <td>dev</td>\n",
       "      <td>norepinephrine</td>\n",
       "      <td>monoamine oxidase inhibitors</td>\n",
       "      <td>Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: norepinephrine\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: effect</td>\n",
       "      <td>Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug1: norepinephrine\\nDrug2: monoamine oxidase inhibitors\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: anesthetic solutions\\nDrug 2: epinephrine\\nInteraction: none\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: anesthetic solutions\\nDrug 2: norepinephrine\\nInteraction: none\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: anesthetic solutions\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: none\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>196</th>\n",
       "      <td>12582</td>\n",
       "      <td>DDI-DrugBank.d485.s10.p2</td>\n",
       "      <td>Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d485</td>\n",
       "      <td>dev</td>\n",
       "      <td>hormonal contraceptives</td>\n",
       "      <td>coumarin derivatives</td>\n",
       "      <td>Sentence: Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.\\nDrug 1: hormonal contraceptives\\nDrug 2: coumarin derivatives\\nInteraction: effect</td>\n",
       "      <td>Sentence: Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.\\nDrug1: hormonal contraceptives\\nDrug2: coumarin derivatives\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Warfarin\\nDrug 2: Quinolones\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Warfarin\\nDrug 2: anticoagulant\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Warfarin\\nDrug 2: warfarin\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Quinolones\\nDrug 2: anticoagulant\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Quinolones\\nDrug 2: warfarin\\nInteraction: effect\\n\\nSentence: Anticoagulants: Combination hormonal c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>8035</td>\n",
       "      <td>DDI-DrugBank.d522.s23.p3</td>\n",
       "      <td>Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d522</td>\n",
       "      <td>dev</td>\n",
       "      <td>erythromycin</td>\n",
       "      <td>ergotamine</td>\n",
       "      <td>Sentence: Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: ergotamine\\nInteraction: effect</td>\n",
       "      <td>Sentence: Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug1: erythromycin\\nDrug2: ergotamine\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: ergotamine\\nInteraction: effect\\n\\nSentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: dihydroergotamine\\nInteraction: effect\\n\\nSentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: ergotamine\\nDrug 2: dihydroergotamine\\nInteraction: none\\n\\nSentence: Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>929</td>\n",
       "      <td>DDI-DrugBank.d246.s0.p3</td>\n",
       "      <td>Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.</td>\n",
       "      <td>DDI-effect</td>\n",
       "      <td>DDI-DrugBank.d246</td>\n",
       "      <td>dev</td>\n",
       "      <td>butorphanol</td>\n",
       "      <td>tranquilizers</td>\n",
       "      <td>Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug 1: butorphanol\\nDrug 2: tranquilizers\\nInteraction: effect</td>\n",
       "      <td>Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: tranquilizers\\nInteraction:</td>\n",
       "      <td>effect</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: alcohol\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: CNS depressants\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: hypnotics\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: sedatives\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1560</th>\n",
       "      <td>21139</td>\n",
       "      <td>DDI-DrugBank.d413.s20.p9</td>\n",
       "      <td>Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d413</td>\n",
       "      <td>dev</td>\n",
       "      <td>allopurinol</td>\n",
       "      <td>chlorpropamide</td>\n",
       "      <td>Sentence: Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.\\nDrug 1: allopurinol\\nDrug 2: chlorpropamide\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.\\nDrug1: allopurinol\\nDrug2: chlorpropamide\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: aspirin\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1283</th>\n",
       "      <td>4216</td>\n",
       "      <td>DDI-DrugBank.d487.s1.p7</td>\n",
       "      <td>Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d487</td>\n",
       "      <td>dev</td>\n",
       "      <td>rifampin</td>\n",
       "      <td>corticosteroids</td>\n",
       "      <td>Sentence: Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\\nDrug 1: rifampin\\nDrug 2: corticosteroids\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\\nDrug1: rifampin\\nDrug2: corticosteroids\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: macrolide antibiotics\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: erythromycin\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: corticosteroids\\nInteraction: mechanism\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: macrolide antibiotics\\nD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1458</th>\n",
       "      <td>14400</td>\n",
       "      <td>DDI-DrugBank.d157.s1.p0</td>\n",
       "      <td>(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d157</td>\n",
       "      <td>dev</td>\n",
       "      <td>Femara</td>\n",
       "      <td>tamoxifen</td>\n",
       "      <td>Sentence: (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.\\nDrug 1: Femara\\nDrug 2: tamoxifen\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.\\nDrug1: Femara\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: VIOXX\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rifampin\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rofecoxib\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: VIOXX\\nDrug 2: rifampin\\nInteraction: mechanism\\n\\nSentence: Ri...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1462</th>\n",
       "      <td>14502</td>\n",
       "      <td>DDI-DrugBank.d198.s22.p3</td>\n",
       "      <td>In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d198</td>\n",
       "      <td>dev</td>\n",
       "      <td>nitrates</td>\n",
       "      <td>vardenafil</td>\n",
       "      <td>Sentence: In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.\\nDrug 1: nitrates\\nDrug 2: vardenafil\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.\\nDrug1: nitrates\\nDrug2: vardenafil\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: Vardenafil\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: terazosin\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Vardenafil\\nDrug 2: terazosin\\nInteraction: effect\\n\\nSentence: Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1501</th>\n",
       "      <td>15384</td>\n",
       "      <td>DDI-DrugBank.d94.s11.p27</td>\n",
       "      <td>Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d94</td>\n",
       "      <td>dev</td>\n",
       "      <td>EQUETROTM</td>\n",
       "      <td>nortriptyline</td>\n",
       "      <td>Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug 1: EQUETROTM\\nDrug 2: nortriptyline\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: nortriptyline\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1558</th>\n",
       "      <td>21031</td>\n",
       "      <td>DDI-DrugBank.d195.s8.p0</td>\n",
       "      <td>Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d195</td>\n",
       "      <td>dev</td>\n",
       "      <td>anastrozole</td>\n",
       "      <td>tamoxifen</td>\n",
       "      <td>Sentence: Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.\\nDrug 1: anastrozole\\nDrug 2: tamoxifen\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.\\nDrug1: anastrozole\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: verapamil\\nInteraction: mechanism\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: verapamil\\nDrug 2: dofetilide\\nInteraction: no...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1490</th>\n",
       "      <td>15373</td>\n",
       "      <td>DDI-DrugBank.d94.s11.p16</td>\n",
       "      <td>Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d94</td>\n",
       "      <td>dev</td>\n",
       "      <td>EQUETROTM</td>\n",
       "      <td>felbamate</td>\n",
       "      <td>Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug 1: EQUETROTM\\nDrug 2: felbamate\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: felbamate\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1493</th>\n",
       "      <td>15376</td>\n",
       "      <td>DDI-DrugBank.d94.s11.p19</td>\n",
       "      <td>Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d94</td>\n",
       "      <td>dev</td>\n",
       "      <td>EQUETROTM</td>\n",
       "      <td>haloperidol</td>\n",
       "      <td>Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug 1: EQUETROTM\\nDrug 2: haloperidol\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: haloperidol\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1319</th>\n",
       "      <td>6252</td>\n",
       "      <td>DDI-DrugBank.d236.s23.p2</td>\n",
       "      <td>Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d236</td>\n",
       "      <td>dev</td>\n",
       "      <td>Amphetamines</td>\n",
       "      <td>phenobarbital</td>\n",
       "      <td>Sentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug 1: Amphetamines\\nDrug 2: phenobarbital\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Amphetamines\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1312</th>\n",
       "      <td>5648</td>\n",
       "      <td>DDI-DrugBank.d506.s5.p0</td>\n",
       "      <td>Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d506</td>\n",
       "      <td>dev</td>\n",
       "      <td>Norpace</td>\n",
       "      <td>quinidine</td>\n",
       "      <td>Sentence: Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.\\nDrug 1: Norpace\\nDrug 2: quinidine\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.\\nDrug1: Norpace\\nDrug2: quinidine\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: mechanism\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: tricyclic antidepressants\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.\\nDrug 1: Aspirin\\nDrug 2: diflunis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1337</th>\n",
       "      <td>7549</td>\n",
       "      <td>DDI-DrugBank.d382.s18.p9</td>\n",
       "      <td>Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>DDI-DrugBank.d382</td>\n",
       "      <td>dev</td>\n",
       "      <td>tolbutamide</td>\n",
       "      <td>Aprepitant</td>\n",
       "      <td>Sentence: Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.\\nDrug 1: tolbutamide\\nDrug 2: Aprepitant\\nInteraction: mechanism</td>\n",
       "      <td>Sentence: Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.\\nDrug1: tolbutamide\\nDrug2: Aprepitant\\nInteraction:</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: Aprepitant\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: midazolam\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>923</th>\n",
       "      <td>1772</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p167</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>perchlorate</td>\n",
       "      <td>iodine-containing compounds</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: perchlorate\\nDrug 2: iodine-containing compounds\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: iodine-containing compounds\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>667</th>\n",
       "      <td>1516</td>\n",
       "      <td>DDI-DrugBank.d411.s3.p64</td>\n",
       "      <td>Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>clofibrate</td>\n",
       "      <td>5-fluorouracil</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: clofibrate\\nDrug 2: 5-fluorouracil\\nInteraction: none</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: clofibrate\\nDrug2: 5-fluorouracil\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>625</th>\n",
       "      <td>1474</td>\n",
       "      <td>DDI-DrugBank.d411.s3.p22</td>\n",
       "      <td>Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>androgens</td>\n",
       "      <td>5-fluorouracil</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: androgens\\nDrug 2: 5-fluorouracil\\nInteraction: none</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: androgens\\nDrug2: 5-fluorouracil\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>907</th>\n",
       "      <td>1756</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p151</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>thiocyanate</td>\n",
       "      <td>somatostatin analogs</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: thiocyanate\\nDrug 2: somatostatin analogs\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: somatostatin analogs\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>455</th>\n",
       "      <td>438</td>\n",
       "      <td>DDI-DrugBank.d561.s4.p5</td>\n",
       "      <td>Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d561</td>\n",
       "      <td>dev</td>\n",
       "      <td>spironolactone</td>\n",
       "      <td>triamterene</td>\n",
       "      <td>Sentence: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.\\nDrug 1: spironolactone\\nDrug 2: triamterene\\nInteraction: none</td>\n",
       "      <td>Sentence: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.\\nDrug1: spironolactone\\nDrug2: triamterene\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.\\nDrug 1: Potassium-sparing diuretics\\nDrug 2: spironolactone\\nInteraction: none\\n\\nSentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.\\nDrug 1: Potassium-sparing diuretics\\nDrug 2: triamterene\\nInteraction: none\\n\\nSentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.\\nDrug 1: Potassium-sparing diuretics\\nDrug 2: amiloride\\nInteraction: none\\n\\nSentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>416</th>\n",
       "      <td>195</td>\n",
       "      <td>DDI-DrugBank.d5.s19.p1</td>\n",
       "      <td>MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d5</td>\n",
       "      <td>dev</td>\n",
       "      <td>MAO Inhibitors</td>\n",
       "      <td>MAO inhibitor</td>\n",
       "      <td>Sentence: MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .\\nDrug 1: MAO Inhibitors\\nDrug 2: MAO inhibitor\\nInteraction: none</td>\n",
       "      <td>Sentence: MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .\\nDrug1: MAO Inhibitors\\nDrug2: MAO inhibitor\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.\\nDrug 1: Clonazepam\\nDrug 2: ranitidine\\nInteraction: none\\n\\nSentence: Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.\\nDrug 1: Clonazepam\\nDrug 2: clonazepam\\nInteraction: none\\n\\nSentence: Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.\\nDrug 1: ranitidine\\nDrug 2: clonazepam\\nInteraction: none\\n\\nSentence: It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.\\nDrug 1: dopami...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>834</th>\n",
       "      <td>1683</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p78</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>amiodarone</td>\n",
       "      <td>heparin</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: amiodarone\\nDrug 2: heparin\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: heparin\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>727</th>\n",
       "      <td>1576</td>\n",
       "      <td>DDI-DrugBank.d411.s3.p124</td>\n",
       "      <td>Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>glucocorticoids</td>\n",
       "      <td>tamoxifen</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: glucocorticoids\\nDrug 2: tamoxifen\\nInteraction: none</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: glucocorticoids\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>734</th>\n",
       "      <td>1583</td>\n",
       "      <td>DDI-DrugBank.d411.s3.p131</td>\n",
       "      <td>Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>meclofenamic acid</td>\n",
       "      <td>tamoxifen</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: meclofenamic acid\\nDrug 2: tamoxifen\\nInteraction: none</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: meclofenamic acid\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>607</th>\n",
       "      <td>1298</td>\n",
       "      <td>DDI-DrugBank.d328.s27.p1</td>\n",
       "      <td>Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d328</td>\n",
       "      <td>dev</td>\n",
       "      <td>Fluconazole</td>\n",
       "      <td>Ketoconazole</td>\n",
       "      <td>Sentence: Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.\\nDrug 1: Fluconazole\\nDrug 2: Ketoconazole\\nInteraction: none</td>\n",
       "      <td>Sentence: Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.\\nDrug1: Fluconazole\\nDrug2: Ketoconazole\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: ketoconazole\\nDrug 2: itraconazole\\nInteraction: none\\n\\nSentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: ketoconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: ketoconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: itraconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>763</th>\n",
       "      <td>1612</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p7</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>aminoglutethimide</td>\n",
       "      <td>b-adrenergic blocking agents</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: aminoglutethimide\\nDrug 2: b-adrenergic blocking agents\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: b-adrenergic blocking agents\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>780</th>\n",
       "      <td>1629</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p24</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>aminoglutethimide</td>\n",
       "      <td>nitroprusside</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: aminoglutethimide\\nDrug 2: nitroprusside\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: nitroprusside\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>841</th>\n",
       "      <td>1690</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p85</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>amiodarone</td>\n",
       "      <td>metoclopramide</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: amiodarone\\nDrug 2: metoclopramide\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: metoclopramide\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>915</th>\n",
       "      <td>1764</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p159</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>perchlorate</td>\n",
       "      <td>chloral hydrate</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: perchlorate\\nDrug 2: chloral hydrate\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: chloral hydrate\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>655</th>\n",
       "      <td>1504</td>\n",
       "      <td>DDI-DrugBank.d411.s3.p52</td>\n",
       "      <td>Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>asparaginase</td>\n",
       "      <td>furosemide</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: asparaginase\\nDrug 2: furosemide\\nInteraction: none</td>\n",
       "      <td>Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: asparaginase\\nDrug2: furosemide\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>494</th>\n",
       "      <td>611</td>\n",
       "      <td>DDI-DrugBank.d202.s16.p24</td>\n",
       "      <td>Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d202</td>\n",
       "      <td>dev</td>\n",
       "      <td>carbamazepine</td>\n",
       "      <td>encainide</td>\n",
       "      <td>Sentence: Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.\\nDrug 1: carbamazepine\\nDrug 2: encainide\\nInteraction: none</td>\n",
       "      <td>Sentence: Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.\\nDrug1: carbamazepine\\nDrug2: encainide\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: antidepressants\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: phenothiazines\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>426</th>\n",
       "      <td>283</td>\n",
       "      <td>DDI-DrugBank.d568.s11.p0</td>\n",
       "      <td>Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d568</td>\n",
       "      <td>dev</td>\n",
       "      <td>lithium</td>\n",
       "      <td>lithium</td>\n",
       "      <td>Sentence: Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.\\nDrug 1: lithium\\nDrug 2: lithium\\nInteraction: none</td>\n",
       "      <td>Sentence: Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.\\nDrug1: lithium\\nDrug2: lithium\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.\\nDrug 1: metformin\\nDrug 2: cephalexin\\nInteraction: none\\n\\nSentence: Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.\\nDrug 1: metformin\\nDrug 2: metformin\\nInteraction: none\\n\\nSentence: Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.\\nDrug 1: cephalexin\\nDrug 2: metformin\\nInteraction: advice\\n\\nSentence: In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.\\nDrug 1: lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.\\nDrug 1: cyclosporine\\n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>977</th>\n",
       "      <td>1826</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p221</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>antithyroid drugs</td>\n",
       "      <td>levodopa</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: antithyroid drugs\\nDrug 2: levodopa\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: antithyroid drugs\\nDrug2: levodopa\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>896</th>\n",
       "      <td>1745</td>\n",
       "      <td>DDI-DrugBank.d411.s4.p140</td>\n",
       "      <td>Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.</td>\n",
       "      <td>DDI-false</td>\n",
       "      <td>DDI-DrugBank.d411</td>\n",
       "      <td>dev</td>\n",
       "      <td>thiocyanate</td>\n",
       "      <td>levodopa</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: thiocyanate\\nDrug 2: levodopa\\nInteraction: none</td>\n",
       "      <td>Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: levodopa\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1591</th>\n",
       "      <td>6697</td>\n",
       "      <td>DDI-DrugBank.d205.s0.p1</td>\n",
       "      <td>Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).</td>\n",
       "      <td>DDI-int</td>\n",
       "      <td>DDI-DrugBank.d205</td>\n",
       "      <td>dev</td>\n",
       "      <td>Zarontin</td>\n",
       "      <td>antiepileptic drugs</td>\n",
       "      <td>Sentence: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).\\nDrug 1: Zarontin\\nDrug 2: antiepileptic drugs\\nInteraction: other</td>\n",
       "      <td>Sentence: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).\\nDrug1: Zarontin\\nDrug2: antiepileptic drugs\\nInteraction:</td>\n",
       "      <td>other</td>\n",
       "      <td>{effect, other, mechanism, none, advice}</td>\n",
       "      <td>Sentence: If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.\\nDrug 1: desipramine hydrochloride\\nDrug 2: psychotropic agents\\nInteraction: effect\\n\\nSentence: If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.\\nDrug 1: desipramine hydrochloride\\nDrug 2: tranquilizers\\nInteraction: effect\\n\\nSentence: If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given t...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0                      index  \\\n",
       "1065        4386    DDI-DrugBank.d48.s12.p2   \n",
       "1157       17780     DDI-DrugBank.d31.s0.p0   \n",
       "1096        9530   DDI-DrugBank.d165.s16.p2   \n",
       "1164       19325    DDI-DrugBank.d297.s5.p0   \n",
       "1133       14414   DDI-DrugBank.d364.s10.p1   \n",
       "30           930    DDI-DrugBank.d246.s0.p4   \n",
       "299        19162    DDI-DrugBank.d222.s0.p0   \n",
       "177        10039    DDI-DrugBank.d176.s6.p9   \n",
       "204        12858    DDI-DrugBank.d335.s3.p4   \n",
       "354        21838    DDI-DrugBank.d558.s8.p0   \n",
       "265        17981   DDI-DrugBank.d396.s0.p18   \n",
       "41          2563   DDI-DrugBank.d132.s14.p0   \n",
       "13           643    DDI-DrugBank.d238.s4.p0   \n",
       "55          3227    DDI-DrugBank.d564.s0.p7   \n",
       "196        12582   DDI-DrugBank.d485.s10.p2   \n",
       "137         8035   DDI-DrugBank.d522.s23.p3   \n",
       "29           929    DDI-DrugBank.d246.s0.p3   \n",
       "1560       21139   DDI-DrugBank.d413.s20.p9   \n",
       "1283        4216    DDI-DrugBank.d487.s1.p7   \n",
       "1458       14400    DDI-DrugBank.d157.s1.p0   \n",
       "1462       14502   DDI-DrugBank.d198.s22.p3   \n",
       "1501       15384   DDI-DrugBank.d94.s11.p27   \n",
       "1558       21031    DDI-DrugBank.d195.s8.p0   \n",
       "1490       15373   DDI-DrugBank.d94.s11.p16   \n",
       "1493       15376   DDI-DrugBank.d94.s11.p19   \n",
       "1319        6252   DDI-DrugBank.d236.s23.p2   \n",
       "1312        5648    DDI-DrugBank.d506.s5.p0   \n",
       "1337        7549   DDI-DrugBank.d382.s18.p9   \n",
       "923         1772  DDI-DrugBank.d411.s4.p167   \n",
       "667         1516   DDI-DrugBank.d411.s3.p64   \n",
       "625         1474   DDI-DrugBank.d411.s3.p22   \n",
       "907         1756  DDI-DrugBank.d411.s4.p151   \n",
       "455          438    DDI-DrugBank.d561.s4.p5   \n",
       "416          195     DDI-DrugBank.d5.s19.p1   \n",
       "834         1683   DDI-DrugBank.d411.s4.p78   \n",
       "727         1576  DDI-DrugBank.d411.s3.p124   \n",
       "734         1583  DDI-DrugBank.d411.s3.p131   \n",
       "607         1298   DDI-DrugBank.d328.s27.p1   \n",
       "763         1612    DDI-DrugBank.d411.s4.p7   \n",
       "780         1629   DDI-DrugBank.d411.s4.p24   \n",
       "841         1690   DDI-DrugBank.d411.s4.p85   \n",
       "915         1764  DDI-DrugBank.d411.s4.p159   \n",
       "655         1504   DDI-DrugBank.d411.s3.p52   \n",
       "494          611  DDI-DrugBank.d202.s16.p24   \n",
       "426          283   DDI-DrugBank.d568.s11.p0   \n",
       "977         1826  DDI-DrugBank.d411.s4.p221   \n",
       "896         1745  DDI-DrugBank.d411.s4.p140   \n",
       "1591        6697    DDI-DrugBank.d205.s0.p1   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              sentence  \\\n",
       "1065                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.   \n",
       "1157                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MAO inhibitors should be used with caution in patients receiving hydralazine.   \n",
       "1096                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.   \n",
       "1164                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.   \n",
       "1133                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.   \n",
       "30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.   \n",
       "299                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.   \n",
       "177                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.   \n",
       "204                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.   \n",
       "354                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.   \n",
       "265                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.   \n",
       "41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.   \n",
       "55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.   \n",
       "196                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.   \n",
       "137                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.   \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.   \n",
       "1560                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.   \n",
       "1283                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.   \n",
       "1458                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.   \n",
       "1462                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.   \n",
       "1501                                                                                                         Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.   \n",
       "1558                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.   \n",
       "1490                                                                                                         Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.   \n",
       "1493                                                                                                         Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.   \n",
       "1319                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;   \n",
       "1312                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.   \n",
       "1337                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.   \n",
       "923   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "667                                                                                                                                                                                                                                                                                                                                                                                                                               Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.   \n",
       "625                                                                                                                                                                                                                                                                                                                                                                                                                               Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.   \n",
       "907   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "455                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.   \n",
       "416                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .   \n",
       "834   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "727                                                                                                                                                                                                                                                                                                                                                                                                                               Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.   \n",
       "734                                                                                                                                                                                                                                                                                                                                                                                                                               Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.   \n",
       "607                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.   \n",
       "763   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "780   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "841   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "915   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "655                                                                                                                                                                                                                                                                                                                                                                                                                               Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.   \n",
       "494                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.   \n",
       "426                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.   \n",
       "977   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "896   Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.   \n",
       "1591                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).   \n",
       "\n",
       "              label                doc split                    entity1  \\\n",
       "1065     DDI-advise   DDI-DrugBank.d48   dev     proton pump inhibitors   \n",
       "1157     DDI-advise   DDI-DrugBank.d31   dev             MAO inhibitors   \n",
       "1096     DDI-advise  DDI-DrugBank.d165   dev               Cyclosporine   \n",
       "1164     DDI-advise  DDI-DrugBank.d297   dev                    ORENCIA   \n",
       "1133     DDI-advise  DDI-DrugBank.d364   dev                  alosetron   \n",
       "30       DDI-effect  DDI-DrugBank.d246   dev                butorphanol   \n",
       "299      DDI-effect  DDI-DrugBank.d222   dev                   atropine   \n",
       "177      DDI-effect  DDI-DrugBank.d176   dev             ACE inhibitors   \n",
       "204      DDI-effect  DDI-DrugBank.d335   dev            benzodiazepines   \n",
       "354      DDI-effect  DDI-DrugBank.d558   dev                  verapamil   \n",
       "265      DDI-effect  DDI-DrugBank.d396   dev                    alcohol   \n",
       "41       DDI-effect  DDI-DrugBank.d132   dev                 diflunisal   \n",
       "13       DDI-effect  DDI-DrugBank.d238   dev  tricyclic antidepressants   \n",
       "55       DDI-effect  DDI-DrugBank.d564   dev             norepinephrine   \n",
       "196      DDI-effect  DDI-DrugBank.d485   dev    hormonal contraceptives   \n",
       "137      DDI-effect  DDI-DrugBank.d522   dev               erythromycin   \n",
       "29       DDI-effect  DDI-DrugBank.d246   dev                butorphanol   \n",
       "1560  DDI-mechanism  DDI-DrugBank.d413   dev                allopurinol   \n",
       "1283  DDI-mechanism  DDI-DrugBank.d487   dev                   rifampin   \n",
       "1458  DDI-mechanism  DDI-DrugBank.d157   dev                     Femara   \n",
       "1462  DDI-mechanism  DDI-DrugBank.d198   dev                   nitrates   \n",
       "1501  DDI-mechanism   DDI-DrugBank.d94   dev                  EQUETROTM   \n",
       "1558  DDI-mechanism  DDI-DrugBank.d195   dev                anastrozole   \n",
       "1490  DDI-mechanism   DDI-DrugBank.d94   dev                  EQUETROTM   \n",
       "1493  DDI-mechanism   DDI-DrugBank.d94   dev                  EQUETROTM   \n",
       "1319  DDI-mechanism  DDI-DrugBank.d236   dev               Amphetamines   \n",
       "1312  DDI-mechanism  DDI-DrugBank.d506   dev                    Norpace   \n",
       "1337  DDI-mechanism  DDI-DrugBank.d382   dev                tolbutamide   \n",
       "923       DDI-false  DDI-DrugBank.d411   dev                perchlorate   \n",
       "667       DDI-false  DDI-DrugBank.d411   dev                 clofibrate   \n",
       "625       DDI-false  DDI-DrugBank.d411   dev                  androgens   \n",
       "907       DDI-false  DDI-DrugBank.d411   dev                thiocyanate   \n",
       "455       DDI-false  DDI-DrugBank.d561   dev             spironolactone   \n",
       "416       DDI-false    DDI-DrugBank.d5   dev             MAO Inhibitors   \n",
       "834       DDI-false  DDI-DrugBank.d411   dev                 amiodarone   \n",
       "727       DDI-false  DDI-DrugBank.d411   dev            glucocorticoids   \n",
       "734       DDI-false  DDI-DrugBank.d411   dev          meclofenamic acid   \n",
       "607       DDI-false  DDI-DrugBank.d328   dev                Fluconazole   \n",
       "763       DDI-false  DDI-DrugBank.d411   dev          aminoglutethimide   \n",
       "780       DDI-false  DDI-DrugBank.d411   dev          aminoglutethimide   \n",
       "841       DDI-false  DDI-DrugBank.d411   dev                 amiodarone   \n",
       "915       DDI-false  DDI-DrugBank.d411   dev                perchlorate   \n",
       "655       DDI-false  DDI-DrugBank.d411   dev               asparaginase   \n",
       "494       DDI-false  DDI-DrugBank.d202   dev              carbamazepine   \n",
       "426       DDI-false  DDI-DrugBank.d568   dev                    lithium   \n",
       "977       DDI-false  DDI-DrugBank.d411   dev          antithyroid drugs   \n",
       "896       DDI-false  DDI-DrugBank.d411   dev                thiocyanate   \n",
       "1591        DDI-int  DDI-DrugBank.d205   dev                   Zarontin   \n",
       "\n",
       "                           entity2  \\\n",
       "1065                       SPRYCEL   \n",
       "1157                   hydralazine   \n",
       "1096                  Itraconazole   \n",
       "1164                      anakinra   \n",
       "1133                 telithromycin   \n",
       "30                  antihistamines   \n",
       "299                    pralidoxime   \n",
       "177                        lithium   \n",
       "204                antidepressants   \n",
       "354                     dofetilide   \n",
       "265                    hydrocodone   \n",
       "41                   acetaminophen   \n",
       "13                    guanethidine   \n",
       "55    monoamine oxidase inhibitors   \n",
       "196           coumarin derivatives   \n",
       "137                     ergotamine   \n",
       "29                   tranquilizers   \n",
       "1560                chlorpropamide   \n",
       "1283               corticosteroids   \n",
       "1458                     tamoxifen   \n",
       "1462                    vardenafil   \n",
       "1501                 nortriptyline   \n",
       "1558                     tamoxifen   \n",
       "1490                     felbamate   \n",
       "1493                   haloperidol   \n",
       "1319                 phenobarbital   \n",
       "1312                     quinidine   \n",
       "1337                    Aprepitant   \n",
       "923    iodine-containing compounds   \n",
       "667                 5-fluorouracil   \n",
       "625                 5-fluorouracil   \n",
       "907           somatostatin analogs   \n",
       "455                    triamterene   \n",
       "416                  MAO inhibitor   \n",
       "834                        heparin   \n",
       "727                      tamoxifen   \n",
       "734                      tamoxifen   \n",
       "607                   Ketoconazole   \n",
       "763   b-adrenergic blocking agents   \n",
       "780                  nitroprusside   \n",
       "841                 metoclopramide   \n",
       "915                chloral hydrate   \n",
       "655                     furosemide   \n",
       "494                      encainide   \n",
       "426                        lithium   \n",
       "977                       levodopa   \n",
       "896                       levodopa   \n",
       "1591           antiepileptic drugs   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             prompts  \\\n",
       "1065                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\\nDrug 1: proton pump inhibitors\\nDrug 2: SPRYCEL\\nInteraction: advice   \n",
       "1157                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: MAO inhibitors should be used with caution in patients receiving hydralazine.\\nDrug 1: MAO inhibitors\\nDrug 2: hydralazine\\nInteraction: advice   \n",
       "1096                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.\\nDrug 1: Cyclosporine\\nDrug 2: Itraconazole\\nInteraction: advice   \n",
       "1164                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Sentence: There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.\\nDrug 1: ORENCIA\\nDrug 2: anakinra\\nInteraction: advice   \n",
       "1133                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.\\nDrug 1: alosetron\\nDrug 2: telithromycin\\nInteraction: advice   \n",
       "30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug 1: butorphanol\\nDrug 2: antihistamines\\nInteraction: effect   \n",
       "299                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Sentence: When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.\\nDrug 1: atropine\\nDrug 2: pralidoxime\\nInteraction: effect   \n",
       "177                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: ACE inhibitors\\nDrug 2: lithium\\nInteraction: effect   \n",
       "204                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Sentence: The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.\\nDrug 1: benzodiazepines\\nDrug 2: antidepressants\\nInteraction: effect   \n",
       "354                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug 1: verapamil\\nDrug 2: dofetilide\\nInteraction: effect   \n",
       "265                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Sentence: Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.\\nDrug 1: alcohol\\nDrug 2: hydrocodone\\nInteraction: effect   \n",
       "41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.\\nDrug 1: diflunisal\\nDrug 2: acetaminophen\\nInteraction: effect   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sentence: Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.\\nDrug 1: tricyclic antidepressants\\nDrug 2: guanethidine\\nInteraction: effect   \n",
       "55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: norepinephrine\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: effect   \n",
       "196                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Sentence: Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.\\nDrug 1: hormonal contraceptives\\nDrug 2: coumarin derivatives\\nInteraction: effect   \n",
       "137                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Sentence: Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: ergotamine\\nInteraction: effect   \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug 1: butorphanol\\nDrug 2: tranquilizers\\nInteraction: effect   \n",
       "1560                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sentence: Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.\\nDrug 1: allopurinol\\nDrug 2: chlorpropamide\\nInteraction: mechanism   \n",
       "1283                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\\nDrug 1: rifampin\\nDrug 2: corticosteroids\\nInteraction: mechanism   \n",
       "1458                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sentence: (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.\\nDrug 1: Femara\\nDrug 2: tamoxifen\\nInteraction: mechanism   \n",
       "1462                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.\\nDrug 1: nitrates\\nDrug 2: vardenafil\\nInteraction: mechanism   \n",
       "1501                                                                                                                           Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug 1: EQUETROTM\\nDrug 2: nortriptyline\\nInteraction: mechanism   \n",
       "1558                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.\\nDrug 1: anastrozole\\nDrug 2: tamoxifen\\nInteraction: mechanism   \n",
       "1490                                                                                                                               Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug 1: EQUETROTM\\nDrug 2: felbamate\\nInteraction: mechanism   \n",
       "1493                                                                                                                             Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug 1: EQUETROTM\\nDrug 2: haloperidol\\nInteraction: mechanism   \n",
       "1319                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug 1: Amphetamines\\nDrug 2: phenobarbital\\nInteraction: mechanism   \n",
       "1312                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Sentence: Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.\\nDrug 1: Norpace\\nDrug 2: quinidine\\nInteraction: mechanism   \n",
       "1337                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.\\nDrug 1: tolbutamide\\nDrug 2: Aprepitant\\nInteraction: mechanism   \n",
       "923          Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: perchlorate\\nDrug 2: iodine-containing compounds\\nInteraction: none   \n",
       "667                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: clofibrate\\nDrug 2: 5-fluorouracil\\nInteraction: none   \n",
       "625                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: androgens\\nDrug 2: 5-fluorouracil\\nInteraction: none   \n",
       "907                 Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: thiocyanate\\nDrug 2: somatostatin analogs\\nInteraction: none   \n",
       "455                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.\\nDrug 1: spironolactone\\nDrug 2: triamterene\\nInteraction: none   \n",
       "416                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .\\nDrug 1: MAO Inhibitors\\nDrug 2: MAO inhibitor\\nInteraction: none   \n",
       "834                               Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: amiodarone\\nDrug 2: heparin\\nInteraction: none   \n",
       "727                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: glucocorticoids\\nDrug 2: tamoxifen\\nInteraction: none   \n",
       "734                                                                                                                                                                                                                                                                                                                                                                                                                                                  Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: meclofenamic acid\\nDrug 2: tamoxifen\\nInteraction: none   \n",
       "607                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sentence: Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.\\nDrug 1: Fluconazole\\nDrug 2: Ketoconazole\\nInteraction: none   \n",
       "763   Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: aminoglutethimide\\nDrug 2: b-adrenergic blocking agents\\nInteraction: none   \n",
       "780                  Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: aminoglutethimide\\nDrug 2: nitroprusside\\nInteraction: none   \n",
       "841                        Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: amiodarone\\nDrug 2: metoclopramide\\nInteraction: none   \n",
       "915                      Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: perchlorate\\nDrug 2: chloral hydrate\\nInteraction: none   \n",
       "655                                                                                                                                                                                                                                                                                                                                                                                                                                                      Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug 1: asparaginase\\nDrug 2: furosemide\\nInteraction: none   \n",
       "494                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.\\nDrug 1: carbamazepine\\nDrug 2: encainide\\nInteraction: none   \n",
       "426                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sentence: Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.\\nDrug 1: lithium\\nDrug 2: lithium\\nInteraction: none   \n",
       "977                       Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: antithyroid drugs\\nDrug 2: levodopa\\nInteraction: none   \n",
       "896                             Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug 1: thiocyanate\\nDrug 2: levodopa\\nInteraction: none   \n",
       "1591                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).\\nDrug 1: Zarontin\\nDrug 2: antiepileptic drugs\\nInteraction: other   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                empty_prompts  \\\n",
       "1065                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\\nDrug1: proton pump inhibitors\\nDrug2: SPRYCEL\\nInteraction:   \n",
       "1157                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: MAO inhibitors should be used with caution in patients receiving hydralazine.\\nDrug1: MAO inhibitors\\nDrug2: hydralazine\\nInteraction:   \n",
       "1096                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.\\nDrug1: Cyclosporine\\nDrug2: Itraconazole\\nInteraction:   \n",
       "1164                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Sentence: There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.\\nDrug1: ORENCIA\\nDrug2: anakinra\\nInteraction:   \n",
       "1133                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Sentence: Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.\\nDrug1: alosetron\\nDrug2: telithromycin\\nInteraction:   \n",
       "30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: antihistamines\\nInteraction:   \n",
       "299                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.\\nDrug1: atropine\\nDrug2: pralidoxime\\nInteraction:   \n",
       "177                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug1: ACE inhibitors\\nDrug2: lithium\\nInteraction:   \n",
       "204                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.\\nDrug1: benzodiazepines\\nDrug2: antidepressants\\nInteraction:   \n",
       "354                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sentence: In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug1: verapamil\\nDrug2: dofetilide\\nInteraction:   \n",
       "265                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Sentence: Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.\\nDrug1: alcohol\\nDrug2: hydrocodone\\nInteraction:   \n",
       "41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.\\nDrug1: diflunisal\\nDrug2: acetaminophen\\nInteraction:   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.\\nDrug1: tricyclic antidepressants\\nDrug2: guanethidine\\nInteraction:   \n",
       "55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug1: norepinephrine\\nDrug2: monoamine oxidase inhibitors\\nInteraction:   \n",
       "196                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.\\nDrug1: hormonal contraceptives\\nDrug2: coumarin derivatives\\nInteraction:   \n",
       "137                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Sentence: Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug1: erythromycin\\nDrug2: ergotamine\\nInteraction:   \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: tranquilizers\\nInteraction:   \n",
       "1560                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sentence: Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.\\nDrug1: allopurinol\\nDrug2: chlorpropamide\\nInteraction:   \n",
       "1283                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\\nDrug1: rifampin\\nDrug2: corticosteroids\\nInteraction:   \n",
       "1458                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.\\nDrug1: Femara\\nDrug2: tamoxifen\\nInteraction:   \n",
       "1462                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Sentence: In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.\\nDrug1: nitrates\\nDrug2: vardenafil\\nInteraction:   \n",
       "1501                                                                                                                                Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: nortriptyline\\nInteraction:   \n",
       "1558                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sentence: Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.\\nDrug1: anastrozole\\nDrug2: tamoxifen\\nInteraction:   \n",
       "1490                                                                                                                                    Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: felbamate\\nInteraction:   \n",
       "1493                                                                                                                                  Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: haloperidol\\nInteraction:   \n",
       "1319                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:   \n",
       "1312                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sentence: Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.\\nDrug1: Norpace\\nDrug2: quinidine\\nInteraction:   \n",
       "1337                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sentence: Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.\\nDrug1: tolbutamide\\nDrug2: Aprepitant\\nInteraction:   \n",
       "923          Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: iodine-containing compounds\\nInteraction:   \n",
       "667                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: clofibrate\\nDrug2: 5-fluorouracil\\nInteraction:   \n",
       "625                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: androgens\\nDrug2: 5-fluorouracil\\nInteraction:   \n",
       "907                 Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: somatostatin analogs\\nInteraction:   \n",
       "455                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.\\nDrug1: spironolactone\\nDrug2: triamterene\\nInteraction:   \n",
       "416                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .\\nDrug1: MAO Inhibitors\\nDrug2: MAO inhibitor\\nInteraction:   \n",
       "834                               Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: heparin\\nInteraction:   \n",
       "727                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: glucocorticoids\\nDrug2: tamoxifen\\nInteraction:   \n",
       "734                                                                                                                                                                                                                                                                                                                                                                                                                                                  Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: meclofenamic acid\\nDrug2: tamoxifen\\nInteraction:   \n",
       "607                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sentence: Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.\\nDrug1: Fluconazole\\nDrug2: Ketoconazole\\nInteraction:   \n",
       "763   Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: b-adrenergic blocking agents\\nInteraction:   \n",
       "780                  Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: nitroprusside\\nInteraction:   \n",
       "841                        Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: metoclopramide\\nInteraction:   \n",
       "915                      Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: chloral hydrate\\nInteraction:   \n",
       "655                                                                                                                                                                                                                                                                                                                                                                                                                                                      Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: asparaginase\\nDrug2: furosemide\\nInteraction:   \n",
       "494                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.\\nDrug1: carbamazepine\\nDrug2: encainide\\nInteraction:   \n",
       "426                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sentence: Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.\\nDrug1: lithium\\nDrug2: lithium\\nInteraction:   \n",
       "977                       Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: antithyroid drugs\\nDrug2: levodopa\\nInteraction:   \n",
       "896                             Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: levodopa\\nInteraction:   \n",
       "1591                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sentence: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).\\nDrug1: Zarontin\\nDrug2: antiepileptic drugs\\nInteraction:   \n",
       "\n",
       "         labels                             unique_labels  \\\n",
       "1065     advice  {effect, other, mechanism, none, advice}   \n",
       "1157     advice  {effect, other, mechanism, none, advice}   \n",
       "1096     advice  {effect, other, mechanism, none, advice}   \n",
       "1164     advice  {effect, other, mechanism, none, advice}   \n",
       "1133     advice  {effect, other, mechanism, none, advice}   \n",
       "30       effect  {effect, other, mechanism, none, advice}   \n",
       "299      effect  {effect, other, mechanism, none, advice}   \n",
       "177      effect  {effect, other, mechanism, none, advice}   \n",
       "204      effect  {effect, other, mechanism, none, advice}   \n",
       "354      effect  {effect, other, mechanism, none, advice}   \n",
       "265      effect  {effect, other, mechanism, none, advice}   \n",
       "41       effect  {effect, other, mechanism, none, advice}   \n",
       "13       effect  {effect, other, mechanism, none, advice}   \n",
       "55       effect  {effect, other, mechanism, none, advice}   \n",
       "196      effect  {effect, other, mechanism, none, advice}   \n",
       "137      effect  {effect, other, mechanism, none, advice}   \n",
       "29       effect  {effect, other, mechanism, none, advice}   \n",
       "1560  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1283  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1458  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1462  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1501  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1558  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1490  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1493  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1319  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1312  mechanism  {effect, other, mechanism, none, advice}   \n",
       "1337  mechanism  {effect, other, mechanism, none, advice}   \n",
       "923        none  {effect, other, mechanism, none, advice}   \n",
       "667        none  {effect, other, mechanism, none, advice}   \n",
       "625        none  {effect, other, mechanism, none, advice}   \n",
       "907        none  {effect, other, mechanism, none, advice}   \n",
       "455        none  {effect, other, mechanism, none, advice}   \n",
       "416        none  {effect, other, mechanism, none, advice}   \n",
       "834        none  {effect, other, mechanism, none, advice}   \n",
       "727        none  {effect, other, mechanism, none, advice}   \n",
       "734        none  {effect, other, mechanism, none, advice}   \n",
       "607        none  {effect, other, mechanism, none, advice}   \n",
       "763        none  {effect, other, mechanism, none, advice}   \n",
       "780        none  {effect, other, mechanism, none, advice}   \n",
       "841        none  {effect, other, mechanism, none, advice}   \n",
       "915        none  {effect, other, mechanism, none, advice}   \n",
       "655        none  {effect, other, mechanism, none, advice}   \n",
       "494        none  {effect, other, mechanism, none, advice}   \n",
       "426        none  {effect, other, mechanism, none, advice}   \n",
       "977        none  {effect, other, mechanism, none, advice}   \n",
       "896        none  {effect, other, mechanism, none, advice}   \n",
       "1591      other  {effect, other, mechanism, none, advice}   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            test_ready_prompt  \n",
       "1065  Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: antacids\\nDrug 2: H2 blockers\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: antacids\\nDrug 2: proton pump inhibitors\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: antacids\\nDrug 2: SPRYCEL\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: H2 blockers\\nDrug 2: proton pump inhibitors\\nInteraction: none\\n\\nSentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\\nDrug 1: H2 blockers\\nDrug 2: S...  \n",
       "1157  Sentence: Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.\\nDrug 1: Cevimeline\\nDrug 2: beta adrenergic antagonists\\nInteraction: advice\\n\\nSentence: All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.\\nDrug 1: vasopressors\\nDrug 2: monoamine oxidase (MAO) inhibitors\\nInteraction: advice\\n\\nSentence: DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.\\nDrug 1: DISULFIRAM\\nDrug 2: PHENYTOIN\\nInteraction: advice\\n\\nSentence: NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.\\nDrug 1: NSAIDs\\nDrug 2: cyclosporine\\nInteraction: advice\\n\\nSentence: NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.\\nDrug 1: NSAIDs\\nDrug 2: cyclosporine\\nInteraction: advice\\n\\nSentence...  \n",
       "1096  Sentence: For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.\\nDrug 1: tacrolimus\\nDrug 2: tacrolimus\\nInteraction: none\\n\\nSentence: The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.\\nDrug 1: itraconazole\\nDrug 2: Itraconazole\\nInteraction: none\\n\\nSentence: Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.\\nDrug 1: cyclosporine\\nDrug 2: cyclosporine\\nInteraction: none\\n\\nSentence: Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.\\nDrug 1: cyclosporine\\nDrug 2: cyclosporine\\nInteraction: none\\n\\nSentence: Coadministration of Itraconazole and cyclospori...  \n",
       "1164  Sentence: Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.\\nDrug 1: lidocaine\\nDrug 2: Bretylium Tosylate\\nInteraction: none\\n\\nSentence: The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.\\nDrug 1: anakinra\\nDrug 2: HUMIRA\\nInteraction: none\\n\\nSentence: Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.\\nDrug 1: Aspirin\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.\\nDrug 1: Aspirin\\nDrug 2: Ponstel\\nInteraction: none\\n\\nSentence: Aspirin: As with other NSAIDs, concomi...  \n",
       "1133  Sentence: Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.\\nDrug 1: alosetron\\nDrug 2: quinolone antibiotics\\nInteraction: advice\\n\\nSentence: Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.\\nDrug 1: alosetron\\nDrug 2: cimetidine\\nInteraction: advice\\n\\nSentence: Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.\\nDrug 1: quinolone antibiotics\\nDrug 2: cimetidine\\nInteraction: none\\n\\nSentence: Consequently, concom...  \n",
       "30    Sentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: alcohol\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: CNS depressants\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: hypnotics\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: sedatives\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, ...  \n",
       "299   Sentence: Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.\\nDrug 1: ROMAZICON\\nDrug 2: cyclic antidepressants\\nInteraction: effect\\n\\nSentence: Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.\\nDrug 1: ROMAZICON\\nDrug 2: benzodiazepine\\nInteraction: none\\n\\nSentence: Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants)...  \n",
       "177   Sentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: ACE inhibitors\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug 1: Lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been ...  \n",
       "204   Sentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: benzodiazepines\\nDrug 2: anticonvulsants\\nInteraction: effect\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: benzodiazepines\\nDrug 2: antihistamines\\nInteraction: effect\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: benzodiazepines\\nDrug 2: alcohol\\nInteraction: effect\\n\\nSentence: The action of the benzodia...  \n",
       "354   Sentence: In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug 1: digoxin\\nDrug 2: dofetilide\\nInteraction: effect\\n\\nSentence: In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.\\nDrug 1: Angiomax\\nDrug 2: heparin\\nInteraction: effect\\n\\nSentence: In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.\\nDrug 1: Angiomax\\nDrug 2: warfarin\\nInteraction: effect\\n\\nSentence: In clinical trials in patients undergoing PTCA/PCI, co-administration of Ang...  \n",
       "265   Sentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: anesthetics\\nInteraction: none\\n\\nSentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: phenothiazines\\nInteraction: none\\n\\nSentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: tranquilizers...  \n",
       "41    Sentence: Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.\\nDrug 1: Diclofenac\\nDrug 2: Starlix\\nInteraction: none\\n\\nSentence: Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.\\nDrug 1: Diclofenac\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.\\nDrug 1: Starlix\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic in...  \n",
       "13    Sentence: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.\\nDrug 1: Tricyclic antidepressants\\nDrug 2: clonidine\\nInteraction: effect\\n\\nSentence: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.\\nDrug 1: Tricyclic antidepressants\\nDrug 2: ALPHAGAN P\\nInteraction: none\\n\\nSentence: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.\\nDrug 1: clonidine\\nDrug 2: ALPHAGAN P\\nInteraction: none\\n\\nSen...  \n",
       "55    Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: anesthetic solutions\\nDrug 2: epinephrine\\nInteraction: none\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: anesthetic solutions\\nDrug 2: norepinephrine\\nInteraction: none\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: anesthetic solutions\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: none\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or ...  \n",
       "196   Sentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Warfarin\\nDrug 2: Quinolones\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Warfarin\\nDrug 2: anticoagulant\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Warfarin\\nDrug 2: warfarin\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Quinolones\\nDrug 2: anticoagulant\\nInteraction: none\\n\\nSentence: Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.\\nDrug 1: Quinolones\\nDrug 2: warfarin\\nInteraction: effect\\n\\nSentence: Anticoagulants: Combination hormonal c...  \n",
       "137   Sentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: ergotamine\\nInteraction: effect\\n\\nSentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: dihydroergotamine\\nInteraction: effect\\n\\nSentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: ergotamine\\nDrug 2: dihydroergotamine\\nInteraction: none\\n\\nSentence: Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reu...  \n",
       "29    Sentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: alcohol\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: CNS depressants\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: hypnotics\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.\\nDrug 1: Antihistamines\\nDrug 2: sedatives\\nInteraction: effect\\n\\nSentence: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, ...  \n",
       "1560  Sentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: aspirin\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\n...  \n",
       "1283  Sentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: macrolide antibiotics\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: erythromycin\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: corticosteroids\\nInteraction: mechanism\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: macrolide antibiotics\\nD...  \n",
       "1458  Sentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: VIOXX\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rifampin\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rofecoxib\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: VIOXX\\nDrug 2: rifampin\\nInteraction: mechanism\\n\\nSentence: Ri...  \n",
       "1462  Sentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: Vardenafil\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: terazosin\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Vardenafil\\nDrug 2: terazosin\\nInteraction: effect\\n\\nSentence: Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of i...  \n",
       "1501  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...  \n",
       "1558  Sentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: verapamil\\nInteraction: mechanism\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: verapamil\\nDrug 2: dofetilide\\nInteraction: no...  \n",
       "1490  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...  \n",
       "1493  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...  \n",
       "1319                                                                                                                                               Sentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Amphetamines\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:  \n",
       "1312  Sentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: mechanism\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: tricyclic antidepressants\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.\\nDrug 1: Aspirin\\nDrug 2: diflunis...  \n",
       "1337  Sentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: Aprepitant\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: midazolam\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days ...  \n",
       "923   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "667   Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...  \n",
       "625   Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...  \n",
       "907   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "455   Sentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.\\nDrug 1: Potassium-sparing diuretics\\nDrug 2: spironolactone\\nInteraction: none\\n\\nSentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.\\nDrug 1: Potassium-sparing diuretics\\nDrug 2: triamterene\\nInteraction: none\\n\\nSentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.\\nDrug 1: Potassium-sparing diuretics\\nDrug 2: amiloride\\nInteraction: none\\n\\nSentence: Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containin...  \n",
       "416   Sentence: Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.\\nDrug 1: Clonazepam\\nDrug 2: ranitidine\\nInteraction: none\\n\\nSentence: Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.\\nDrug 1: Clonazepam\\nDrug 2: clonazepam\\nInteraction: none\\n\\nSentence: Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.\\nDrug 1: ranitidine\\nDrug 2: clonazepam\\nInteraction: none\\n\\nSentence: It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.\\nDrug 1: dopami...  \n",
       "834   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "727   Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...  \n",
       "734   Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...  \n",
       "607   Sentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: ketoconazole\\nDrug 2: itraconazole\\nInteraction: none\\n\\nSentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: ketoconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: ketoconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: itraconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: ...  \n",
       "763   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "780   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "841   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "915   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "655   Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: glyburide\\nInteraction: none\\n\\nSentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did ...  \n",
       "494   Sentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: antidepressants\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: phenothiazines\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flec...  \n",
       "426   Sentence: Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.\\nDrug 1: metformin\\nDrug 2: cephalexin\\nInteraction: none\\n\\nSentence: Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.\\nDrug 1: metformin\\nDrug 2: metformin\\nInteraction: none\\n\\nSentence: Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.\\nDrug 1: cephalexin\\nDrug 2: metformin\\nInteraction: advice\\n\\nSentence: In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.\\nDrug 1: lithium\\nDrug 2: lithium\\nInteraction: none\\n\\nSentence: Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.\\nDrug 1: cyclosporine\\n...  \n",
       "977   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "896   Sentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: platelet inhibitors\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: acetylsalicylic acid\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.\\nDrug 1: anticoagulants\\nDrug 2: NSAIDs\\nInteraction: none\\n\\nSentence: These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including k...  \n",
       "1591  Sentence: If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.\\nDrug 1: desipramine hydrochloride\\nDrug 2: psychotropic agents\\nInteraction: effect\\n\\nSentence: If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.\\nDrug 1: desipramine hydrochloride\\nDrug 2: tranquilizers\\nInteraction: effect\\n\\nSentence: If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given t...  "
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_ready_prompt_dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'DataFrame' object has no attribute 'entities'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-32-14c6f7857798>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mtest_ready_prompt_dataframe\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'num_tokens'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtokenizer\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mencode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msep\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mjoin\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mset\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ments\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0ments\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mtest_ready_prompt_dataframe\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mentities\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/generic.py\u001b[0m in \u001b[0;36m__getattr__\u001b[0;34m(self, name)\u001b[0m\n\u001b[1;32m   5463\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_info_axis\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_can_hold_identifiers_and_holds_name\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mname\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   5464\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mname\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 5465\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mobject\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m__getattribute__\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mname\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   5466\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   5467\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m__setattr__\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mname\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m->\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mAttributeError\u001b[0m: 'DataFrame' object has no attribute 'entities'"
     ]
    }
   ],
   "source": [
    "test_ready_prompt_dataframe['num_tokens'] = [len(tokenizer.encode(sep.join(set(ents)))) for ents in test_ready_prompt_dataframe.entities]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyError",
     "evalue": "'num_tokens'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36mget_loc\u001b[0;34m(self, key, method, tolerance)\u001b[0m\n\u001b[1;32m   3079\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3080\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_engine\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcasted_key\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3081\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mKeyError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/index.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/index.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;31mKeyError\u001b[0m: 'num_tokens'",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-34-e5aa57c93ac4>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtest_ready_prompt_dataframe\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mtest_ready_prompt_dataframe\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'num_tokens'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m<\u001b[0m \u001b[0;36m20\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m__getitem__\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   3022\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcolumns\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mnlevels\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3023\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_getitem_multilevel\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3024\u001b[0;31m             \u001b[0mindexer\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcolumns\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3025\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mis_integer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mindexer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3026\u001b[0m                 \u001b[0mindexer\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mindexer\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36mget_loc\u001b[0;34m(self, key, method, tolerance)\u001b[0m\n\u001b[1;32m   3080\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_engine\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcasted_key\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3081\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mKeyError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3082\u001b[0;31m                 \u001b[0;32mraise\u001b[0m \u001b[0mKeyError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfrom\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3083\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3084\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mtolerance\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyError\u001b[0m: 'num_tokens'"
     ]
    }
   ],
   "source": [
    "len(test_ready_prompt_dataframe[test_ready_prompt_dataframe['num_tokens'] < 20])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: antacids\n",
      "Drug 2: H2 blockers\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: antacids\n",
      "Drug 2: proton pump inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: antacids\n",
      "Drug 2: SPRYCEL\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: H2 blockers\n",
      "Drug 2: proton pump inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: H2 blockers\n",
      "Drug 2: SPRYCEL\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\n",
      "Drug1: proton pump inhibitors\n",
      "Drug2: SPRYCEL\n",
      "Interaction:\n"
     ]
    }
   ],
   "source": [
    "print(prompts[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_gpt3(engine, prompt, logit_bias_text, max_tokens=10, sep=None, logit_bias=0.1):\n",
    "    #constrain potential output to tokens in test sentence using logit bias\n",
    "    logit_biases = {}\n",
    "    tokens = tokenizer.encode(logit_bias_text)\n",
    "    for token in tokens:\n",
    "        logit_biases[token] = logit_bias\n",
    "    \n",
    "    if sep is not None:\n",
    "        sep_token = tokenizer.encode(sep)\n",
    "        logit_biases[sep_token[0]] = logit_bias     \n",
    "    \n",
    "    #use API to generate completion\n",
    "    sample = openai.Completion.create(engine=engine,\n",
    "                                      prompt=prompt,\n",
    "                                      max_tokens=max_tokens,\n",
    "                                      temperature=0,\n",
    "                                      logit_bias = logit_biases,\n",
    "                                      presence_penalty=-0.001,\n",
    "                                      logprobs=1,\n",
    "                                      stop=[\"\\n\", \"<|endoftext|>\"])\n",
    "    return sample"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 926,
   "metadata": {},
   "outputs": [],
   "source": [
    "filter_prompt = \"\"\"Does the phrase \"adverse events\" refer to a disease?\n",
    "No\n",
    "\n",
    "Does the phrase \"intracarotid drug delivery system\" refer to a disease?\n",
    "No\n",
    "\n",
    "Does the phrase \"hypotension\" refer to a disease?\n",
    "Yes\n",
    "\n",
    "Does the phrase \"respiratory arrest\" refer to a disease?\n",
    "Yes\n",
    "\n",
    "Does the phrase \"desipramine\" refer to a disease?\n",
    "No\n",
    "\n",
    "Does the phrase \"myocardial infarction\" refer to a disease?\n",
    "Yes\n",
    "\"\"\"\n",
    "\n",
    "template_prompt = 'Does the phrase \"{}\" refer to a disease?'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 944,
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_gpt3_ner(engine, \n",
    "                 prompt, \n",
    "                 logit_bias_text, \n",
    "                 max_tokens=10, \n",
    "                 sep=None, \n",
    "                 logit_bias=0.1, \n",
    "                 sep_logit_bias=0.1, \n",
    "                 new_line_logit_bias=0.1):\n",
    "    \n",
    "    #constrain potential output to tokens in test sentence using logit bias\n",
    "    logit_biases = {}\n",
    "    tokens = tokenizer.encode(logit_bias_text)\n",
    "    for token in tokens:\n",
    "        logit_biases[token] = logit_bias\n",
    "    \n",
    "    #Adding bias for separator\n",
    "    if sep is not None:\n",
    "        sep_token = tokenizer.encode(sep)\n",
    "        logit_biases[sep_token[0]] = sep_logit_bias         \n",
    "\n",
    "    #Adding bias for newline (token id 198)\n",
    "    logit_biases[198] = new_line_logit_bias \n",
    "    \n",
    "    #use API to generate completion\n",
    "    print(prompt,max_tokens,logit_biases)\n",
    "    sample = openai.Completion.create(engine=engine,\n",
    "                                      prompt=prompt,\n",
    "                                      max_tokens=max_tokens,\n",
    "                                      temperature=0.0,\n",
    "                                      logit_bias = logit_biases,\n",
    "                                      logprobs=1,\n",
    "                                      presence_penalty=-0.001,\n",
    "                                      stop=[\"\\n\", \"<|endoftext|>\"])\n",
    "    print(sample)\n",
    "    return sample\n",
    "\n",
    "def run_gpt3_ner_post_filtering(engine, \n",
    "                                     filtering_prompt,\n",
    "                                     filter_template,\n",
    "                                    entities):\n",
    "    \n",
    "    logit_biases = {}\n",
    "    tokens = ['Yes','No']\n",
    "    \n",
    "    for token in tokens:\n",
    "        token_id = tokenizer.encode(token)[0]\n",
    "        logit_biases[token_id] = 10\n",
    "    \n",
    "    #Adding bias for newline (token id 198)\n",
    "    logit_biases[198] = -10 \n",
    "\n",
    "    entity_probs = {}\n",
    "    \n",
    "    for entity in entities:\n",
    "        filter_prompt = filtering_prompt + filter_template.format(entity)\n",
    "        filter_sample = openai.Completion.create(engine=engine,\n",
    "                                          prompt=filter_prompt,\n",
    "                                          max_tokens=1,\n",
    "                                          temperature=0.0,\n",
    "                                          logprobs=2,\n",
    "                                          logit_bias = logit_biases,\n",
    "                                          stop=[\"\\n\", \"<|endoftext|>\"])\n",
    "        filter_dict = dict(filter_sample['choices'][0]['logprobs']['top_logprobs'][0])\n",
    "        \n",
    "        entity_logits = []\n",
    "        for opt in ['No','Yes']:\n",
    "            entity_logits.append(filter_dict[opt])\n",
    "        \n",
    "        entity_probs[entity] = scipy.special.softmax(entity_logits)\n",
    "\n",
    "    return entity_probs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 922,
   "metadata": {},
   "outputs": [],
   "source": [
    "logit_bias = 10\n",
    "sep_logit_bias = 10\n",
    "new_line_logit_bias = 10"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 797,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "50it [00:29,  1.69it/s]\n"
     ]
    }
   ],
   "source": [
    "#GENERATE NER PREDICTIONS\n",
    "gpt3_output = []\n",
    "predictions = []\n",
    "filtering=False\n",
    "for i, prompt in tqdm(enumerate(prompts)):\n",
    "    \n",
    "    \n",
    "    test_sent = test_ready_prompt_dataframe.sents.values[i]\n",
    "    sample = run_gpt3_ner(engine, \n",
    "                          prompt, \n",
    "                          test_sent, \n",
    "                          30, \n",
    "                          sep, \n",
    "                          logit_bias=logit_bias, \n",
    "                          sep_logit_bias=sep_logit_bias, \n",
    "                          new_line_logit_bias=new_line_logit_bias)\n",
    "    \n",
    "    gpt3_output.append(sample)\n",
    "    prediction = sample['choices'][0]['text']\n",
    "    #Lowercasing all predictions\n",
    "    prediction = prediction.lower().strip()\n",
    "    predictions.append(prediction)\n",
    "    \n",
    "df = test_ready_prompt_dataframe\n",
    "df[filename_root] = [p.split(sep) for p in predictions]\n",
    "df['gpt3_output_{}'.format(filename_root)] = gpt3_output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 923,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .\n",
      "Diseases: 30 {3646: 10, 11797: 10, 373: 10, 6789: 10, 329: 10, 20766: 10, 25385: 10, 290: 10, 262: 10, 15144: 10, 14623: 10, 578: 10, 39601: 10, 19802: 10, 66: 10, 14520: 10, 500: 10, 1262: 10, 27679: 10, 532: 10, 36631: 10, 16217: 10, 78: 10, 562: 10, 323: 10, 20411: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          996,\n",
      "          1003,\n",
      "          1005,\n",
      "          1014,\n",
      "          1020,\n",
      "          1021,\n",
      "          1024,\n",
      "          1026,\n",
      "          1038,\n",
      "          1038,\n",
      "          1038,\n",
      "          1038,\n",
      "          1038,\n",
      "          1038,\n",
      "          1038,\n",
      "          1038\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.83946985,\n",
      "          -0.30309016,\n",
      "          -0.0018577697,\n",
      "          -0.015393434,\n",
      "          -2.1649737e-05,\n",
      "          -1.7595703e-05,\n",
      "          -5.197998e-06,\n",
      "          -0.14432234,\n",
      "          -0.66646177,\n",
      "          -8.3045044e-05,\n",
      "          -0.7914731,\n",
      "          -0.0031377613,\n",
      "          -0.1391006,\n",
      "          -0.0020034255,\n",
      "          -0.010400449,\n",
      "          -0.28635666\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" enzyme\",\n",
      "          \" -\",\n",
      "          \" mediated\",\n",
      "          \" immun\",\n",
      "          \"o\",\n",
      "          \"ass\",\n",
      "          \"ay\",\n",
      "          \" methodology\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Pl\",\n",
      "          \"asma\",\n",
      "          \" was\",\n",
      "          \" tested\",\n",
      "          \" for\",\n",
      "          \" amp\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" enzyme\": -0.83946985\n",
      "          },\n",
      "          {\n",
      "            \" -\": -0.30309016\n",
      "          },\n",
      "          {\n",
      "            \" mediated\": -0.0018577697\n",
      "          },\n",
      "          {\n",
      "            \" immun\": -0.015393434\n",
      "          },\n",
      "          {\n",
      "            \"o\": -2.1649737e-05\n",
      "          },\n",
      "          {\n",
      "            \"ass\": -1.7595703e-05\n",
      "          },\n",
      "          {\n",
      "            \"ay\": -5.197998e-06\n",
      "          },\n",
      "          {\n",
      "            \" methodology\": -0.14432234\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.66646177\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -8.3045044e-05\n",
      "          },\n",
      "          {\n",
      "            \"Pl\": -0.7914731\n",
      "          },\n",
      "          {\n",
      "            \"asma\": -0.0031377613\n",
      "          },\n",
      "          {\n",
      "            \" was\": -0.1391006\n",
      "          },\n",
      "          {\n",
      "            \" tested\": -0.0020034255\n",
      "          },\n",
      "          {\n",
      "            \" for\": -0.010400449\n",
      "          },\n",
      "          {\n",
      "            \" amp\": -0.28635666\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" enzyme - mediated immunoassay methodology\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786564,\n",
      "  \"id\": \"cmpl-4GHgKCQRLkB5NIXeePh33JogwCDsw\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "1it [00:01,  1.30s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: 4 .\n",
      "Diseases: 30 {19: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "2it [00:01,  1.09it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          873,\n",
      "          873,\n",
      "          873,\n",
      "          873,\n",
      "          873,\n",
      "          873,\n",
      "          873,\n",
      "          873\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.010510372,\n",
      "          -0.0010320023,\n",
      "          -0.25774306,\n",
      "          -0.13479705,\n",
      "          -0.0023730106,\n",
      "          -0.007326117,\n",
      "          -0.007979758,\n",
      "          -0.030622963\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"4\",\n",
      "          \" .\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"4\",\n",
      "          \" .\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \"\\n\": -0.010510372\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.0010320023\n",
      "          },\n",
      "          {\n",
      "            \"4\": -0.25774306\n",
      "          },\n",
      "          {\n",
      "            \" .\": -0.13479705\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.0023730106\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.007326117\n",
      "          },\n",
      "          {\n",
      "            \"4\": -0.007979758\n",
      "          },\n",
      "          {\n",
      "            \" .\": -0.030622963\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \"\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786565,\n",
      "  \"id\": \"cmpl-4GHgL6v5wBA3eKOCJoOoQc2JYBD23\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .\n",
      "Diseases: 30 {35320: 10, 874: 10, 547: 10, 6789: 10, 329: 10, 1440: 10, 12785: 10, 1528: 10, 357: 10, 604: 10, 4473: 10, 1220: 10, 1110: 10, 1267: 10, 287: 10, 337: 10, 22117: 10, 1141: 10, 543: 10, 262: 10, 2292: 10, 286: 10, 7104: 10, 3859: 10, 373: 10, 21588: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "3it [00:02,  1.24it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1001,\n",
      "          1003,\n",
      "          1005,\n",
      "          1005,\n",
      "          1005,\n",
      "          1005,\n",
      "          1005,\n",
      "          1005\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.24306794,\n",
      "          -0.0004051084,\n",
      "          -0.59074175,\n",
      "          -2.1649737e-05,\n",
      "          -0.22381988,\n",
      "          -0.0023847802,\n",
      "          -0.5220463,\n",
      "          -1.0506203\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" M\",\n",
      "          \"WM\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Sent\",\n",
      "          \"ence\",\n",
      "          \" (\",\n",
      "          \" in\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" M\": -0.24306794\n",
      "          },\n",
      "          {\n",
      "            \"WM\": -0.0004051084\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.59074175\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -2.1649737e-05\n",
      "          },\n",
      "          {\n",
      "            \"Sent\": -0.22381988\n",
      "          },\n",
      "          {\n",
      "            \"ence\": -0.0023847802\n",
      "          },\n",
      "          {\n",
      "            \" (\": -0.5220463\n",
      "          },\n",
      "          {\n",
      "            \" in\": -1.0506203\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" MWM\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786565,\n",
      "  \"id\": \"cmpl-4GHgLgHQJjsC4Yjf3RgrI3k9ytTK0\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .\n",
      "Diseases: 30 {32: 10, 2026: 10, 10527: 10, 2440: 10, 11248: 10, 324: 10, 505: 10, 10742: 10, 373: 10, 3917: 10, 351: 10, 257: 10, 352: 10, 764: 10, 362: 10, 357: 10, 6957: 10, 4064: 10, 14514: 10, 284: 10, 604: 10, 1267: 10, 1661: 10, 10402: 10, 329: 10, 17510: 10, 3008: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "4it [00:03,  1.42it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          986,\n",
      "          991,\n",
      "          994,\n",
      "          994,\n",
      "          994,\n",
      "          994,\n",
      "          994,\n",
      "          994\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.027523667,\n",
      "          -6.6619094e-07,\n",
      "          -0.18833578,\n",
      "          -6.623567e-05,\n",
      "          -0.056436796,\n",
      "          -1.3889661,\n",
      "          -0.7548082,\n",
      "          -0.5337293\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" sync\",\n",
      "          \"ope\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"A\",\n",
      "          \" 2\",\n",
      "          \",\",\n",
      "          \" 4\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" sync\": -0.027523667\n",
      "          },\n",
      "          {\n",
      "            \"ope\": -6.6619094e-07\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.18833578\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -6.623567e-05\n",
      "          },\n",
      "          {\n",
      "            \"A\": -0.056436796\n",
      "          },\n",
      "          {\n",
      "            \" 2\": -1.3889661\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.7548082\n",
      "          },\n",
      "          {\n",
      "            \" 4\": -0.5337293\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" syncope\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786566,\n",
      "  \"id\": \"cmpl-4GHgMCI3QgtSpEQxT6OSOb34dxg88\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .\n",
      "Diseases: 30 {464: 10, 18349: 10, 286: 10, 2563: 10, 532: 10, 3519: 10, 10795: 10, 1225: 10, 19687: 10, 373: 10, 6454: 10, 2440: 10, 287: 10, 262: 10, 716: 10, 75: 10, 375: 10, 541: 10, 500: 10, 1448: 10, 837: 10, 3573: 10, 379: 10, 257: 10, 10742: 10, 838: 10, 10527: 10, 583: 10, 1110: 10, 357: 10, 362: 10, 764: 10, 604: 10, 4064: 10, 329: 10, 4019: 10, 410: 10, 874: 10, 433: 10, 272: 10, 2162: 10, 513: 10, 718: 10, 642: 10, 657: 10, 5556: 10, 1478: 10, 1267: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "5it [00:03,  1.51it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1140,\n",
      "          1143,\n",
      "          1146,\n",
      "          1146,\n",
      "          1146,\n",
      "          1146,\n",
      "          1146,\n",
      "          1146\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.6413189,\n",
      "          -4.0040345e-06,\n",
      "          -0.6053973,\n",
      "          -0.00033796768,\n",
      "          -0.009650051,\n",
      "          -0.86854076,\n",
      "          -0.011808909,\n",
      "          -0.25088856\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" ed\",\n",
      "          \"ema\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"The\",\n",
      "          \" incidence\",\n",
      "          \" of\",\n",
      "          \" drug\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" ed\": -0.6413189\n",
      "          },\n",
      "          {\n",
      "            \"ema\": -4.0040345e-06\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.6053973\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.00033796768\n",
      "          },\n",
      "          {\n",
      "            \"The\": -0.009650051\n",
      "          },\n",
      "          {\n",
      "            \" incidence\": -0.86854076\n",
      "          },\n",
      "          {\n",
      "            \" of\": -0.011808909\n",
      "          },\n",
      "          {\n",
      "            \" drug\": -0.25088856\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" edema\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786567,\n",
      "  \"id\": \"cmpl-4GHgNpsqtnPgPHRQpz6c8rt7THEAy\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .\n",
      "Diseases: 30 {49: 10, 9189: 10, 2770: 10, 3640: 10, 547: 10, 4632: 10, 3550: 10, 72: 10, 41480: 10, 6157: 10, 351: 10, 1111: 10, 22088: 10, 291: 10, 290: 10, 1729: 10, 532: 10, 6273: 10, 2587: 10, 837: 10, 379: 10, 281: 10, 2811: 10, 10742: 10, 286: 10, 29637: 10, 25962: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "6it [00:04,  1.59it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1009,\n",
      "          1013,\n",
      "          1014,\n",
      "          1023,\n",
      "          1023,\n",
      "          1023,\n",
      "          1023,\n",
      "          1023\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.59316385,\n",
      "          -1.3422466e-05,\n",
      "          -0.0001010493,\n",
      "          -0.64572597,\n",
      "          -4.799487e-05,\n",
      "          -1.0412303,\n",
      "          -0.09634363,\n",
      "          -0.0025302155\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" ang\",\n",
      "          \"i\",\n",
      "          \"ographies\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"R\",\n",
      "          \"adi\",\n",
      "          \"ological\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" ang\": -0.59316385\n",
      "          },\n",
      "          {\n",
      "            \"i\": -1.3422466e-05\n",
      "          },\n",
      "          {\n",
      "            \"ographies\": -0.0001010493\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.64572597\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.799487e-05\n",
      "          },\n",
      "          {\n",
      "            \"R\": -1.0412303\n",
      "          },\n",
      "          {\n",
      "            \"adi\": -0.09634363\n",
      "          },\n",
      "          {\n",
      "            \"ological\": -0.0025302155\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" angiographies\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786567,\n",
      "  \"id\": \"cmpl-4GHgNc6sSQvwu3wQKJN4tfGFPE93q\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .\n",
      "Diseases: 30 {26591: 10, 532: 10, 17283: 10, 290: 10, 360: 10, 6080: 10, 31919: 10, 6605: 10, 262: 10, 8779: 10, 18268: 10, 8718: 10, 490: 10, 20730: 10, 355: 10, 880: 10, 29858: 10, 287: 10, 33334: 10, 20965: 10, 3842: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          984,\n",
      "          990,\n",
      "          994,\n",
      "          997,\n",
      "          998,\n",
      "          1004,\n",
      "          1008,\n",
      "          1017\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.23734213,\n",
      "          -1.2468796e-05,\n",
      "          -5.460492e-07,\n",
      "          -0.19455406,\n",
      "          -0.07757054,\n",
      "          -2.4543265e-06,\n",
      "          -0.014787904,\n",
      "          -0.26701227\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" hyper\",\n",
      "          \"ther\",\n",
      "          \"mia\",\n",
      "          \",\",\n",
      "          \" locom\",\n",
      "          \"otor\",\n",
      "          \" activity\",\n",
      "          \"\\n\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" hyper\": -0.23734213\n",
      "          },\n",
      "          {\n",
      "            \"ther\": -1.2468796e-05\n",
      "          },\n",
      "          {\n",
      "            \"mia\": -5.460492e-07\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.19455406\n",
      "          },\n",
      "          {\n",
      "            \" locom\": -0.07757054\n",
      "          },\n",
      "          {\n",
      "            \"otor\": -2.4543265e-06\n",
      "          },\n",
      "          {\n",
      "            \" activity\": -0.014787904\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.26701227\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" hyperthermia, locomotor activity\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786568,\n",
      "  \"id\": \"cmpl-4GHgOC9TKtmT5Wj04CcWwdbGDvi02\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "7it [00:04,  1.55it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .\n",
      "Diseases: 30 {10265: 10, 262: 10, 1803: 10, 273: 10, 290: 10, 865: 10, 4597: 10, 9517: 10, 544: 10, 3048: 10, 286: 10, 10774: 10, 1031: 10, 14453: 10, 547: 10, 32424: 10, 287: 10, 10726: 10, 279: 10, 3247: 10, 418: 10, 259: 10, 5716: 10, 6006: 10, 49: 10, 357: 10, 299: 10, 796: 10, 604: 10, 1267: 10, 355: 10, 3688: 10, 284: 10, 41539: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1026,\n",
      "          1030,\n",
      "          1032,\n",
      "          1037,\n",
      "          1038,\n",
      "          1040,\n",
      "          1043,\n",
      "          1045,\n",
      "          1047,\n",
      "          1048,\n",
      "          1051,\n",
      "          1052,\n",
      "          1052,\n",
      "          1052,\n",
      "          1052,\n",
      "          1052\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -1.0802063,\n",
      "          -1.7400124e-06,\n",
      "          -4.721163e-06,\n",
      "          -0.07705615,\n",
      "          -1.1530445,\n",
      "          -0.00019189759,\n",
      "          -3.201996e-05,\n",
      "          -9.130952e-06,\n",
      "          -0.19297272,\n",
      "          -0.64678395,\n",
      "          -1.42597355e-05,\n",
      "          -0.5205776,\n",
      "          -4.751897e-05,\n",
      "          -0.6354086,\n",
      "          -0.74485767,\n",
      "          -0.8327487\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" cir\",\n",
      "          \"az\",\n",
      "          \"oline\",\n",
      "          \",\",\n",
      "          \" p\",\n",
      "          \"raz\",\n",
      "          \"os\",\n",
      "          \"in\",\n",
      "          \",\",\n",
      "          \" SH\",\n",
      "          \"R\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"R\",\n",
      "          \"az\",\n",
      "          \"in\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" cir\": -1.0802063\n",
      "          },\n",
      "          {\n",
      "            \"az\": -1.7400124e-06\n",
      "          },\n",
      "          {\n",
      "            \"oline\": -4.721163e-06\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.07705615\n",
      "          },\n",
      "          {\n",
      "            \" p\": -1.1530445\n",
      "          },\n",
      "          {\n",
      "            \"raz\": -0.00019189759\n",
      "          },\n",
      "          {\n",
      "            \"os\": -3.201996e-05\n",
      "          },\n",
      "          {\n",
      "            \"in\": -9.130952e-06\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.19297272\n",
      "          },\n",
      "          {\n",
      "            \" SH\": -0.64678395\n",
      "          },\n",
      "          {\n",
      "            \"R\": -1.42597355e-05\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.5205776\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.751897e-05\n",
      "          },\n",
      "          {\n",
      "            \"R\": -0.6354086\n",
      "          },\n",
      "          {\n",
      "            \"az\": -0.74485767\n",
      "          },\n",
      "          {\n",
      "            \"in\": -0.8327487\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" cirazoline, prazosin, SHR\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786568,\n",
      "  \"id\": \"cmpl-4GHgO3UsIc1UEZIcUt6B8v59pIOEv\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "8it [00:06,  1.27it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Arterial thromboembolism is a recognized complication of systemic heparin therapy .\n",
      "Diseases: 30 {3163: 10, 353: 10, 498: 10, 294: 10, 398: 10, 2127: 10, 24419: 10, 349: 10, 1042: 10, 318: 10, 257: 10, 8018: 10, 45185: 10, 286: 10, 21971: 10, 339: 10, 1845: 10, 259: 10, 9102: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "9it [00:06,  1.43it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          953,\n",
      "          956,\n",
      "          959,\n",
      "          961,\n",
      "          964,\n",
      "          966,\n",
      "          969,\n",
      "          969\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.2559922,\n",
      "          -3.076318e-07,\n",
      "          -4.6010214e-06,\n",
      "          -5.0856816e-05,\n",
      "          -2.3360508e-06,\n",
      "          -2.0815281e-05,\n",
      "          -0.66624755,\n",
      "          -2.3912831e-05\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" th\",\n",
      "          \"rom\",\n",
      "          \"bo\",\n",
      "          \"emb\",\n",
      "          \"ol\",\n",
      "          \"ism\",\n",
      "          \"\\n\",\n",
      "          \"\\n\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" th\": -0.2559922\n",
      "          },\n",
      "          {\n",
      "            \"rom\": -3.076318e-07\n",
      "          },\n",
      "          {\n",
      "            \"bo\": -4.6010214e-06\n",
      "          },\n",
      "          {\n",
      "            \"emb\": -5.0856816e-05\n",
      "          },\n",
      "          {\n",
      "            \"ol\": -2.3360508e-06\n",
      "          },\n",
      "          {\n",
      "            \"ism\": -2.0815281e-05\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.66624755\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -2.3912831e-05\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" thromboembolism\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786570,\n",
      "  \"id\": \"cmpl-4GHgQobvmSjCZ4zLq8d3e1dz3V8nn\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .\n",
      "Diseases: 30 {14291: 10, 3662: 10, 286: 10, 777: 10, 6554: 10, 837: 10, 262: 10, 4931: 10, 290: 10, 4922: 10, 7751: 10, 291: 10, 1741: 10, 547: 10, 15276: 10, 22632: 10, 319: 10, 257: 10, 1440: 10, 966: 10, 5046: 10, 416: 10, 530: 10, 20725: 10, 508: 10, 373: 10, 38497: 10, 284: 10, 2563: 10, 17169: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "10it [00:07,  1.55it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1063,\n",
      "          1068,\n",
      "          1070,\n",
      "          1077,\n",
      "          1077,\n",
      "          1077,\n",
      "          1077,\n",
      "          1077\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.2021421,\n",
      "          -1.6207987e-06,\n",
      "          -5.79217e-06,\n",
      "          -0.1773889,\n",
      "          -9.251094e-06,\n",
      "          -0.57734597,\n",
      "          -0.004984241,\n",
      "          -0.6590793\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" fasc\",\n",
      "          \"ic\",\n",
      "          \"ulation\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Sent\",\n",
      "          \"ence\",\n",
      "          \":\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" fasc\": -0.2021421\n",
      "          },\n",
      "          {\n",
      "            \"ic\": -1.6207987e-06\n",
      "          },\n",
      "          {\n",
      "            \"ulation\": -5.79217e-06\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.1773889\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -9.251094e-06\n",
      "          },\n",
      "          {\n",
      "            \"Sent\": -0.57734597\n",
      "          },\n",
      "          {\n",
      "            \"ence\": -0.004984241\n",
      "          },\n",
      "          {\n",
      "            \":\": -0.6590793\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" fasciculation\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786570,\n",
      "  \"id\": \"cmpl-4GHgQzenh0853gqj9SNvKsurHC9Zj\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .\n",
      "Diseases: 30 {2514: 10, 3128: 10, 837: 10, 691: 10, 1115: 10, 2663: 10, 286: 10, 24715: 10, 3917: 10, 351: 10, 30139: 10, 38571: 10, 259: 10, 347: 10, 423: 10, 587: 10, 2098: 10, 287: 10, 262: 10, 9285: 10, 475: 10, 11409: 10, 9549: 10, 815: 10, 307: 10, 3910: 10, 2785: 10, 329: 10, 428: 10, 4071: 10, 12681: 10, 1245: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "11it [00:07,  1.64it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1067,\n",
      "          1076,\n",
      "          1076,\n",
      "          1076,\n",
      "          1076,\n",
      "          1076,\n",
      "          1076,\n",
      "          1076\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.09579987,\n",
      "          -0.5974221,\n",
      "          -2.6180607e-05,\n",
      "          -0.38284847,\n",
      "          -0.120035045,\n",
      "          -0.58090466,\n",
      "          -0.22149591,\n",
      "          -0.0067953602\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" seizures\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"To\",\n",
      "          \" date\",\n",
      "          \" ,\",\n",
      "          \" only\",\n",
      "          \" three\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" seizures\": -0.09579987\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.5974221\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -2.6180607e-05\n",
      "          },\n",
      "          {\n",
      "            \"To\": -0.38284847\n",
      "          },\n",
      "          {\n",
      "            \" date\": -0.120035045\n",
      "          },\n",
      "          {\n",
      "            \" ,\": -0.58090466\n",
      "          },\n",
      "          {\n",
      "            \" only\": -0.22149591\n",
      "          },\n",
      "          {\n",
      "            \" three\": -0.0067953602\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" seizures\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786571,\n",
      "  \"id\": \"cmpl-4GHgRtuzEXZvAr9rpfW1KhnjIOyJo\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Data on mid - and long - term LMWH administration in these patients are sparse .\n",
      "Diseases: 30 {6601: 10, 319: 10, 3095: 10, 532: 10, 290: 10, 890: 10, 3381: 10, 37125: 10, 12418: 10, 3662: 10, 287: 10, 777: 10, 3871: 10, 389: 10, 29877: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "12it [00:08,  1.73it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          950,\n",
      "          953,\n",
      "          955,\n",
      "          970,\n",
      "          970,\n",
      "          970,\n",
      "          970,\n",
      "          970\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.43177155,\n",
      "          -7.818713e-06,\n",
      "          -1.0733017,\n",
      "          -0.63162696,\n",
      "          -6.921402e-05,\n",
      "          -0.5769221,\n",
      "          -0.6341583,\n",
      "          -0.3695818\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" LM\",\n",
      "          \"WH\",\n",
      "          \" administration\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Data\",\n",
      "          \" on\",\n",
      "          \" mid\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" LM\": -0.43177155\n",
      "          },\n",
      "          {\n",
      "            \"WH\": -7.818713e-06\n",
      "          },\n",
      "          {\n",
      "            \" administration\": -1.0733017\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.63162696\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -6.921402e-05\n",
      "          },\n",
      "          {\n",
      "            \"Data\": -0.5769221\n",
      "          },\n",
      "          {\n",
      "            \" on\": -0.6341583\n",
      "          },\n",
      "          {\n",
      "            \" mid\": -0.3695818\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" LMWH administration\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786571,\n",
      "  \"id\": \"cmpl-4GHgR1v1c9zCOHNqS5IA6QxBbGm4s\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .\n",
      "Diseases: 30 {34: 10, 541: 10, 305: 10, 2704: 10, 1140: 10, 330: 10, 259: 10, 468: 10, 587: 10, 3917: 10, 351: 10, 1811: 10, 1735: 10, 3048: 10, 1390: 10, 987: 10, 18167: 10, 497: 10, 746: 10, 27398: 10, 290: 10, 16869: 10, 3366: 10, 13370: 10, 281: 10, 22859: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          985,\n",
      "          989,\n",
      "          992,\n",
      "          995,\n",
      "          998,\n",
      "          1002,\n",
      "          1003,\n",
      "          1009,\n",
      "          1016,\n",
      "          1019,\n",
      "          1021,\n",
      "          1026,\n",
      "          1026,\n",
      "          1026,\n",
      "          1026,\n",
      "          1026\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.35075137,\n",
      "          -6.3900848e-06,\n",
      "          -7.8540467e-07,\n",
      "          -0.0009255631,\n",
      "          -1.8601542e-06,\n",
      "          -0.037411954,\n",
      "          -0.092737556,\n",
      "          -4.277735e-07,\n",
      "          -0.0004606249,\n",
      "          -1.5006569e-06,\n",
      "          -1.688045e-05,\n",
      "          -0.0850463,\n",
      "          -0.00010545909,\n",
      "          -0.12710324,\n",
      "          -0.36276844,\n",
      "          -0.00026862667\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" hem\",\n",
      "          \"oly\",\n",
      "          \"tic\",\n",
      "          \" an\",\n",
      "          \"emia\",\n",
      "          \",\",\n",
      "          \" inter\",\n",
      "          \"stitial\",\n",
      "          \" ne\",\n",
      "          \"ph\",\n",
      "          \"ritis\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"C\",\n",
      "          \"ip\",\n",
      "          \"ro\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" hem\": -0.35075137\n",
      "          },\n",
      "          {\n",
      "            \"oly\": -6.3900848e-06\n",
      "          },\n",
      "          {\n",
      "            \"tic\": -7.8540467e-07\n",
      "          },\n",
      "          {\n",
      "            \" an\": -0.0009255631\n",
      "          },\n",
      "          {\n",
      "            \"emia\": -1.8601542e-06\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.037411954\n",
      "          },\n",
      "          {\n",
      "            \" inter\": -0.092737556\n",
      "          },\n",
      "          {\n",
      "            \"stitial\": -4.277735e-07\n",
      "          },\n",
      "          {\n",
      "            \" ne\": -0.0004606249\n",
      "          },\n",
      "          {\n",
      "            \"ph\": -1.5006569e-06\n",
      "          },\n",
      "          {\n",
      "            \"ritis\": -1.688045e-05\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.0850463\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.00010545909\n",
      "          },\n",
      "          {\n",
      "            \"C\": -0.12710324\n",
      "          },\n",
      "          {\n",
      "            \"ip\": -0.36276844\n",
      "          },\n",
      "          {\n",
      "            \"ro\": -0.00026862667\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" hemolytic anemia, interstitial nephritis\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786572,\n",
      "  \"id\": \"cmpl-4GHgSFTjMW28zdibHH7RJ23sqgKwy\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "13it [00:09,  1.46it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .\n",
      "Diseases: 30 {1135: 10, 12565: 10, 262: 10, 2776: 10, 1022: 10, 25419: 10, 341: 10, 286: 10, 26234: 10, 5584: 10, 16890: 10, 290: 10, 14916: 10, 399: 10, 532: 10, 27664: 10, 288: 10, 355: 10, 3911: 10, 378: 10, 357: 10, 28692: 10, 5631: 10, 1267: 10, 20099: 10, 706: 10, 11943: 10, 897: 10, 498: 10, 43948: 10, 1708: 10, 257: 10, 1729: 10, 259: 10, 73: 10, 16421: 10, 16654: 10, 419: 10, 291: 10, 1609: 10, 75: 10, 4241: 10, 287: 10, 13623: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1104,\n",
      "          1109,\n",
      "          1111,\n",
      "          1114,\n",
      "          1123,\n",
      "          1124,\n",
      "          1126,\n",
      "          1129,\n",
      "          1131,\n",
      "          1135,\n",
      "          1136,\n",
      "          1141,\n",
      "          1142,\n",
      "          1149,\n",
      "          1155,\n",
      "          1163,\n",
      "          1164,\n",
      "          1167,\n",
      "          1169,\n",
      "          1179,\n",
      "          1179,\n",
      "          1179,\n",
      "          1179,\n",
      "          1179\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -1.1960199,\n",
      "          -6.2699432e-06,\n",
      "          -3.595572e-05,\n",
      "          -0.0037834318,\n",
      "          -0.1746963,\n",
      "          -1.2401848,\n",
      "          -0.001477988,\n",
      "          -9.490449e-06,\n",
      "          -0.00062289607,\n",
      "          -0.00011440349,\n",
      "          -1.2622395e-06,\n",
      "          -0.25416052,\n",
      "          -1.3590548,\n",
      "          -0.02419772,\n",
      "          -0.0032647687,\n",
      "          -0.39582416,\n",
      "          -0.5772386,\n",
      "          -4.7279616e-05,\n",
      "          -0.094983906,\n",
      "          -0.34033602,\n",
      "          -4.751897e-05,\n",
      "          -0.19819364,\n",
      "          -0.03271338,\n",
      "          -0.02975562\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" neur\",\n",
      "          \"ax\",\n",
      "          \"ial\",\n",
      "          \" morphine\",\n",
      "          \",\",\n",
      "          \" a\",\n",
      "          \"ort\",\n",
      "          \"ic\",\n",
      "          \" occ\",\n",
      "          \"l\",\n",
      "          \"usion\",\n",
      "          \",\",\n",
      "          \" spinal\",\n",
      "          \" motor\",\n",
      "          \" neurons\",\n",
      "          \",\",\n",
      "          \" NM\",\n",
      "          \"DA\",\n",
      "          \" receptors\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"We\",\n",
      "          \" investigated\",\n",
      "          \" the\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" neur\": -1.1960199\n",
      "          },\n",
      "          {\n",
      "            \"ax\": -6.2699432e-06\n",
      "          },\n",
      "          {\n",
      "            \"ial\": -3.595572e-05\n",
      "          },\n",
      "          {\n",
      "            \" morphine\": -0.0037834318\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.1746963\n",
      "          },\n",
      "          {\n",
      "            \" a\": -1.2401848\n",
      "          },\n",
      "          {\n",
      "            \"ort\": -0.001477988\n",
      "          },\n",
      "          {\n",
      "            \"ic\": -9.490449e-06\n",
      "          },\n",
      "          {\n",
      "            \" occ\": -0.00062289607\n",
      "          },\n",
      "          {\n",
      "            \"l\": -0.00011440349\n",
      "          },\n",
      "          {\n",
      "            \"usion\": -1.2622395e-06\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.25416052\n",
      "          },\n",
      "          {\n",
      "            \" spinal\": -1.3590548\n",
      "          },\n",
      "          {\n",
      "            \" motor\": -0.02419772\n",
      "          },\n",
      "          {\n",
      "            \" neurons\": -0.0032647687\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.39582416\n",
      "          },\n",
      "          {\n",
      "            \" NM\": -0.5772386\n",
      "          },\n",
      "          {\n",
      "            \"DA\": -4.7279616e-05\n",
      "          },\n",
      "          {\n",
      "            \" receptors\": -0.094983906\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.34033602\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.751897e-05\n",
      "          },\n",
      "          {\n",
      "            \"We\": -0.19819364\n",
      "          },\n",
      "          {\n",
      "            \" investigated\": -0.03271338\n",
      "          },\n",
      "          {\n",
      "            \" the\": -0.02975562\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" neuraxial morphine, aortic occlusion, spinal motor neurons, NMDA receptors\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786573,\n",
      "  \"id\": \"cmpl-4GHgTHNHd2gdSOBFadGAAbUmsJrUh\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "14it [00:10,  1.07it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .\n",
      "Diseases: 30 {464: 10, 1459: 10, 10081: 10, 341: 10, 8435: 10, 34322: 10, 3220: 10, 262: 10, 2494: 10, 286: 10, 4388: 10, 357: 10, 1498: 10, 284: 10, 1844: 10, 19560: 10, 2050: 10, 1267: 10, 618: 10, 1262: 10, 36017: 10, 1150: 10, 316: 10, 296: 10, 39422: 10, 3436: 10, 422: 10, 10495: 10, 764: 10, 807: 10, 4064: 10, 10111: 10, 718: 10, 350: 10, 796: 10, 657: 10, 3571: 10, 24: 10, 837: 10, 8868: 10, 9079: 10, 329: 10, 9224: 10, 84: 10, 4520: 10, 28145: 10, 30973: 10, 65: 10, 1287: 10, 287: 10, 1785: 10, 5287: 10, 351: 10, 290: 10, 11832: 10, 1612: 10, 7628: 10, 640: 10, 416: 10, 838: 10, 949: 10, 1279: 10, 16: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1248,\n",
      "          1252,\n",
      "          1257,\n",
      "          1258,\n",
      "          1262,\n",
      "          1265,\n",
      "          1267,\n",
      "          1269,\n",
      "          1274,\n",
      "          1275,\n",
      "          1280,\n",
      "          1284,\n",
      "          1285,\n",
      "          1289,\n",
      "          1290,\n",
      "          1299,\n",
      "          1304,\n",
      "          1304,\n",
      "          1304,\n",
      "          1304,\n",
      "          1304,\n",
      "          1304,\n",
      "          1304,\n",
      "          1304\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.07127039,\n",
      "          -6.194322e-05,\n",
      "          -0.42606035,\n",
      "          -0.8718517,\n",
      "          -0.00017878464,\n",
      "          -8.924483e-05,\n",
      "          -1.5567284e-05,\n",
      "          -0.00013800588,\n",
      "          -0.36190552,\n",
      "          -0.44892573,\n",
      "          -8.8051806e-05,\n",
      "          -4.1080762e-05,\n",
      "          -2.8138238e-06,\n",
      "          -0.6266221,\n",
      "          -0.54026175,\n",
      "          -0.30977502,\n",
      "          -0.15602894,\n",
      "          -0.0003282479,\n",
      "          -0.05186666,\n",
      "          -0.9661186,\n",
      "          -0.5559598,\n",
      "          -1.1753544e-05,\n",
      "          -0.0009549785,\n",
      "          -0.024242481\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" sed\",\n",
      "          \"ation\",\n",
      "          \",\",\n",
      "          \" dex\",\n",
      "          \"med\",\n",
      "          \"et\",\n",
      "          \"om\",\n",
      "          \"idine\",\n",
      "          \",\",\n",
      "          \" pent\",\n",
      "          \"obar\",\n",
      "          \"b\",\n",
      "          \"ital\",\n",
      "          \",\",\n",
      "          \" recovery\",\n",
      "          \" time\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"The\",\n",
      "          \" current\",\n",
      "          \" sed\",\n",
      "          \"ation\",\n",
      "          \" protocol\",\n",
      "          \" progressively\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" sed\": -0.07127039\n",
      "          },\n",
      "          {\n",
      "            \"ation\": -6.194322e-05\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.42606035\n",
      "          },\n",
      "          {\n",
      "            \" dex\": -0.8718517\n",
      "          },\n",
      "          {\n",
      "            \"med\": -0.00017878464\n",
      "          },\n",
      "          {\n",
      "            \"et\": -8.924483e-05\n",
      "          },\n",
      "          {\n",
      "            \"om\": -1.5567284e-05\n",
      "          },\n",
      "          {\n",
      "            \"idine\": -0.00013800588\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.36190552\n",
      "          },\n",
      "          {\n",
      "            \" pent\": -0.44892573\n",
      "          },\n",
      "          {\n",
      "            \"obar\": -8.8051806e-05\n",
      "          },\n",
      "          {\n",
      "            \"b\": -4.1080762e-05\n",
      "          },\n",
      "          {\n",
      "            \"ital\": -2.8138238e-06\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.6266221\n",
      "          },\n",
      "          {\n",
      "            \" recovery\": -0.54026175\n",
      "          },\n",
      "          {\n",
      "            \" time\": -0.30977502\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.15602894\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.0003282479\n",
      "          },\n",
      "          {\n",
      "            \"The\": -0.05186666\n",
      "          },\n",
      "          {\n",
      "            \" current\": -0.9661186\n",
      "          },\n",
      "          {\n",
      "            \" sed\": -0.5559598\n",
      "          },\n",
      "          {\n",
      "            \"ation\": -1.1753544e-05\n",
      "          },\n",
      "          {\n",
      "            \" protocol\": -0.0009549785\n",
      "          },\n",
      "          {\n",
      "            \" progressively\": -0.024242481\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" sedation, dexmedetomidine, pentobarbital, recovery time\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786574,\n",
      "  \"id\": \"cmpl-4GHgU3mpOKLn6saJlPTT2kgk8t7wa\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "15it [00:12,  1.14s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .\n",
      "Diseases: 30 {5317: 10, 430: 10, 37320: 10, 3833: 10, 532: 10, 21683: 10, 33624: 10, 547: 10, 3177: 10, 257: 10, 1943: 10, 357: 10, 1281: 10, 27173: 10, 314: 10, 3185: 10, 286: 10, 718: 10, 2310: 10, 8085: 10, 367: 10, 70: 10, 351: 10, 393: 10, 1231: 10, 3224: 10, 14103: 10, 1267: 10, 287: 10, 7600: 10, 764: 10, 352: 10, 4064: 10, 2951: 10, 379: 10, 614: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1060,\n",
      "          1062,\n",
      "          1064,\n",
      "          1065,\n",
      "          1067,\n",
      "          1069,\n",
      "          1078,\n",
      "          1089,\n",
      "          1090,\n",
      "          1092,\n",
      "          1094,\n",
      "          1103,\n",
      "          1113,\n",
      "          1113,\n",
      "          1113,\n",
      "          1113\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.34748715,\n",
      "          -1.676031e-05,\n",
      "          -0.9985128,\n",
      "          -0.34649122,\n",
      "          -1.5448071e-05,\n",
      "          -0.3275152,\n",
      "          -0.41431662,\n",
      "          -0.61438847,\n",
      "          -0.6425977,\n",
      "          -6.6294406e-06,\n",
      "          -0.25858712,\n",
      "          -0.042165354,\n",
      "          -0.6380662,\n",
      "          -5.0976956e-05,\n",
      "          -0.59266216,\n",
      "          -0.0048773214\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" I\",\n",
      "          \"OP\",\n",
      "          \",\",\n",
      "          \" I\",\n",
      "          \"OP\",\n",
      "          \" lowering\",\n",
      "          \" medication\",\n",
      "          \",\",\n",
      "          \" I\",\n",
      "          \"OP\",\n",
      "          \" lowering\",\n",
      "          \" surgeries\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Sent\",\n",
      "          \"ence\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" I\": -0.34748715\n",
      "          },\n",
      "          {\n",
      "            \"OP\": -1.676031e-05\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.9985128\n",
      "          },\n",
      "          {\n",
      "            \" I\": -0.34649122\n",
      "          },\n",
      "          {\n",
      "            \"OP\": -1.5448071e-05\n",
      "          },\n",
      "          {\n",
      "            \" lowering\": -0.3275152\n",
      "          },\n",
      "          {\n",
      "            \" medication\": -0.41431662\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.61438847\n",
      "          },\n",
      "          {\n",
      "            \" I\": -0.6425977\n",
      "          },\n",
      "          {\n",
      "            \"OP\": -6.6294406e-06\n",
      "          },\n",
      "          {\n",
      "            \" lowering\": -0.25858712\n",
      "          },\n",
      "          {\n",
      "            \" surgeries\": -0.042165354\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.6380662\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -5.0976956e-05\n",
      "          },\n",
      "          {\n",
      "            \"Sent\": -0.59266216\n",
      "          },\n",
      "          {\n",
      "            \"ence\": -0.0048773214\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" IOP, IOP lowering medication, IOP lowering surgeries\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786576,\n",
      "  \"id\": \"cmpl-4GHgWjDJXX3zZ3dsMf7RG5wTG6Boe\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "16it [00:13,  1.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .\n",
      "Diseases: 30 {3198: 10, 550: 10, 14805: 10, 275: 10, 291: 10, 17723: 10, 312: 10, 257: 10, 419: 10, 22580: 10, 290: 10, 11607: 10, 842: 10, 3686: 10, 3780: 10, 326: 10, 28775: 10, 284: 10, 10768: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "17it [00:14,  1.01it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          982,\n",
      "          984,\n",
      "          987,\n",
      "          989,\n",
      "          993,\n",
      "          996,\n",
      "          1003,\n",
      "          1003\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.4387881,\n",
      "          -0.0017181013,\n",
      "          -1.022884e-06,\n",
      "          -0.039033893,\n",
      "          -2.3360508e-06,\n",
      "          -5.3955304e-05,\n",
      "          -0.59490955,\n",
      "          -2.9636725e-05\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" a\",\n",
      "          \"ort\",\n",
      "          \"ic\",\n",
      "          \" reg\",\n",
      "          \"urg\",\n",
      "          \"itation\",\n",
      "          \"\\n\",\n",
      "          \"\\n\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" a\": -0.4387881\n",
      "          },\n",
      "          {\n",
      "            \"ort\": -0.0017181013\n",
      "          },\n",
      "          {\n",
      "            \"ic\": -1.022884e-06\n",
      "          },\n",
      "          {\n",
      "            \" reg\": -0.039033893\n",
      "          },\n",
      "          {\n",
      "            \"urg\": -2.3360508e-06\n",
      "          },\n",
      "          {\n",
      "            \"itation\": -5.3955304e-05\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.59490955\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -2.9636725e-05\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" aortic regurgitation\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786577,\n",
      "  \"id\": \"cmpl-4GHgXm5oxKxLej2e7Yy0wOfUu197B\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .\n",
      "Diseases: 30 {1026: 10, 318: 10, 7151: 10, 326: 10, 466: 10, 87: 10, 273: 10, 549: 10, 291: 10, 259: 10, 35997: 10, 307: 10, 18939: 10, 10770: 10, 287: 10, 1751: 10, 351: 10, 5187: 10, 907: 10, 22359: 10, 286: 10, 262: 10, 1364: 10, 21919: 10, 508: 10, 3328: 10, 1281: 10, 27173: 10, 47537: 10, 3920: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1021,\n",
      "          1025,\n",
      "          1027,\n",
      "          1033,\n",
      "          1034,\n",
      "          1039,\n",
      "          1046,\n",
      "          1047,\n",
      "          1052,\n",
      "          1061,\n",
      "          1067,\n",
      "          1073,\n",
      "          1073,\n",
      "          1073,\n",
      "          1073,\n",
      "          1073\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.6128085,\n",
      "          -1.0323977e-05,\n",
      "          -0.0015270549,\n",
      "          -0.508028,\n",
      "          -0.5791238,\n",
      "          -0.014417882,\n",
      "          -0.48116127,\n",
      "          -0.39000258,\n",
      "          -0.00015481713,\n",
      "          -0.006645222,\n",
      "          -4.361666e-06,\n",
      "          -0.4856995,\n",
      "          -4.048565e-05,\n",
      "          -0.3641388,\n",
      "          -0.00060882105,\n",
      "          -0.32039914\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" Wil\",\n",
      "          \"ms\",\n",
      "          \" tumor\",\n",
      "          \",\",\n",
      "          \" left\",\n",
      "          \" kidney\",\n",
      "          \",\",\n",
      "          \" post\",\n",
      "          \"operative\",\n",
      "          \" irrad\",\n",
      "          \"iation\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"It\",\n",
      "          \" is\",\n",
      "          \" recommended\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" Wil\": -0.6128085\n",
      "          },\n",
      "          {\n",
      "            \"ms\": -1.0323977e-05\n",
      "          },\n",
      "          {\n",
      "            \" tumor\": -0.0015270549\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.508028\n",
      "          },\n",
      "          {\n",
      "            \" left\": -0.5791238\n",
      "          },\n",
      "          {\n",
      "            \" kidney\": -0.014417882\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.48116127\n",
      "          },\n",
      "          {\n",
      "            \" post\": -0.39000258\n",
      "          },\n",
      "          {\n",
      "            \"operative\": -0.00015481713\n",
      "          },\n",
      "          {\n",
      "            \" irrad\": -0.006645222\n",
      "          },\n",
      "          {\n",
      "            \"iation\": -4.361666e-06\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.4856995\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.048565e-05\n",
      "          },\n",
      "          {\n",
      "            \"It\": -0.3641388\n",
      "          },\n",
      "          {\n",
      "            \" is\": -0.00060882105\n",
      "          },\n",
      "          {\n",
      "            \" recommended\": -0.32039914\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" Wilms tumor, left kidney, postoperative irradiation\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786578,\n",
      "  \"id\": \"cmpl-4GHgYFsHps4WQVx1AzKmGE39XCjVc\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "18it [00:15,  1.05s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .\n",
      "Diseases: 30 {5990: 10, 1140: 10, 271: 10, 2586: 10, 287: 10, 32070: 10, 16911: 10, 290: 10, 8718: 10, 489: 10, 3477: 10, 662: 10, 710: 10, 20106: 10, 14383: 10, 35258: 10, 18268: 10, 10693: 10, 416: 10, 5323: 10, 39719: 10, 17130: 10, 532: 10, 39601: 10, 1734: 10, 17910: 10, 620: 10, 4685: 10, 485: 10, 547: 10, 11068: 10, 1554: 10, 18958: 10, 1146: 10, 11538: 10, 21145: 10, 404: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1056,\n",
      "          1062,\n",
      "          1066,\n",
      "          1067,\n",
      "          1073,\n",
      "          1075,\n",
      "          1080,\n",
      "          1084,\n",
      "          1086,\n",
      "          1089,\n",
      "          1094,\n",
      "          1100,\n",
      "          1108,\n",
      "          1108,\n",
      "          1108,\n",
      "          1108\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.80928993,\n",
      "          -0.00033594016,\n",
      "          -0.15460661,\n",
      "          -0.31590062,\n",
      "          -2.2365928e-05,\n",
      "          -9.055464e-07,\n",
      "          -0.06127049,\n",
      "          -2.3675353e-05,\n",
      "          -0.0003917514,\n",
      "          -9.055464e-07,\n",
      "          -0.032720525,\n",
      "          -0.005720058,\n",
      "          -0.51186955,\n",
      "          -4.847264e-05,\n",
      "          -0.65036255,\n",
      "          -0.0015682494\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" hepat\",\n",
      "          \"omas\",\n",
      "          \",\",\n",
      "          \" hyper\",\n",
      "          \"pl\",\n",
      "          \"astic\",\n",
      "          \" pre\",\n",
      "          \"ne\",\n",
      "          \"opl\",\n",
      "          \"astic\",\n",
      "          \" liver\",\n",
      "          \" lesions\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Per\",\n",
      "          \"ox\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" hepat\": -0.80928993\n",
      "          },\n",
      "          {\n",
      "            \"omas\": -0.00033594016\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.15460661\n",
      "          },\n",
      "          {\n",
      "            \" hyper\": -0.31590062\n",
      "          },\n",
      "          {\n",
      "            \"pl\": -2.2365928e-05\n",
      "          },\n",
      "          {\n",
      "            \"astic\": -9.055464e-07\n",
      "          },\n",
      "          {\n",
      "            \" pre\": -0.06127049\n",
      "          },\n",
      "          {\n",
      "            \"ne\": -2.3675353e-05\n",
      "          },\n",
      "          {\n",
      "            \"opl\": -0.0003917514\n",
      "          },\n",
      "          {\n",
      "            \"astic\": -9.055464e-07\n",
      "          },\n",
      "          {\n",
      "            \" liver\": -0.032720525\n",
      "          },\n",
      "          {\n",
      "            \" lesions\": -0.005720058\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.51186955\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.847264e-05\n",
      "          },\n",
      "          {\n",
      "            \"Per\": -0.65036255\n",
      "          },\n",
      "          {\n",
      "            \"ox\": -0.0015682494\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" hepatomas, hyperplastic preneoplastic liver lesions\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786579,\n",
      "  \"id\": \"cmpl-4GHgZvQGwHqrLHujY696B6V4rw8bt\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "19it [00:16,  1.06s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .\n",
      "Diseases: 30 {37: 10, 10254: 10, 257: 10, 489: 10, 3477: 10, 281: 10, 22859: 10, 1708: 10, 39867: 10, 3662: 10, 286: 10, 267: 10, 48118: 10, 9383: 10, 20207: 10, 696: 10, 831: 10, 27045: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          956,\n",
      "          958,\n",
      "          960,\n",
      "          965,\n",
      "          968,\n",
      "          972,\n",
      "          973,\n",
      "          981,\n",
      "          996,\n",
      "          997,\n",
      "          999,\n",
      "          1005,\n",
      "          1008,\n",
      "          1014,\n",
      "          1017,\n",
      "          1020,\n",
      "          1024,\n",
      "          1024,\n",
      "          1024,\n",
      "          1024,\n",
      "          1024,\n",
      "          1024,\n",
      "          1024,\n",
      "          1024\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.068988055,\n",
      "          -2.9311614e-06,\n",
      "          -1.8841804e-07,\n",
      "          -0.0006612456,\n",
      "          -2.0966954e-06,\n",
      "          -0.557252,\n",
      "          -0.37631476,\n",
      "          -0.21242705,\n",
      "          -0.6227313,\n",
      "          -0.2035143,\n",
      "          -1.8668587e-05,\n",
      "          -1.2231317e-05,\n",
      "          -0.44023326,\n",
      "          -4.1232483e-06,\n",
      "          -4.277735e-07,\n",
      "          -1.0561456e-05,\n",
      "          -0.04787185,\n",
      "          -4.501652e-05,\n",
      "          -0.1910158,\n",
      "          -0.02793026,\n",
      "          -0.21065208,\n",
      "          -9.370307e-06,\n",
      "          -6.6619094e-07,\n",
      "          -0.000280908\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" a\",\n",
      "          \"pl\",\n",
      "          \"astic\",\n",
      "          \" an\",\n",
      "          \"emia\",\n",
      "          \",\",\n",
      "          \" topical\",\n",
      "          \" administration\",\n",
      "          \",\",\n",
      "          \" o\",\n",
      "          \"phthal\",\n",
      "          \"mic\",\n",
      "          \" chlor\",\n",
      "          \"amp\",\n",
      "          \"hen\",\n",
      "          \"icol\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"F\",\n",
      "          \"atal\",\n",
      "          \" a\",\n",
      "          \"pl\",\n",
      "          \"astic\",\n",
      "          \" an\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" a\": -0.068988055\n",
      "          },\n",
      "          {\n",
      "            \"pl\": -2.9311614e-06\n",
      "          },\n",
      "          {\n",
      "            \"astic\": -1.8841804e-07\n",
      "          },\n",
      "          {\n",
      "            \" an\": -0.0006612456\n",
      "          },\n",
      "          {\n",
      "            \"emia\": -2.0966954e-06\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.557252\n",
      "          },\n",
      "          {\n",
      "            \" topical\": -0.37631476\n",
      "          },\n",
      "          {\n",
      "            \" administration\": -0.21242705\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.6227313\n",
      "          },\n",
      "          {\n",
      "            \" o\": -0.2035143\n",
      "          },\n",
      "          {\n",
      "            \"phthal\": -1.8668587e-05\n",
      "          },\n",
      "          {\n",
      "            \"mic\": -1.2231317e-05\n",
      "          },\n",
      "          {\n",
      "            \" chlor\": -0.44023326\n",
      "          },\n",
      "          {\n",
      "            \"amp\": -4.1232483e-06\n",
      "          },\n",
      "          {\n",
      "            \"hen\": -4.277735e-07\n",
      "          },\n",
      "          {\n",
      "            \"icol\": -1.0561456e-05\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.04787185\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.501652e-05\n",
      "          },\n",
      "          {\n",
      "            \"F\": -0.1910158\n",
      "          },\n",
      "          {\n",
      "            \"atal\": -0.02793026\n",
      "          },\n",
      "          {\n",
      "            \" a\": -0.21065208\n",
      "          },\n",
      "          {\n",
      "            \"pl\": -9.370307e-06\n",
      "          },\n",
      "          {\n",
      "            \"astic\": -6.6619094e-07\n",
      "          },\n",
      "          {\n",
      "            \" an\": -0.000280908\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" aplastic anemia, topical administration, ophthalmic chloramphenicol\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786580,\n",
      "  \"id\": \"cmpl-4GHgaavhXywu49jT3kZfx2NDWpPc5\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "20it [00:17,  1.21s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .\n",
      "Diseases: 30 {464: 10, 22577: 10, 33344: 10, 1988: 10, 286: 10, 23145: 10, 375: 10, 26186: 10, 49815: 10, 329: 10, 262: 10, 8055: 10, 3952: 10, 7899: 10, 666: 10, 705: 10, 572: 10, 5895: 10, 290: 10, 406: 10, 2389: 10, 1180: 10, 35811: 10, 7435: 10, 1373: 10, 10287: 10, 295: 10, 6115: 10, 351: 10, 13147: 10, 74: 10, 1127: 10, 4448: 10, 7603: 10, 326: 10, 48631: 10, 393: 10, 3108: 10, 39665: 10, 15071: 10, 47294: 10, 689: 10, 743: 10, 307: 10, 4497: 10, 5270: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1242,\n",
      "          1246,\n",
      "          1247,\n",
      "          1251,\n",
      "          1254,\n",
      "          1255,\n",
      "          1260,\n",
      "          1265,\n",
      "          1268,\n",
      "          1270,\n",
      "          1274,\n",
      "          1276,\n",
      "          1282,\n",
      "          1283,\n",
      "          1287,\n",
      "          1289,\n",
      "          1292,\n",
      "          1307,\n",
      "          1307,\n",
      "          1307,\n",
      "          1307,\n",
      "          1307,\n",
      "          1307,\n",
      "          1307\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.64828235,\n",
      "          -2.4543265e-06,\n",
      "          -3.7684315e-06,\n",
      "          -0.000111420464,\n",
      "          -0.027638,\n",
      "          -0.5407027,\n",
      "          -2.9311614e-06,\n",
      "          -0.0036752608,\n",
      "          -0.27793804,\n",
      "          -0.0011262194,\n",
      "          -0.0008276665,\n",
      "          -0.00205455,\n",
      "          -0.6758224,\n",
      "          -0.17076302,\n",
      "          -9.130952e-06,\n",
      "          -3.076318e-07,\n",
      "          -0.04425228,\n",
      "          -0.64229023,\n",
      "          -0.0002824577,\n",
      "          -0.014054222,\n",
      "          -1.2397912,\n",
      "          -0.013928256,\n",
      "          -1.0022683,\n",
      "          -0.8274139\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" dys\",\n",
      "          \"k\",\n",
      "          \"ines\",\n",
      "          \"ias\",\n",
      "          \",\",\n",
      "          \" park\",\n",
      "          \"inson\",\n",
      "          \"ian\",\n",
      "          \" '\",\n",
      "          \" off\",\n",
      "          \" '\",\n",
      "          \" signs\",\n",
      "          \",\",\n",
      "          \" lev\",\n",
      "          \"od\",\n",
      "          \"opa\",\n",
      "          \" responsiveness\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"The\",\n",
      "          \" L\",\n",
      "          \"ID\",\n",
      "          \" and\",\n",
      "          \" dys\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" dys\": -0.64828235\n",
      "          },\n",
      "          {\n",
      "            \"k\": -2.4543265e-06\n",
      "          },\n",
      "          {\n",
      "            \"ines\": -3.7684315e-06\n",
      "          },\n",
      "          {\n",
      "            \"ias\": -0.000111420464\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.027638\n",
      "          },\n",
      "          {\n",
      "            \" park\": -0.5407027\n",
      "          },\n",
      "          {\n",
      "            \"inson\": -2.9311614e-06\n",
      "          },\n",
      "          {\n",
      "            \"ian\": -0.0036752608\n",
      "          },\n",
      "          {\n",
      "            \" '\": -0.27793804\n",
      "          },\n",
      "          {\n",
      "            \" off\": -0.0011262194\n",
      "          },\n",
      "          {\n",
      "            \" '\": -0.0008276665\n",
      "          },\n",
      "          {\n",
      "            \" signs\": -0.00205455\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.6758224\n",
      "          },\n",
      "          {\n",
      "            \" lev\": -0.17076302\n",
      "          },\n",
      "          {\n",
      "            \"od\": -9.130952e-06\n",
      "          },\n",
      "          {\n",
      "            \"opa\": -3.076318e-07\n",
      "          },\n",
      "          {\n",
      "            \" responsiveness\": -0.04425228\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.64229023\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.0002824577\n",
      "          },\n",
      "          {\n",
      "            \"The\": -0.014054222\n",
      "          },\n",
      "          {\n",
      "            \" L\": -1.2397912\n",
      "          },\n",
      "          {\n",
      "            \"ID\": -0.013928256\n",
      "          },\n",
      "          {\n",
      "            \" and\": -1.0022683\n",
      "          },\n",
      "          {\n",
      "            \" dys\": -0.8274139\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" dyskinesias, parkinsonian ' off ' signs, levodopa responsiveness\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786581,\n",
      "  \"id\": \"cmpl-4GHgbMCGLbnjFGCQNPPlVerMn7XTO\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "21it [00:19,  1.35s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .\n",
      "Diseases: 30 {4093: 10, 45: 10, 52: 10, 373: 10, 973: 10, 749: 10, 8811: 10, 287: 10, 262: 10, 3513: 10, 286: 10, 28837: 10, 6086: 10, 837: 10, 17288: 10, 2685: 10, 11814: 10, 454: 10, 3632: 10, 1554: 10, 72: 10, 13733: 10, 13370: 10, 4662: 10, 290: 10, 21240: 10, 2978: 10, 5151: 10, 1773: 10, 291: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1013,\n",
      "          1019,\n",
      "          1022,\n",
      "          1023,\n",
      "          1028,\n",
      "          1033,\n",
      "          1037,\n",
      "          1040,\n",
      "          1041,\n",
      "          1047,\n",
      "          1051,\n",
      "          1054,\n",
      "          1055,\n",
      "          1060,\n",
      "          1061,\n",
      "          1064,\n",
      "          1067,\n",
      "          1071,\n",
      "          1075,\n",
      "          1076,\n",
      "          1081,\n",
      "          1084,\n",
      "          1087,\n",
      "          1090,\n",
      "          1092,\n",
      "          1098,\n",
      "          1101,\n",
      "          1101,\n",
      "          1101,\n",
      "          1101\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.743981,\n",
      "          -0.00010545909,\n",
      "          -0.02336095,\n",
      "          -0.22632834,\n",
      "          -0.0052524623,\n",
      "          -0.008621819,\n",
      "          -0.018546712,\n",
      "          -0.017166521,\n",
      "          -0.01907919,\n",
      "          -0.0002869914,\n",
      "          -0.0023958338,\n",
      "          -0.011121397,\n",
      "          -0.01308685,\n",
      "          -0.00055591954,\n",
      "          -5.460492e-07,\n",
      "          -2.9756868e-05,\n",
      "          -0.0016311728,\n",
      "          -0.20042911,\n",
      "          -0.09507299,\n",
      "          -0.005956755,\n",
      "          -5.460492e-07,\n",
      "          -0.0077839843,\n",
      "          -1.7400124e-06,\n",
      "          -6.408898e-05,\n",
      "          -0.011759456,\n",
      "          -3.166233e-05,\n",
      "          -0.060816664,\n",
      "          -8.7337496e-05,\n",
      "          -0.3901799,\n",
      "          -0.89937896\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" lymph\",\n",
      "          \"oma\",\n",
      "          \",\",\n",
      "          \" mast\",\n",
      "          \" cell\",\n",
      "          \" tum\",\n",
      "          \"our\",\n",
      "          \",\",\n",
      "          \" brain\",\n",
      "          \" tum\",\n",
      "          \"our\",\n",
      "          \",\",\n",
      "          \" hist\",\n",
      "          \"i\",\n",
      "          \"ocy\",\n",
      "          \"tic\",\n",
      "          \" tum\",\n",
      "          \"ours\",\n",
      "          \",\",\n",
      "          \" epit\",\n",
      "          \"hel\",\n",
      "          \"iot\",\n",
      "          \"rop\",\n",
      "          \"ic\",\n",
      "          \" lymph\",\n",
      "          \"oma\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"N\",\n",
      "          \"CC\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" lymph\": -0.743981\n",
      "          },\n",
      "          {\n",
      "            \"oma\": -0.00010545909\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.02336095\n",
      "          },\n",
      "          {\n",
      "            \" mast\": -0.22632834\n",
      "          },\n",
      "          {\n",
      "            \" cell\": -0.0052524623\n",
      "          },\n",
      "          {\n",
      "            \" tum\": -0.008621819\n",
      "          },\n",
      "          {\n",
      "            \"our\": -0.018546712\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.017166521\n",
      "          },\n",
      "          {\n",
      "            \" brain\": -0.01907919\n",
      "          },\n",
      "          {\n",
      "            \" tum\": -0.0002869914\n",
      "          },\n",
      "          {\n",
      "            \"our\": -0.0023958338\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.011121397\n",
      "          },\n",
      "          {\n",
      "            \" hist\": -0.01308685\n",
      "          },\n",
      "          {\n",
      "            \"i\": -0.00055591954\n",
      "          },\n",
      "          {\n",
      "            \"ocy\": -5.460492e-07\n",
      "          },\n",
      "          {\n",
      "            \"tic\": -2.9756868e-05\n",
      "          },\n",
      "          {\n",
      "            \" tum\": -0.0016311728\n",
      "          },\n",
      "          {\n",
      "            \"ours\": -0.20042911\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.09507299\n",
      "          },\n",
      "          {\n",
      "            \" epit\": -0.005956755\n",
      "          },\n",
      "          {\n",
      "            \"hel\": -5.460492e-07\n",
      "          },\n",
      "          {\n",
      "            \"iot\": -0.0077839843\n",
      "          },\n",
      "          {\n",
      "            \"rop\": -1.7400124e-06\n",
      "          },\n",
      "          {\n",
      "            \"ic\": -6.408898e-05\n",
      "          },\n",
      "          {\n",
      "            \" lymph\": -0.011759456\n",
      "          },\n",
      "          {\n",
      "            \"oma\": -3.166233e-05\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.060816664\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -8.7337496e-05\n",
      "          },\n",
      "          {\n",
      "            \"N\": -0.3901799\n",
      "          },\n",
      "          {\n",
      "            \"CC\": -0.89937896\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" lymphoma, mast cell tumour, brain tumour, histiocytic tumours, epitheliotropic lymphoma\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786583,\n",
      "  \"id\": \"cmpl-4GHgdxl9eIR9nmmcgelCes8Bed0fK\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "22it [00:21,  1.58s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .\n",
      "Diseases: 30 {39668: 10, 276: 10, 3585: 10, 7476: 10, 286: 10, 37151: 10, 37646: 10, 4369: 10, 547: 10, 352: 10, 764: 10, 657: 10, 837: 10, 9773: 10, 7388: 10, 2608: 10, 290: 10, 10495: 10, 357: 10, 350: 10, 329: 10, 5182: 10, 796: 10, 5534: 10, 1267: 10, 14000: 10, 6740: 10, 2242: 10, 362: 10, 2534: 10, 7632: 10, 1279: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1088,\n",
      "          1097,\n",
      "          1104,\n",
      "          1112,\n",
      "          1113,\n",
      "          1120,\n",
      "          1120,\n",
      "          1120\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.131997,\n",
      "          -0.011560572,\n",
      "          -0.00088756083,\n",
      "          -0.021313742,\n",
      "          -0.023277001,\n",
      "          -0.11931498,\n",
      "          -2.7371756e-05,\n",
      "          -0.3452592\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" coronary\",\n",
      "          \" artery\",\n",
      "          \" disease\",\n",
      "          \",\",\n",
      "          \" stroke\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Sent\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" coronary\": -0.131997\n",
      "          },\n",
      "          {\n",
      "            \" artery\": -0.011560572\n",
      "          },\n",
      "          {\n",
      "            \" disease\": -0.00088756083\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.021313742\n",
      "          },\n",
      "          {\n",
      "            \" stroke\": -0.023277001\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.11931498\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -2.7371756e-05\n",
      "          },\n",
      "          {\n",
      "            \"Sent\": -0.3452592\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" coronary artery disease, stroke\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786585,\n",
      "  \"id\": \"cmpl-4GHgff0jflkBMgXF8dg5wlh8klJgA\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "23it [00:22,  1.34s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Chlorpropamide - induced optic neuropathy .\n",
      "Diseases: 30 {1925: 10, 4685: 10, 22930: 10, 37905: 10, 532: 10, 18268: 10, 43151: 10, 7669: 10, 16786: 10, 764: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "24it [00:23,  1.13s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          913,\n",
      "          919,\n",
      "          925,\n",
      "          930,\n",
      "          930,\n",
      "          930,\n",
      "          930,\n",
      "          930\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.009764585,\n",
      "          -0.00027995434,\n",
      "          -8.5358415e-06,\n",
      "          -0.17028114,\n",
      "          -4.5255874e-05,\n",
      "          -0.7154106,\n",
      "          -8.209043e-05,\n",
      "          -9.866513e-05\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" optic\",\n",
      "          \" neuro\",\n",
      "          \"pathy\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Ch\",\n",
      "          \"lor\",\n",
      "          \"prop\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" optic\": -0.009764585\n",
      "          },\n",
      "          {\n",
      "            \" neuro\": -0.00027995434\n",
      "          },\n",
      "          {\n",
      "            \"pathy\": -8.5358415e-06\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.17028114\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.5255874e-05\n",
      "          },\n",
      "          {\n",
      "            \"Ch\": -0.7154106\n",
      "          },\n",
      "          {\n",
      "            \"lor\": -8.209043e-05\n",
      "          },\n",
      "          {\n",
      "            \"prop\": -9.866513e-05\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" optic neuropathy\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786586,\n",
      "  \"id\": \"cmpl-4GHggdePQAfQKKRRpTHq2kZrXCucZ\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: METHOD : Medically healthy\n",
      "Diseases: 30 {49273: 10, 1058: 10, 2019: 10, 1146: 10, 5448: 10, 11: 10, 198: 10}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "25it [00:23,  1.03it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          896,\n",
      "          904,\n",
      "          904,\n",
      "          904,\n",
      "          904,\n",
      "          904,\n",
      "          904,\n",
      "          904\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.1962738,\n",
      "          -0.081056535,\n",
      "          -0.00040403462,\n",
      "          -0.25452232,\n",
      "          -0.0028736936,\n",
      "          -0.047908556,\n",
      "          -0.5398434,\n",
      "          -0.12817986\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" healthy\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Sent\",\n",
      "          \"ence\",\n",
      "          \" :\",\n",
      "          \"\\n\",\n",
      "          \"\\n\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" healthy\": -0.1962738\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.081056535\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.00040403462\n",
      "          },\n",
      "          {\n",
      "            \"Sent\": -0.25452232\n",
      "          },\n",
      "          {\n",
      "            \"ence\": -0.0028736936\n",
      "          },\n",
      "          {\n",
      "            \" :\": -0.047908556\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.5398434\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.12817986\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" healthy\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786587,\n",
      "  \"id\": \"cmpl-4GHgh9Q4Vdwsaj2Sga5GapwyIZpFt\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n",
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .\n",
      "Diseases: 30 {42: 10, 316: 10, 9862: 10, 43614: 10, 14916: 10, 2458: 10, 287: 10, 5448: 10, 7481: 10, 2092: 10, 284: 10, 883: 10, 6515: 10, 3871: 10, 351: 10, 22794: 10, 837: 10, 3573: 10, 30424: 10, 290: 10, 21964: 10, 3632: 10, 7652: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1037,\n",
      "          1051,\n",
      "          1051,\n",
      "          1051,\n",
      "          1051,\n",
      "          1051,\n",
      "          1051,\n",
      "          1051\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.045278475,\n",
      "          -0.2738904,\n",
      "          -4.4181128e-05,\n",
      "          -0.37678817,\n",
      "          -0.0016114115,\n",
      "          -0.00016268677,\n",
      "          -1.2110966,\n",
      "          -0.03847991\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" schizophrenia\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"K\",\n",
      "          \"et\",\n",
      "          \"amine\",\n",
      "          \" induces\",\n",
      "          \" activation\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" schizophrenia\": -0.045278475\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.2738904\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -4.4181128e-05\n",
      "          },\n",
      "          {\n",
      "            \"K\": -0.37678817\n",
      "          },\n",
      "          {\n",
      "            \"et\": -0.0016114115\n",
      "          },\n",
      "          {\n",
      "            \"amine\": -0.00016268677\n",
      "          },\n",
      "          {\n",
      "            \" induces\": -1.2110966\n",
      "          },\n",
      "          {\n",
      "            \" activation\": -0.03847991\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" schizophrenia\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786587,\n",
      "  \"id\": \"cmpl-4GHghjQrXaheeunGBt0wP2t78eLKB\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "26it [00:24,  1.16it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .\n",
      "Diseases: 30 {34: 10, 1386: 10, 286: 10, 886: 10, 908: 10, 4454: 10, 4890: 10, 14641: 10, 706: 10, 9296: 10, 357: 10, 299: 10, 796: 10, 17501: 10, 1267: 10, 290: 10, 604: 10, 3134: 10, 6973: 10, 14451: 10, 329: 10, 2479: 10, 837: 10, 614: 10, 13669: 10, 4436: 10, 9441: 10, 640: 10, 351: 10, 281: 10, 16572: 10, 41303: 10, 547: 10, 3017: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          1078,\n",
      "          1082,\n",
      "          1086,\n",
      "          1090,\n",
      "          1097,\n",
      "          1098,\n",
      "          1105,\n",
      "          1112\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.20455883,\n",
      "          -5.5556293e-06,\n",
      "          -6.827632e-08,\n",
      "          -0.006349757,\n",
      "          -0.7054535,\n",
      "          -0.055584498,\n",
      "          -0.00047433955,\n",
      "          -0.33764273\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" end\",\n",
      "          \"omet\",\n",
      "          \"rial\",\n",
      "          \" cancer\",\n",
      "          \",\",\n",
      "          \" breast\",\n",
      "          \" cancer\",\n",
      "          \"\\n\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" end\": -0.20455883\n",
      "          },\n",
      "          {\n",
      "            \"omet\": -5.5556293e-06\n",
      "          },\n",
      "          {\n",
      "            \"rial\": -6.827632e-08\n",
      "          },\n",
      "          {\n",
      "            \" cancer\": -0.006349757\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.7054535\n",
      "          },\n",
      "          {\n",
      "            \" breast\": -0.055584498\n",
      "          },\n",
      "          {\n",
      "            \" cancer\": -0.00047433955\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.33764273\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" endometrial cancer, breast cancer\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786588,\n",
      "  \"id\": \"cmpl-4GHgibRxgWjsyyRqmSQk2sVbw9lyY\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "27it [00:25,  1.21it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .\n",
      "Diseases: 30 {24849: 10, 3552: 10, 290: 10, 29816: 10, 2526: 10, 286: 10, 8710: 10, 516: 10, 294: 10, 398: 10, 2127: 10, 24419: 10, 349: 10, 1042: 10, 287: 10, 1466: 10, 319: 10, 5929: 10, 3075: 10, 1676: 10, 353: 10, 505: 10, 25174: 10, 378: 10, 4555: 10, 19754: 10, 395: 10, 6335: 10, 1669: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          990,\n",
      "          994,\n",
      "          997,\n",
      "          1000,\n",
      "          1003,\n",
      "          1005,\n",
      "          1008,\n",
      "          1010,\n",
      "          1013,\n",
      "          1013,\n",
      "          1013,\n",
      "          1013,\n",
      "          1013,\n",
      "          1013,\n",
      "          1013,\n",
      "          1013\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -0.05923505,\n",
      "          -3.4762696e-05,\n",
      "          -0.00017616016,\n",
      "          -1.8601542e-06,\n",
      "          -2.8138238e-06,\n",
      "          -1.8310955e-05,\n",
      "          -4.361666e-06,\n",
      "          -6.337372e-05,\n",
      "          -0.6743682,\n",
      "          -0.00021753216,\n",
      "          -0.60890585,\n",
      "          -0.004106628,\n",
      "          -0.6669335,\n",
      "          -0.35077924,\n",
      "          -0.075892724,\n",
      "          -0.25086972\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" ven\",\n",
      "          \"ous\",\n",
      "          \" th\",\n",
      "          \"rom\",\n",
      "          \"bo\",\n",
      "          \"emb\",\n",
      "          \"ol\",\n",
      "          \"ism\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Sent\",\n",
      "          \"ence\",\n",
      "          \":\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"Abs\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" ven\": -0.05923505\n",
      "          },\n",
      "          {\n",
      "            \"ous\": -3.4762696e-05\n",
      "          },\n",
      "          {\n",
      "            \" th\": -0.00017616016\n",
      "          },\n",
      "          {\n",
      "            \"rom\": -1.8601542e-06\n",
      "          },\n",
      "          {\n",
      "            \"bo\": -2.8138238e-06\n",
      "          },\n",
      "          {\n",
      "            \"emb\": -1.8310955e-05\n",
      "          },\n",
      "          {\n",
      "            \"ol\": -4.361666e-06\n",
      "          },\n",
      "          {\n",
      "            \"ism\": -6.337372e-05\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.6743682\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.00021753216\n",
      "          },\n",
      "          {\n",
      "            \"Sent\": -0.60890585\n",
      "          },\n",
      "          {\n",
      "            \"ence\": -0.004106628\n",
      "          },\n",
      "          {\n",
      "            \":\": -0.6669335\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.35077924\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.075892724\n",
      "          },\n",
      "          {\n",
      "            \"Abs\": -0.25086972\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" venous thromboembolism\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786589,\n",
      "  \"id\": \"cmpl-4GHgjNv91kLWXJRZuplpBgrtpbxFZ\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "28it [00:25,  1.18it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .\n",
      "Diseases: vasospasm\n",
      "\n",
      "Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .\n",
      "Diseases: arthrogryposis\n",
      "\n",
      "Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .\n",
      "Diseases: \n",
      "\n",
      "Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .\n",
      "Diseases: penile pain, erectile dysfunction\n",
      "\n",
      "Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .\n",
      "Diseases: eosinophilia, renal failure, hypersensitivity, erythroderma, leukemoid reaction, hyponatremia\n",
      "\n",
      "Sentence: The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .\n",
      "Diseases: 30 {464: 10, 7460: 10, 286: 10, 39278: 10, 357: 10, 337: 10, 20702: 10, 1267: 10, 532: 10, 18268: 10, 37926: 10, 389: 10, 2092: 10, 284: 10, 883: 10, 30285: 10, 2099: 10, 22794: 10, 764: 10, 11: 10, 198: 10}\n",
      "{\n",
      "  \"choices\": [\n",
      "    {\n",
      "      \"finish_reason\": \"stop\",\n",
      "      \"index\": 0,\n",
      "      \"logprobs\": {\n",
      "        \"text_offset\": [\n",
      "          984,\n",
      "          994,\n",
      "          995,\n",
      "          1009,\n",
      "          1009,\n",
      "          1009,\n",
      "          1009,\n",
      "          1009\n",
      "        ],\n",
      "        \"token_logprobs\": [\n",
      "          -1.1138846,\n",
      "          -0.2666895,\n",
      "          -0.53785145,\n",
      "          -0.2618263,\n",
      "          -0.00023977255,\n",
      "          -0.012320254,\n",
      "          -0.45946348,\n",
      "          -0.01164445\n",
      "        ],\n",
      "        \"tokens\": [\n",
      "          \" psychosis\",\n",
      "          \",\",\n",
      "          \" schizophrenia\",\n",
      "          \"\\n\",\n",
      "          \"\\n\",\n",
      "          \"The\",\n",
      "          \" symptoms\",\n",
      "          \" of\"\n",
      "        ],\n",
      "        \"top_logprobs\": [\n",
      "          {\n",
      "            \" psychosis\": -1.1138846\n",
      "          },\n",
      "          {\n",
      "            \",\": -0.2666895\n",
      "          },\n",
      "          {\n",
      "            \" schizophrenia\": -0.53785145\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.2618263\n",
      "          },\n",
      "          {\n",
      "            \"\\n\": -0.00023977255\n",
      "          },\n",
      "          {\n",
      "            \"The\": -0.012320254\n",
      "          },\n",
      "          {\n",
      "            \" symptoms\": -0.45946348\n",
      "          },\n",
      "          {\n",
      "            \" of\": -0.01164445\n",
      "          }\n",
      "        ]\n",
      "      },\n",
      "      \"text\": \" psychosis, schizophrenia\"\n",
      "    }\n",
      "  ],\n",
      "  \"created\": 1639786589,\n",
      "  \"id\": \"cmpl-4GHgjGgFsNc0X8nfF4vwdvd0iKkuS\",\n",
      "  \"model\": \"davinci:2020-05-03\",\n",
      "  \"object\": \"text_completion\"\n",
      "}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "29it [00:26,  1.08it/s]\n"
     ]
    },
    {
     "ename": "ValueError",
     "evalue": "Length of values (29) does not match length of index (50)",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-923-d073205c619b>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     36\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     37\u001b[0m \u001b[0mdf\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtest_ready_prompt_dataframe\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 38\u001b[0;31m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mfilename_root\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpredictions\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     39\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'unfiltered_{}'\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfilename_root\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0munfiltered_predictions\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     40\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'gpt3_output_{}'\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfilename_root\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mgpt3_output\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m__setitem__\u001b[0;34m(self, key, value)\u001b[0m\n\u001b[1;32m   3161\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3162\u001b[0m             \u001b[0;31m# set column\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3163\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_set_item\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3164\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3165\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_setitem_slice\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkey\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mslice\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m_set_item\u001b[0;34m(self, key, value)\u001b[0m\n\u001b[1;32m   3240\u001b[0m         \"\"\"\n\u001b[1;32m   3241\u001b[0m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_ensure_valid_index\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3242\u001b[0;31m         \u001b[0mvalue\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sanitize_column\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3243\u001b[0m         \u001b[0mNDFrame\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_set_item\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkey\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3244\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m_sanitize_column\u001b[0;34m(self, key, value, broadcast)\u001b[0m\n\u001b[1;32m   3897\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3898\u001b[0m             \u001b[0;31m# turn me into an ndarray\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3899\u001b[0;31m             \u001b[0mvalue\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msanitize_index\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mindex\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3900\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mndarray\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mIndex\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3901\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mlist\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0;36m0\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/scispacy/lib/python3.9/site-packages/pandas/core/internals/construction.py\u001b[0m in \u001b[0;36msanitize_index\u001b[0;34m(data, index)\u001b[0m\n\u001b[1;32m    749\u001b[0m     \"\"\"\n\u001b[1;32m    750\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdata\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m!=\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mindex\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 751\u001b[0;31m         raise ValueError(\n\u001b[0m\u001b[1;32m    752\u001b[0m             \u001b[0;34m\"Length of values \"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    753\u001b[0m             \u001b[0;34mf\"({len(data)}) \"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mValueError\u001b[0m: Length of values (29) does not match length of index (50)"
     ]
    }
   ],
   "source": [
    "#GENERATE NER PREDICTIONS with Filtering\n",
    "positive_entity_threshold = 0.4\n",
    "filtering = True\n",
    "gpt3_output = []\n",
    "predictions = []\n",
    "unfiltered_predictions = []\n",
    "\n",
    "for i, prompt in tqdm(enumerate(prompts)):    \n",
    "    test_sent = test_ready_prompt_dataframe.sents.values[i]\n",
    "    sample = run_gpt3_ner(engine,\n",
    "                          prompt, \n",
    "                          test_sent, \n",
    "                          30, \n",
    "                          sep, \n",
    "                          logit_bias=logit_bias, \n",
    "                          sep_logit_bias=sep_logit_bias, \n",
    "                          new_line_logit_bias=new_line_logit_bias)\n",
    "    \n",
    "    prediction = sample['choices'][0]['text']\n",
    "    #Lowercasing all predictions\n",
    "    prediction = prediction.lower().strip()\n",
    "    entities = prediction.split(sep)\n",
    "    \n",
    "    entity_probs = run_gpt3_ner_post_filtering(engine, filter_prompt, template_prompt, entities)\n",
    "    \n",
    "    filtered_entities = []\n",
    "    for entity in entities:\n",
    "        if entity_probs[entity][1] > positive_entity_threshold:\n",
    "            filtered_entities.append(entity)\n",
    "\n",
    "    unfiltered_predictions.append(entities)\n",
    "    predictions.append(filtered_entities)\n",
    "    gpt3_output.append((sample, entity_probs))\n",
    "\n",
    "df = test_ready_prompt_dataframe\n",
    "df[filename_root] = predictions\n",
    "df['unfiltered_{}'.format(filename_root)] = unfiltered_predictions\n",
    "df['gpt3_output_{}'.format(filename_root)] = gpt3_output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([{'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '},\n",
       "       {'No Interaction', 'Unspecified', 'Recommendation', 'Effect Alteration', 'Metabolic Mechanism '}],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_ready_prompt_dataframe.unique_labels.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'davinci'"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "engine"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "48it [00:17,  2.80it/s]\n"
     ]
    }
   ],
   "source": [
    "#GENERATE Relation Extraction PREDICTIONS\n",
    "gpt3_output = []\n",
    "predictions = []\n",
    "\n",
    "for i, prompt in tqdm(enumerate(prompts)):\n",
    "    \n",
    "    test_sent = ' '+' '.join(list(test_ready_prompt_dataframe.unique_labels.values[i]))+' '\n",
    "    sample = run_gpt3(engine, prompt, test_sent, 1, sep, 10)\n",
    "    \n",
    "    gpt3_output.append((sample,prompt,test_sent))\n",
    "    prediction = sample['choices'][0]['text']\n",
    "    #Lowercasing all predictions\n",
    "    prediction = prediction.lower().strip()\n",
    "    predictions.append(prediction)\n",
    "    \n",
    "df = test_ready_prompt_dataframe\n",
    "df[filename_root] = predictions\n",
    "df['gpt3_output_{}'.format(filename_root)] = gpt3_output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>sentence</th>\n",
       "      <th>label</th>\n",
       "      <th>test_ready_prompt</th>\n",
       "      <th>ddi_test_prompts_random_42.5.50.perm_0.</th>\n",
       "      <th>gpt3_output_ddi_test_prompts_random_42.5.50.perm_0.</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1560</th>\n",
       "      <td>Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: aspirin\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\n...</td>\n",
       "      <td>none</td>\n",
       "      <td>({'id': 'cmpl-4IU93kBZdiYjlFcIdAfisMwAE6Wff', 'object': 'text_completion', 'created': 1640311129, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1865\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.678508\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.678508\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1283</th>\n",
       "      <td>Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: macrolide antibiotics\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: erythromycin\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: corticosteroids\\nInteraction: mechanism\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: macrolide antibiotics\\nD...</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>({'id': 'cmpl-4IU93OJiZV0Pcty6bu1Kcd7rhAfK1', 'object': 'text_completion', 'created': 1640311129, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1552\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.24739274\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.24739274\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: macrolide antibiotics\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: erythromycin\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1458</th>\n",
       "      <td>(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: VIOXX\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rifampin\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rofecoxib\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: VIOXX\\nDrug 2: rifampin\\nInteraction: mechanism\\n\\nSentence: Ri...</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>({'id': 'cmpl-4IU940JPgGvVuIy87rHlTgE157C88', 'object': 'text_completion', 'created': 1640311130, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1407\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.17020744\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.17020744\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: VIOXX\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rifampin\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1462</th>\n",
       "      <td>In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: Vardenafil\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: terazosin\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Vardenafil\\nDrug 2: terazosin\\nInteraction: effect\\n\\nSentence: Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of i...</td>\n",
       "      <td>none</td>\n",
       "      <td>({'id': 'cmpl-4IU949UpdxinXS2xEoafOHHr3xzhl', 'object': 'text_completion', 'created': 1640311130, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1863\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.65847224\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.65847224\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: Vardenafil\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: terazosin\\nInteraction:...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1501</th>\n",
       "      <td>Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>({'id': 'cmpl-4IU94DzxLKaC4SBCHFkpddeik1b1h', 'object': 'text_completion', 'created': 1640311130, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      3687\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.009376137\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.009376137\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolami...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1558</th>\n",
       "      <td>Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: verapamil\\nInteraction: mechanism\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: verapamil\\nDrug 2: dofetilide\\nInteraction: no...</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>({'id': 'cmpl-4IU95CQN5l9BvOQfemmEHSZDf1L7x', 'object': 'text_completion', 'created': 1640311131, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1446\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.34936067\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.34936067\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: verapamil\\nInteraction: mechanism\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapam...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1490</th>\n",
       "      <td>Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>({'id': 'cmpl-4IU951QrcyXDzJ44AaK4gLYs0nqnv', 'object': 'text_completion', 'created': 1640311131, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      3683\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.0077295625\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.0077295625\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazola...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1493</th>\n",
       "      <td>Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>({'id': 'cmpl-4IU96ayh7tt8DLK8TaK3YdPQoeMcZ', 'object': 'text_completion', 'created': 1640311132, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      3685\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.010059679\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.010059679\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolami...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1319</th>\n",
       "      <td>Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Amphetamines\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:</td>\n",
       "      <td>none</td>\n",
       "      <td>({'id': 'cmpl-4IU96vH6rN9gevBy0fZ76Qf3L6VL7', 'object': 'text_completion', 'created': 1640311132, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      830\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.51959467\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.51959467\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Amphetamines\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: non...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1312</th>\n",
       "      <td>Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: mechanism\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: tricyclic antidepressants\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.\\nDrug 1: Aspirin\\nDrug 2: diflunis...</td>\n",
       "      <td>none</td>\n",
       "      <td>({'id': 'cmpl-4IU97xpRZl62zbq8GzYBoqiYzdEqi', 'object': 'text_completion', 'created': 1640311133, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1440\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.5518371\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.5518371\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: mechanism\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Concurrent administration of cimetidine a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1337</th>\n",
       "      <td>Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.</td>\n",
       "      <td>DDI-mechanism</td>\n",
       "      <td>Sentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: Aprepitant\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: midazolam\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days ...</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>({'id': 'cmpl-4IU97EaM8RxtCedc0syOs1DwFspOH', 'object': 'text_completion', 'created': 1640311133, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      2166\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.38207775\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.38207775\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: Aprepitant\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadminister...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       sentence  \\\n",
       "1560                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.   \n",
       "1283                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.   \n",
       "1458                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.   \n",
       "1462                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.   \n",
       "1501  Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.   \n",
       "1558                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.   \n",
       "1490  Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.   \n",
       "1493  Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.   \n",
       "1319                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;   \n",
       "1312                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.   \n",
       "1337                                                                                                                                                                                                                                                                                                                                                                                                                    Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.   \n",
       "\n",
       "              label  \\\n",
       "1560  DDI-mechanism   \n",
       "1283  DDI-mechanism   \n",
       "1458  DDI-mechanism   \n",
       "1462  DDI-mechanism   \n",
       "1501  DDI-mechanism   \n",
       "1558  DDI-mechanism   \n",
       "1490  DDI-mechanism   \n",
       "1493  DDI-mechanism   \n",
       "1319  DDI-mechanism   \n",
       "1312  DDI-mechanism   \n",
       "1337  DDI-mechanism   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            test_ready_prompt  \\\n",
       "1560  Sentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: aspirin\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\n...   \n",
       "1283  Sentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: macrolide antibiotics\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: erythromycin\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: corticosteroids\\nInteraction: mechanism\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: macrolide antibiotics\\nD...   \n",
       "1458  Sentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: VIOXX\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rifampin\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rofecoxib\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: VIOXX\\nDrug 2: rifampin\\nInteraction: mechanism\\n\\nSentence: Ri...   \n",
       "1462  Sentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: Vardenafil\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: terazosin\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Vardenafil\\nDrug 2: terazosin\\nInteraction: effect\\n\\nSentence: Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of i...   \n",
       "1501  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...   \n",
       "1558  Sentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: verapamil\\nInteraction: mechanism\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: verapamil\\nDrug 2: dofetilide\\nInteraction: no...   \n",
       "1490  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...   \n",
       "1493  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolamide\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inh...   \n",
       "1319                                                                                                                                               Sentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Amphetamines\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:   \n",
       "1312  Sentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: mechanism\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: tricyclic antidepressants\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.\\nDrug 1: Aspirin\\nDrug 2: diflunis...   \n",
       "1337  Sentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: Aprepitant\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: midazolam\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days ...   \n",
       "\n",
       "     ddi_test_prompts_random_42.5.50.perm_0.  \\\n",
       "1560                                    none   \n",
       "1283                               mechanism   \n",
       "1458                               mechanism   \n",
       "1462                                    none   \n",
       "1501                               mechanism   \n",
       "1558                               mechanism   \n",
       "1490                               mechanism   \n",
       "1493                               mechanism   \n",
       "1319                                    none   \n",
       "1312                                    none   \n",
       "1337                               mechanism   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          gpt3_output_ddi_test_prompts_random_42.5.50.perm_0.  \n",
       "1560  ({'id': 'cmpl-4IU93kBZdiYjlFcIdAfisMwAE6Wff', 'object': 'text_completion', 'created': 1640311129, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1865\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.678508\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.678508\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.\\nDrug 1: Aspirin\\nDrug 2: diclofenac\\nInteraction: none\\n\\nSentence: Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, p...  \n",
       "1283  ({'id': 'cmpl-4IU93OJiZV0Pcty6bu1Kcd7rhAfK1', 'object': 'text_completion', 'created': 1640311129, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1552\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.24739274\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.24739274\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: macrolide antibiotics\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.\\nDrug 1: ketoconazole\\nDrug 2: erythromycin\\nInteraction: none\\n\\nSentence: Drugs which inhibit CYP 3A4 ...  \n",
       "1458  ({'id': 'cmpl-4IU940JPgGvVuIy87rHlTgE157C88', 'object': 'text_completion', 'created': 1640311130, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1407\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.17020744\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.17020744\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: VIOXX\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.\\nDrug 1: Rifampin\\nDrug 2: rifampin\\nInteraction: none\\n\\nSentence: Rifampin: Co-administration of VIOXX with rifampin 600...  \n",
       "1462  ({'id': 'cmpl-4IU949UpdxinXS2xEoafOHHr3xzhl', 'object': 'text_completion', 'created': 1640311130, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1863\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.65847224\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.65847224\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: Vardenafil\\nInteraction: none\\n\\nSentence: Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.\\nDrug 1: Alpha-blockers\\nDrug 2: terazosin\\nInteraction:...  \n",
       "1501  ({'id': 'cmpl-4IU94DzxLKaC4SBCHFkpddeik1b1h', 'object': 'text_completion', 'created': 1640311130, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      3687\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.009376137\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.009376137\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolami...  \n",
       "1558  ({'id': 'cmpl-4IU95CQN5l9BvOQfemmEHSZDf1L7x', 'object': 'text_completion', 'created': 1640311131, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1446\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.34936067\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.34936067\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: verapamil\\nInteraction: mechanism\\n\\nSentence: Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.\\nDrug 1: TIKOSYN\\nDrug 2: dofetilide\\nInteraction: none\\n\\nSentence: Co-administration of TIKOSYN with verapam...  \n",
       "1490  ({'id': 'cmpl-4IU951QrcyXDzJ44AaK4gLYs0nqnv', 'object': 'text_completion', 'created': 1640311131, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      3683\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.0077295625\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.0077295625\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazola...  \n",
       "1493  ({'id': 'cmpl-4IU96ayh7tt8DLK8TaK3YdPQoeMcZ', 'object': 'text_completion', 'created': 1640311132, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      3685\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.010059679\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.010059679\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: Acetazolami...  \n",
       "1319  ({'id': 'cmpl-4IU96vH6rN9gevBy0fZ76Qf3L6VL7', 'object': 'text_completion', 'created': 1640311132, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      830\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.51959467\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.51959467\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: phenytoin\\nInteraction: none\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Amphetamines\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;\\nDrug 1: Phenytoin\\nDrug 2: Amphetamines\\nInteraction: non...  \n",
       "1312  ({'id': 'cmpl-4IU97xpRZl62zbq8GzYBoqiYzdEqi', 'object': 'text_completion', 'created': 1640311133, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      1440\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.5518371\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" none\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" none\": -0.5518371\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" none\"\n",
       "}]}, Sentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: mechanism\\n\\nSentence: Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.\\nDrug 1: cimetidine\\nDrug 2: tricyclic antidepressants\\nInteraction: none\\n\\nSentence: Concurrent administration of cimetidine a...  \n",
       "1337  ({'id': 'cmpl-4IU97EaM8RxtCedc0syOs1DwFspOH', 'object': 'text_completion', 'created': 1640311133, 'model': 'davinci:2020-05-03', 'choices': [{\n",
       "  \"finish_reason\": \"length\",\n",
       "  \"index\": 0,\n",
       "  \"logprobs\": {\n",
       "    \"text_offset\": [\n",
       "      2166\n",
       "    ],\n",
       "    \"token_logprobs\": [\n",
       "      -0.38207775\n",
       "    ],\n",
       "    \"tokens\": [\n",
       "      \" mechanism\"\n",
       "    ],\n",
       "    \"top_logprobs\": [\n",
       "      {\n",
       "        \" mechanism\": -0.38207775\n",
       "      }\n",
       "    ]\n",
       "  },\n",
       "  \"text\": \" mechanism\"\n",
       "}]}, Sentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.\\nDrug 1: Midazolam\\nDrug 2: Aprepitant\\nInteraction: none\\n\\nSentence: Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadminister...  "
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['labels'] == 'mechanism'][['sentence','label','test_ready_prompt','ddi_test_prompts_random_42.5.50.perm_0.','gpt3_output_ddi_test_prompts_random_42.5.50.perm_0.']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'logit_bias' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-43-1e00b833f149>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mpreds_filename_root\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mfilename_root\u001b[0m\u001b[0;34m+\u001b[0m\u001b[0;34m'.preds.{}'\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mengine\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m+\u001b[0m\u001b[0;34m'{}-{}-{}'\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlogit_bias\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msep_logit_bias\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnew_line_logit_bias\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mfiltering\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m     \u001b[0mpreds_filename_root\u001b[0m \u001b[0;34m+=\u001b[0m \u001b[0;34m'.filter_{}'\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mpositive_entity_threshold\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      4\u001b[0m \u001b[0mpreds_filename\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m'../outputs/'\u001b[0m\u001b[0;34m+\u001b[0m\u001b[0mpreds_filename_root\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m \u001b[0mpreds_filename\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'logit_bias' is not defined"
     ]
    }
   ],
   "source": [
    "preds_filename_root = filename_root+'.preds.{}'.format(engine)+'{}-{}-{}'.format(logit_bias, sep_logit_bias, new_line_logit_bias)\n",
    "if filtering:\n",
    "    preds_filename_root += '.filter_{}'.format(positive_entity_threshold)\n",
    "preds_filename = '../outputs/'+preds_filename_root\n",
    "preds_filename"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'../data/ddi_test_prompts_random_42.5.50.perm_4.KNN.preds'"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "##DDI\n",
    "preds_filename = prompt_filename+'.preds'\n",
    "preds_filename"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "pickle.dump(df, open(preds_filename,'wb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: antacids\n",
      "Drug 2: H2 blockers\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: antacids\n",
      "Drug 2: proton pump inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: antacids\n",
      "Drug 2: SPRYCEL\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: H2 blockers\n",
      "Drug 2: proton pump inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.\n",
      "Drug 1: H2 blockers\n",
      "Drug 2: SPRYCEL\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\n",
      "Drug1: proton pump inhibitors\n",
      "Drug2: SPRYCEL\n",
      "Interaction:\n"
     ]
    }
   ],
   "source": [
    "print(df.loc[1065,'gpt3_output_ddi_test_prompts_random_42.5.50.perm_0.'][1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1065       advice\n",
       "1157       advice\n",
       "1096       advice\n",
       "1164       advice\n",
       "1133       advice\n",
       "30         effect\n",
       "299        effect\n",
       "177        effect\n",
       "204        effect\n",
       "354        effect\n",
       "265        effect\n",
       "41         effect\n",
       "13         effect\n",
       "55         effect\n",
       "196        effect\n",
       "137        effect\n",
       "29         effect\n",
       "1560    mechanism\n",
       "1283    mechanism\n",
       "1458    mechanism\n",
       "1462    mechanism\n",
       "1501    mechanism\n",
       "1558    mechanism\n",
       "1490    mechanism\n",
       "1493    mechanism\n",
       "1319    mechanism\n",
       "1312    mechanism\n",
       "1337    mechanism\n",
       "923          none\n",
       "667          none\n",
       "625          none\n",
       "907          none\n",
       "455          none\n",
       "416          none\n",
       "834          none\n",
       "727          none\n",
       "734          none\n",
       "607          none\n",
       "763          none\n",
       "780          none\n",
       "841          none\n",
       "915          none\n",
       "655          none\n",
       "494          none\n",
       "426          none\n",
       "977          none\n",
       "896          none\n",
       "1591        other\n",
       "Name: labels, dtype: object"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1065         none\n",
       "1157       advice\n",
       "1096         none\n",
       "1164         none\n",
       "1133         none\n",
       "30         effect\n",
       "299          none\n",
       "177          none\n",
       "204        effect\n",
       "354        effect\n",
       "265          none\n",
       "41           none\n",
       "13           none\n",
       "55           none\n",
       "196        effect\n",
       "137        effect\n",
       "29         effect\n",
       "1560         none\n",
       "1283    mechanism\n",
       "1458    mechanism\n",
       "1462         none\n",
       "1501    mechanism\n",
       "1558    mechanism\n",
       "1490    mechanism\n",
       "1493    mechanism\n",
       "1319         none\n",
       "1312         none\n",
       "1337    mechanism\n",
       "923          none\n",
       "667          none\n",
       "625          none\n",
       "907          none\n",
       "455          none\n",
       "416        effect\n",
       "834          none\n",
       "727          none\n",
       "734          none\n",
       "607          none\n",
       "763          none\n",
       "780          none\n",
       "841          none\n",
       "915          none\n",
       "655          none\n",
       "494        advice\n",
       "426          none\n",
       "977          none\n",
       "896          none\n",
       "1591         none\n",
       "Name: ddi_test_prompts_random_42.5.50.perm_0., dtype: object"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[filename_root]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 550,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'No': -0.42320356, 'Yes': -1.064128}"
      ]
     },
     "execution_count": 550,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dict(df['gpt3_output_bc5cdr_disease_test_prompts_random_42.5.50., '].values[0][0]['choices'][0]['logprobs']['top_logprobs'][0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 427,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'../outputs/bc5cdr_disease_test_prompts_random_42.5.50., .preds.davinci10-10-11'"
      ]
     },
     "execution_count": 427,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "preds_filename"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 447,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Creating Filtering Prompt From Training Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 452,
   "metadata": {},
   "outputs": [],
   "source": [
    "correct_entities = []\n",
    "incorrect_entities = []\n",
    "\n",
    "for i,row in df.iterrows():\n",
    "    \n",
    "    true = row['entities']\n",
    "    preds = row[filename_root]\n",
    "    \n",
    "    for pred in preds:\n",
    "        if pred in true:\n",
    "            correct_entities.append(pred)\n",
    "        else:\n",
    "            incorrect_entities.append(pred)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 485,
   "metadata": {},
   "outputs": [],
   "source": [
    "correct_entities = pd.DataFrame(correct_entities)\n",
    "correct_entities['tag'] = 'Yes'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 490,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>tag</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>headache</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>nausea</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>seizures</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>respiratory arrest</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>bradycardia</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>myocardial infarction</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>hemorrhage cystitis</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>rhabdomyolysis</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>hypotension</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>abdominal pain</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>nephrotoxic</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>nausea</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>hiccups</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>headache</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>adenoma</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>diarrhoea</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>hyperactive</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>retinal toxicity</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>glioblastoma</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>glomerulosclerosis</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>diabetic autonomic neuropathy</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>aneurysm</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>chest pain</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>depressed mood</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>hepatic injury</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>chronic allograft nephropathy</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>pcp</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>hemolytic anemia</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>hepatotoxicity</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                0  tag\n",
       "0                        headache  Yes\n",
       "1                          nausea  Yes\n",
       "2                        seizures  Yes\n",
       "3              respiratory arrest  Yes\n",
       "4                     bradycardia  Yes\n",
       "5           myocardial infarction  Yes\n",
       "6             hemorrhage cystitis  Yes\n",
       "7                  rhabdomyolysis  Yes\n",
       "8                     hypotension  Yes\n",
       "9                  abdominal pain  Yes\n",
       "10                    nephrotoxic  Yes\n",
       "11                         nausea  Yes\n",
       "12                        hiccups  Yes\n",
       "13                       headache  Yes\n",
       "14                        adenoma  Yes\n",
       "15                      diarrhoea  Yes\n",
       "16                    hyperactive  Yes\n",
       "17               retinal toxicity  Yes\n",
       "18                   glioblastoma  Yes\n",
       "19             glomerulosclerosis  Yes\n",
       "20  diabetic autonomic neuropathy  Yes\n",
       "21                       aneurysm  Yes\n",
       "22                     chest pain  Yes\n",
       "23                 depressed mood  Yes\n",
       "24                 hepatic injury  Yes\n",
       "25  chronic allograft nephropathy  Yes\n",
       "26                            pcp  Yes\n",
       "27               hemolytic anemia  Yes\n",
       "28                 hepatotoxicity  Yes"
      ]
     },
     "execution_count": 490,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "correct_entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 486,
   "metadata": {},
   "outputs": [],
   "source": [
    "incorrect_entities = pd.DataFrame(incorrect_entities)\n",
    "incorrect_entities['length'] = [len(p.split()) for p in incorrect_entities[0]]\n",
    "incorrect_entities['tag'] = 'No'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 487,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 488,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>length</th>\n",
       "      <th>tag</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>intracarotid drug delivery system</td>\n",
       "      <td>4</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>transfemoral catheterization of the internal carotid or vertebral artery</td>\n",
       "      <td>9</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>200 mg / sq</td>\n",
       "      <td>4</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>beta - carboline - induced seizures</td>\n",
       "      <td>6</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>gaba ( a ) receptor ligands</td>\n",
       "      <td>6</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>follow - up period</td>\n",
       "      <td>4</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>x + / - se</td>\n",
       "      <td>5</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>pilocarpine - induced seizures</td>\n",
       "      <td>4</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                           0  \\\n",
       "0                                          intracarotid drug delivery system   \n",
       "1   transfemoral catheterization of the internal carotid or vertebral artery   \n",
       "2                                                                200 mg / sq   \n",
       "7                                        beta - carboline - induced seizures   \n",
       "8                                                gaba ( a ) receptor ligands   \n",
       "41                                                        follow - up period   \n",
       "51                                                                x + / - se   \n",
       "87                                            pilocarpine - induced seizures   \n",
       "\n",
       "    length tag  \n",
       "0        4  No  \n",
       "1        9  No  \n",
       "2        4  No  \n",
       "7        6  No  \n",
       "8        6  No  \n",
       "41       4  No  \n",
       "51       5  No  \n",
       "87       4  No  "
      ]
     },
     "execution_count": 488,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "incorrect_entities[incorrect_entities['length'] > 3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 489,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>length</th>\n",
       "      <th>tag</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>adverse events</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>desipramine</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>cinacalcet</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>pharmacological effects</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>severe desaturation</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>regurgitation</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>pergolide</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>cumulative dose</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>hemoglobin</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>hematocrit</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>mean corpuscular volume</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>white - cell</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>neutrophil</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>platelet counts</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>vitamin b12</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>fol</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>women</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>age</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>calendar year</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>area of residence</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>control women</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>first myocardial infarction</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>busulfan</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>concomitant drugs</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>simvastatin metabolism</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>aortic segments</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>histological</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>molecular assessments</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>systemic vascular resistance</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>cardiac output</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>raised serum amylase</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>sirolimus</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>calcineurin inhibitors</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>cohorts</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>complete recovery</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>blood transfusion</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>other therapies</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>peripheral blood</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>peripheral blood recovery</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>peripheral blood recovery</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>peripheral blood recovery,</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>prolactin</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>raloxifene hydrochloride</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>calcium</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>amphetamine</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>sucrose</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>chow</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>cyclic</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>control groups</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>ad libitum</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>cyclic</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>chow</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>saline</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>macular ischaemia</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>hplc</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>ms</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>skin test</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>elisa test</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>prick test</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>paramethasone</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>excipients</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>ritonavir</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>cholesterol metabolism</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>macrophages</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>female hormones</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>hiv protease inhibitor</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>intracarotid injection</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>carcinostatics</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>podocyte injury</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>albumin excretion</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>enalapril treatment</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>plasma flow</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>fentanyl</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>dexamethasone</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>group</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>third</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>receive</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>not receive</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>while</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>group</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>third</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>receive</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>not receive</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>105</th>\n",
       "      <td>while,</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>partial response</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>overall response rate</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>postural hypotension</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109</th>\n",
       "      <td>hemodynamic</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>flestolol</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td>beta blockers</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>iceberg</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>nicotine</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>coniine</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>marital happiness</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>116</th>\n",
       "      <td>ces - d</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>117</th>\n",
       "      <td>amhs</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>methyldopa</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>renal allografts</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>121</th>\n",
       "      <td>acute rejection</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>recurrent glomerulonephritis</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>123</th>\n",
       "      <td>stable grafts,</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>124</th>\n",
       "      <td>suxamethonium</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>125</th>\n",
       "      <td>children</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>126</th>\n",
       "      <td>lacrimation</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>intracranial blood flow</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>noxious chemical stimulation</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>facial mucosa</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>acute hepatitis</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>hepatocellular necrosis</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>thienodiazepine derivative</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>clotiazepam</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>134</th>\n",
       "      <td>aids transgenic mice</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>135</th>\n",
       "      <td>mitochondrial cm</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>136</th>\n",
       "      <td>elevated la</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>metoprolol</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>diltiazem</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>plasma concentrations</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>blood sample</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>142</th>\n",
       "      <td>hiv</td>\n",
       "      <td>1</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>143</th>\n",
       "      <td>co - trimoxazole</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>144</th>\n",
       "      <td>hemoglobin e trait</td>\n",
       "      <td>3</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>145</th>\n",
       "      <td>heinz body</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                0  length tag\n",
       "3                  adverse events       2  No\n",
       "4                     desipramine       1  No\n",
       "5                      cinacalcet       1  No\n",
       "6         pharmacological effects       2  No\n",
       "9             severe desaturation       2  No\n",
       "10                  regurgitation       1  No\n",
       "11                      pergolide       1  No\n",
       "12                cumulative dose       2  No\n",
       "13                     hemoglobin       1  No\n",
       "14                     hematocrit       1  No\n",
       "15        mean corpuscular volume       3  No\n",
       "16                   white - cell       3  No\n",
       "17                     neutrophil       1  No\n",
       "18                platelet counts       2  No\n",
       "19                    vitamin b12       2  No\n",
       "20                            fol       1  No\n",
       "21                          women       1  No\n",
       "22                            age       1  No\n",
       "23                  calendar year       2  No\n",
       "24              area of residence       3  No\n",
       "25                  control women       2  No\n",
       "26    first myocardial infarction       3  No\n",
       "27                       busulfan       1  No\n",
       "28                                      0  No\n",
       "29              concomitant drugs       2  No\n",
       "30         simvastatin metabolism       2  No\n",
       "31                aortic segments       2  No\n",
       "32                   histological       1  No\n",
       "33          molecular assessments       2  No\n",
       "34   systemic vascular resistance       3  No\n",
       "35                 cardiac output       2  No\n",
       "36           raised serum amylase       3  No\n",
       "37                      sirolimus       1  No\n",
       "38         calcineurin inhibitors       2  No\n",
       "39                        cohorts       1  No\n",
       "40              complete recovery       2  No\n",
       "42              blood transfusion       2  No\n",
       "43                other therapies       2  No\n",
       "44               peripheral blood       2  No\n",
       "45      peripheral blood recovery       3  No\n",
       "46      peripheral blood recovery       3  No\n",
       "47     peripheral blood recovery,       3  No\n",
       "48                      prolactin       1  No\n",
       "49       raloxifene hydrochloride       2  No\n",
       "50                        calcium       1  No\n",
       "52                    amphetamine       1  No\n",
       "53                        sucrose       1  No\n",
       "54                           chow       1  No\n",
       "55                         cyclic       1  No\n",
       "56                 control groups       2  No\n",
       "57                     ad libitum       2  No\n",
       "58                         cyclic       1  No\n",
       "59                           chow       1  No\n",
       "60                         saline       1  No\n",
       "61              macular ischaemia       2  No\n",
       "62                             ms       1  No\n",
       "63                           hplc       1  No\n",
       "64                             ms       1  No\n",
       "65                             ms       1  No\n",
       "66                             ms       1  No\n",
       "67                             ms       1  No\n",
       "68                             ms       1  No\n",
       "69                             ms       1  No\n",
       "70                             ms       1  No\n",
       "71                             ms       1  No\n",
       "72                             ms       1  No\n",
       "73                             ms       1  No\n",
       "74                             ms       1  No\n",
       "75                             ms       1  No\n",
       "76                             ms       1  No\n",
       "77                      skin test       2  No\n",
       "78                     elisa test       2  No\n",
       "79                     prick test       2  No\n",
       "80                  paramethasone       1  No\n",
       "81                     excipients       1  No\n",
       "82                      ritonavir       1  No\n",
       "83         cholesterol metabolism       2  No\n",
       "84                    macrophages       1  No\n",
       "85                female hormones       2  No\n",
       "86         hiv protease inhibitor       3  No\n",
       "88         intracarotid injection       2  No\n",
       "89                 carcinostatics       1  No\n",
       "90                podocyte injury       2  No\n",
       "91              albumin excretion       2  No\n",
       "92            enalapril treatment       2  No\n",
       "93                    plasma flow       2  No\n",
       "94                       fentanyl       1  No\n",
       "95                  dexamethasone       1  No\n",
       "96                          group       1  No\n",
       "97                          third       1  No\n",
       "98                        receive       1  No\n",
       "99                    not receive       2  No\n",
       "100                         while       1  No\n",
       "101                         group       1  No\n",
       "102                         third       1  No\n",
       "103                       receive       1  No\n",
       "104                   not receive       2  No\n",
       "105                        while,       1  No\n",
       "106              partial response       2  No\n",
       "107         overall response rate       3  No\n",
       "108          postural hypotension       2  No\n",
       "109                   hemodynamic       1  No\n",
       "110                     flestolol       1  No\n",
       "111                 beta blockers       2  No\n",
       "112                       iceberg       1  No\n",
       "113                      nicotine       1  No\n",
       "114                       coniine       1  No\n",
       "115             marital happiness       2  No\n",
       "116                       ces - d       3  No\n",
       "117                          amhs       1  No\n",
       "118                                     0  No\n",
       "119                    methyldopa       1  No\n",
       "120              renal allografts       2  No\n",
       "121               acute rejection       2  No\n",
       "122  recurrent glomerulonephritis       2  No\n",
       "123                stable grafts,       2  No\n",
       "124                 suxamethonium       1  No\n",
       "125                      children       1  No\n",
       "126                   lacrimation       1  No\n",
       "127       intracranial blood flow       3  No\n",
       "128  noxious chemical stimulation       3  No\n",
       "129                 facial mucosa       2  No\n",
       "130               acute hepatitis       2  No\n",
       "131       hepatocellular necrosis       2  No\n",
       "132    thienodiazepine derivative       2  No\n",
       "133                   clotiazepam       1  No\n",
       "134          aids transgenic mice       3  No\n",
       "135              mitochondrial cm       2  No\n",
       "136                   elevated la       2  No\n",
       "137                                     0  No\n",
       "138                    metoprolol       1  No\n",
       "139                     diltiazem       1  No\n",
       "140         plasma concentrations       2  No\n",
       "141                  blood sample       2  No\n",
       "142                           hiv       1  No\n",
       "143              co - trimoxazole       3  No\n",
       "144            hemoglobin e trait       3  No\n",
       "145                    heinz body       2  No"
      ]
     },
     "execution_count": 489,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "incorrect_entities[incorrect_entities['length'] <= 3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 629,
   "metadata": {},
   "outputs": [],
   "source": [
    "correct_entities_sample = correct_entities.loc[[3,5,8,17,20]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 630,
   "metadata": {},
   "outputs": [],
   "source": [
    "incorrect_entities_sample = incorrect_entities.loc[[0, 41, 52, 10, 88]][[0,'tag']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 631,
   "metadata": {},
   "outputs": [],
   "source": [
    "filter_sample = pd.concat([correct_entities_sample, incorrect_entities_sample])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 632,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>tag</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>respiratory arrest</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>myocardial infarction</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>hypotension</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>retinal toxicity</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>diabetic autonomic neuropathy</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>intracarotid drug delivery system</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>follow - up period</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>amphetamine</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>regurgitation</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>intracarotid injection</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                    0  tag\n",
       "3                  respiratory arrest  Yes\n",
       "5               myocardial infarction  Yes\n",
       "8                         hypotension  Yes\n",
       "17                   retinal toxicity  Yes\n",
       "20      diabetic autonomic neuropathy  Yes\n",
       "0   intracarotid drug delivery system   No\n",
       "41                 follow - up period   No\n",
       "52                        amphetamine   No\n",
       "10                      regurgitation   No\n",
       "88             intracarotid injection   No"
      ]
     },
     "execution_count": 632,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filter_sample"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 641,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Does the phrase \"regurgitation\" refer to a disease?\n",
      "No\n",
      "\n",
      "Does the phrase \"retinal toxicity\" refer to a disease?\n",
      "Yes\n",
      "\n",
      "Does the phrase \"hypotension\" refer to a disease?\n",
      "Yes\n",
      "\n",
      "Does the phrase \"intracarotid injection\" refer to a disease?\n",
      "No\n",
      "\n",
      "Does the phrase \"diabetic autonomic neuropathy\" refer to a disease?\n",
      "Yes\n",
      "\n",
      "Does the phrase \"amphetamine\" refer to a disease?\n",
      "No\n",
      "\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n"
     ]
    }
   ],
   "source": [
    "for i, row in filter_sample.sample(6).iterrows():\n",
    "    \n",
    "    phrase = row[0]\n",
    "    tag = row['tag']\n",
    "    \n",
    "    print('Does the phrase \"{}\" refer to a disease?'.format(phrase))\n",
    "    print('{}'.format(tag))\n",
    "    print('')\n",
    "    \n",
    "\n",
    "print(', '.join(['\"{}\"'.format(p) for p in filter_sample[0].values]))\n",
    "print()\n",
    "for i, row in filter_sample.sample(10).iterrows():\n",
    "    \n",
    "    phrase = row[0]\n",
    "    tag = row['tag']\n",
    "    \n",
    "    print('\"{}\": {}'.format(phrase,tag))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Investigating Phrase Filtering Prompt Strategies "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 667,
   "metadata": {},
   "outputs": [],
   "source": [
    "predicted_phrases = pd.read_csv('../outputs/bc5cdr_disease_ner_predicted_phrases.tsv')\n",
    "predicted_phrases = predicted_phrases[pd.notna(predicted_phrases.phrase)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 668,
   "metadata": {},
   "outputs": [],
   "source": [
    "filter_prompt = \"\"\"Determine whether the following phrases are diseases or not:\n",
    "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
    "\n",
    "\"amphetamine\": No\n",
    "\"diabetic autonomic neuropathy\": Yes\n",
    "\"retinal toxicity\": Yes\n",
    "\"intracarotid injection\": No\n",
    "\"myocardial infarction\": Yes\n",
    "\"hypotension\": Yes\n",
    "\"follow - up period\": No\n",
    "\"respiratory arrest\": Yes\n",
    "\"intracarotid drug delivery system\": No\n",
    "\"regurgitation\": No\n",
    "\"\"\"\n",
    "\n",
    "template_prompt = 'Determine whether the following phrases are diseases or not:\\n{}'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 669,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>phrase</th>\n",
       "      <th>negative_prob</th>\n",
       "      <th>positive_prob</th>\n",
       "      <th>true_ent</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>enzyme - mediated immunoassay methodology</td>\n",
       "      <td>0.822346</td>\n",
       "      <td>0.177654</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>mwm</td>\n",
       "      <td>0.722601</td>\n",
       "      <td>0.277399</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>syncope</td>\n",
       "      <td>0.526756</td>\n",
       "      <td>0.473244</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>edema</td>\n",
       "      <td>0.512188</td>\n",
       "      <td>0.487812</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>5</td>\n",
       "      <td>angiographies</td>\n",
       "      <td>0.802028</td>\n",
       "      <td>0.197972</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6</td>\n",
       "      <td>hyperthermia</td>\n",
       "      <td>0.504444</td>\n",
       "      <td>0.495556</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>7</td>\n",
       "      <td>locomotor activity</td>\n",
       "      <td>0.689924</td>\n",
       "      <td>0.310076</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>8</td>\n",
       "      <td>cirazoline</td>\n",
       "      <td>0.858113</td>\n",
       "      <td>0.141887</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>9</td>\n",
       "      <td>prazosin</td>\n",
       "      <td>0.731210</td>\n",
       "      <td>0.268790</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10</td>\n",
       "      <td>shr</td>\n",
       "      <td>0.649296</td>\n",
       "      <td>0.350704</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>11</td>\n",
       "      <td>thromboembolism</td>\n",
       "      <td>0.407613</td>\n",
       "      <td>0.592387</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>12</td>\n",
       "      <td>fasciculation</td>\n",
       "      <td>0.672518</td>\n",
       "      <td>0.327482</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>13</td>\n",
       "      <td>seizures</td>\n",
       "      <td>0.517738</td>\n",
       "      <td>0.482262</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>14</td>\n",
       "      <td>lmwh administration</td>\n",
       "      <td>0.644088</td>\n",
       "      <td>0.355912</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>15</td>\n",
       "      <td>hemolytic anemia</td>\n",
       "      <td>0.513201</td>\n",
       "      <td>0.486799</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>16</td>\n",
       "      <td>interstitial nephritis</td>\n",
       "      <td>0.558821</td>\n",
       "      <td>0.441179</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>17</td>\n",
       "      <td>neuraxial morphine</td>\n",
       "      <td>0.776589</td>\n",
       "      <td>0.223411</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>18</td>\n",
       "      <td>aortic occlusion</td>\n",
       "      <td>0.597155</td>\n",
       "      <td>0.402845</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>19</td>\n",
       "      <td>spinal motor neurons</td>\n",
       "      <td>0.714544</td>\n",
       "      <td>0.285456</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20</td>\n",
       "      <td>nmda receptors</td>\n",
       "      <td>0.839483</td>\n",
       "      <td>0.160517</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>21</td>\n",
       "      <td>sedation</td>\n",
       "      <td>0.622765</td>\n",
       "      <td>0.377235</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>22</td>\n",
       "      <td>dexmedetomidine</td>\n",
       "      <td>0.758458</td>\n",
       "      <td>0.241542</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>23</td>\n",
       "      <td>pentobarbital</td>\n",
       "      <td>0.683429</td>\n",
       "      <td>0.316571</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>24</td>\n",
       "      <td>recovery time</td>\n",
       "      <td>0.696346</td>\n",
       "      <td>0.303654</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>25</td>\n",
       "      <td>iop</td>\n",
       "      <td>0.700419</td>\n",
       "      <td>0.299581</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>26</td>\n",
       "      <td>iop lowering medication</td>\n",
       "      <td>0.608112</td>\n",
       "      <td>0.391888</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>27</td>\n",
       "      <td>iop lowering surgeries</td>\n",
       "      <td>0.647303</td>\n",
       "      <td>0.352697</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>28</td>\n",
       "      <td>aortic regurgitation</td>\n",
       "      <td>0.527187</td>\n",
       "      <td>0.472813</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>29</td>\n",
       "      <td>wilms tumor</td>\n",
       "      <td>0.627262</td>\n",
       "      <td>0.372738</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>30</td>\n",
       "      <td>left kidney</td>\n",
       "      <td>0.711067</td>\n",
       "      <td>0.288933</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>31</td>\n",
       "      <td>postoperative irradiation</td>\n",
       "      <td>0.625696</td>\n",
       "      <td>0.374304</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>32</td>\n",
       "      <td>hepatomas</td>\n",
       "      <td>0.611691</td>\n",
       "      <td>0.388309</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>33</td>\n",
       "      <td>hyperplastic preneoplastic liver lesions</td>\n",
       "      <td>0.666095</td>\n",
       "      <td>0.333905</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>34</td>\n",
       "      <td>aplastic anemia</td>\n",
       "      <td>0.590892</td>\n",
       "      <td>0.409108</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>35</td>\n",
       "      <td>topical administration</td>\n",
       "      <td>0.789903</td>\n",
       "      <td>0.210097</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>36</td>\n",
       "      <td>ophthalmic chloramphenicol</td>\n",
       "      <td>0.720586</td>\n",
       "      <td>0.279414</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>37</td>\n",
       "      <td>dyskinesias</td>\n",
       "      <td>0.569911</td>\n",
       "      <td>0.430089</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>38</td>\n",
       "      <td>parkinsonian ' off ' signs</td>\n",
       "      <td>0.669031</td>\n",
       "      <td>0.330969</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>39</td>\n",
       "      <td>levodopa responsiveness</td>\n",
       "      <td>0.699029</td>\n",
       "      <td>0.300971</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>40</td>\n",
       "      <td>lymphoma</td>\n",
       "      <td>0.475076</td>\n",
       "      <td>0.524924</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>41</td>\n",
       "      <td>mast cell tumour</td>\n",
       "      <td>0.646769</td>\n",
       "      <td>0.353231</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>42</td>\n",
       "      <td>brain tumour</td>\n",
       "      <td>0.486344</td>\n",
       "      <td>0.513656</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>43</td>\n",
       "      <td>histiocytic tumours</td>\n",
       "      <td>0.643041</td>\n",
       "      <td>0.356959</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>44</td>\n",
       "      <td>epit</td>\n",
       "      <td>0.754594</td>\n",
       "      <td>0.245406</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>45</td>\n",
       "      <td>coronary artery disease</td>\n",
       "      <td>0.344695</td>\n",
       "      <td>0.655305</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>46</td>\n",
       "      <td>stroke</td>\n",
       "      <td>0.338162</td>\n",
       "      <td>0.661838</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>47</td>\n",
       "      <td>optic neuropathy</td>\n",
       "      <td>0.486381</td>\n",
       "      <td>0.513619</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>48</td>\n",
       "      <td>healthy</td>\n",
       "      <td>0.818323</td>\n",
       "      <td>0.181677</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>49</td>\n",
       "      <td>schizophrenia</td>\n",
       "      <td>0.502073</td>\n",
       "      <td>0.497927</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>50</td>\n",
       "      <td>endometrial cancer</td>\n",
       "      <td>0.533344</td>\n",
       "      <td>0.466656</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>51</td>\n",
       "      <td>breast cancer</td>\n",
       "      <td>0.516081</td>\n",
       "      <td>0.483919</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>52</td>\n",
       "      <td>venous thromboembolism</td>\n",
       "      <td>0.427185</td>\n",
       "      <td>0.572815</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>53</td>\n",
       "      <td>psychosis</td>\n",
       "      <td>0.453765</td>\n",
       "      <td>0.546235</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>54</td>\n",
       "      <td>schizophrenia</td>\n",
       "      <td>0.491706</td>\n",
       "      <td>0.508294</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>55</td>\n",
       "      <td>af</td>\n",
       "      <td>0.655439</td>\n",
       "      <td>0.344561</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>57</td>\n",
       "      <td>epilepsy</td>\n",
       "      <td>0.486110</td>\n",
       "      <td>0.513890</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>58</td>\n",
       "      <td>non - st - elevation myocardial infarction</td>\n",
       "      <td>0.388187</td>\n",
       "      <td>0.611813</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>59</td>\n",
       "      <td>psychotic disorder</td>\n",
       "      <td>0.486925</td>\n",
       "      <td>0.513075</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>60</td>\n",
       "      <td>hypomania</td>\n",
       "      <td>0.504132</td>\n",
       "      <td>0.495868</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>61</td>\n",
       "      <td>side effects from cytotoxic chemotherapy</td>\n",
       "      <td>0.575711</td>\n",
       "      <td>0.424289</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>62</td>\n",
       "      <td>protein excretion</td>\n",
       "      <td>0.694730</td>\n",
       "      <td>0.305270</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>63</td>\n",
       "      <td>molecular weight</td>\n",
       "      <td>0.846482</td>\n",
       "      <td>0.153518</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>64</td>\n",
       "      <td>dopamine d2 receptor blockade</td>\n",
       "      <td>0.627349</td>\n",
       "      <td>0.372651</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>65</td>\n",
       "      <td>striatum</td>\n",
       "      <td>0.706446</td>\n",
       "      <td>0.293554</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>66</td>\n",
       "      <td>basal ganglia</td>\n",
       "      <td>0.596933</td>\n",
       "      <td>0.403067</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>67</td>\n",
       "      <td>norepinephrine</td>\n",
       "      <td>0.730012</td>\n",
       "      <td>0.269988</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>68</td>\n",
       "      <td>hydrocortisone</td>\n",
       "      <td>0.730624</td>\n",
       "      <td>0.269376</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>69</td>\n",
       "      <td>hypercalcemia</td>\n",
       "      <td>0.481484</td>\n",
       "      <td>0.518516</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>70</td>\n",
       "      <td>adynamic bone disease</td>\n",
       "      <td>0.738927</td>\n",
       "      <td>0.261073</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>71</td>\n",
       "      <td>renal failure</td>\n",
       "      <td>0.440131</td>\n",
       "      <td>0.559869</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>72</td>\n",
       "      <td>parathyroid hormone</td>\n",
       "      <td>0.751272</td>\n",
       "      <td>0.248728</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>73</td>\n",
       "      <td>hypokalemia</td>\n",
       "      <td>0.558369</td>\n",
       "      <td>0.441631</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>74</td>\n",
       "      <td>depletion of body potassium</td>\n",
       "      <td>0.712525</td>\n",
       "      <td>0.287475</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>75</td>\n",
       "      <td>optic neuropathy</td>\n",
       "      <td>0.489768</td>\n",
       "      <td>0.510232</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>76</td>\n",
       "      <td>glycine cleavage system</td>\n",
       "      <td>0.815186</td>\n",
       "      <td>0.184814</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>77</td>\n",
       "      <td>amino acid metabolism</td>\n",
       "      <td>0.735219</td>\n",
       "      <td>0.264781</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>78</td>\n",
       "      <td>brain</td>\n",
       "      <td>0.662036</td>\n",
       "      <td>0.337964</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>79</td>\n",
       "      <td>body compartments</td>\n",
       "      <td>0.822363</td>\n",
       "      <td>0.177637</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>80</td>\n",
       "      <td>ifosfamide</td>\n",
       "      <td>0.619994</td>\n",
       "      <td>0.380006</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>81</td>\n",
       "      <td>mesna</td>\n",
       "      <td>0.797694</td>\n",
       "      <td>0.202306</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>82</td>\n",
       "      <td>cystitis</td>\n",
       "      <td>0.551788</td>\n",
       "      <td>0.448212</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>84</td>\n",
       "      <td>antiarrhythmic</td>\n",
       "      <td>0.655789</td>\n",
       "      <td>0.344211</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>85</td>\n",
       "      <td>aconitine</td>\n",
       "      <td>0.649020</td>\n",
       "      <td>0.350980</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>86</td>\n",
       "      <td>ouabain</td>\n",
       "      <td>0.751513</td>\n",
       "      <td>0.248487</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>87</td>\n",
       "      <td>m ( 3 )</td>\n",
       "      <td>0.706160</td>\n",
       "      <td>0.293840</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>88</td>\n",
       "      <td>nanoparticles</td>\n",
       "      <td>0.857605</td>\n",
       "      <td>0.142395</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>89</td>\n",
       "      <td>nephrotic syndrome</td>\n",
       "      <td>0.567810</td>\n",
       "      <td>0.432190</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>90</td>\n",
       "      <td>reperfusion</td>\n",
       "      <td>0.565601</td>\n",
       "      <td>0.434399</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>91</td>\n",
       "      <td>impotence</td>\n",
       "      <td>0.557581</td>\n",
       "      <td>0.442419</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>92</td>\n",
       "      <td>paradoxical</td>\n",
       "      <td>0.661287</td>\n",
       "      <td>0.338713</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>93</td>\n",
       "      <td>pulmonary hypertension</td>\n",
       "      <td>0.440759</td>\n",
       "      <td>0.559241</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>94</td>\n",
       "      <td>fluoxetine</td>\n",
       "      <td>0.740163</td>\n",
       "      <td>0.259837</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>95</td>\n",
       "      <td>adult rodents</td>\n",
       "      <td>0.723660</td>\n",
       "      <td>0.276340</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0                                      phrase  negative_prob  \\\n",
       "0            0   enzyme - mediated immunoassay methodology       0.822346   \n",
       "2            2                                         mwm       0.722601   \n",
       "3            3                                     syncope       0.526756   \n",
       "4            4                                       edema       0.512188   \n",
       "5            5                               angiographies       0.802028   \n",
       "6            6                                hyperthermia       0.504444   \n",
       "7            7                          locomotor activity       0.689924   \n",
       "8            8                                  cirazoline       0.858113   \n",
       "9            9                                    prazosin       0.731210   \n",
       "10          10                                         shr       0.649296   \n",
       "11          11                             thromboembolism       0.407613   \n",
       "12          12                               fasciculation       0.672518   \n",
       "13          13                                    seizures       0.517738   \n",
       "14          14                         lmwh administration       0.644088   \n",
       "15          15                            hemolytic anemia       0.513201   \n",
       "16          16                      interstitial nephritis       0.558821   \n",
       "17          17                          neuraxial morphine       0.776589   \n",
       "18          18                            aortic occlusion       0.597155   \n",
       "19          19                        spinal motor neurons       0.714544   \n",
       "20          20                              nmda receptors       0.839483   \n",
       "21          21                                    sedation       0.622765   \n",
       "22          22                             dexmedetomidine       0.758458   \n",
       "23          23                               pentobarbital       0.683429   \n",
       "24          24                               recovery time       0.696346   \n",
       "25          25                                         iop       0.700419   \n",
       "26          26                     iop lowering medication       0.608112   \n",
       "27          27                      iop lowering surgeries       0.647303   \n",
       "28          28                        aortic regurgitation       0.527187   \n",
       "29          29                                 wilms tumor       0.627262   \n",
       "30          30                                 left kidney       0.711067   \n",
       "31          31                   postoperative irradiation       0.625696   \n",
       "32          32                                   hepatomas       0.611691   \n",
       "33          33    hyperplastic preneoplastic liver lesions       0.666095   \n",
       "34          34                             aplastic anemia       0.590892   \n",
       "35          35                      topical administration       0.789903   \n",
       "36          36                  ophthalmic chloramphenicol       0.720586   \n",
       "37          37                                 dyskinesias       0.569911   \n",
       "38          38                  parkinsonian ' off ' signs       0.669031   \n",
       "39          39                     levodopa responsiveness       0.699029   \n",
       "40          40                                    lymphoma       0.475076   \n",
       "41          41                            mast cell tumour       0.646769   \n",
       "42          42                                brain tumour       0.486344   \n",
       "43          43                         histiocytic tumours       0.643041   \n",
       "44          44                                        epit       0.754594   \n",
       "45          45                     coronary artery disease       0.344695   \n",
       "46          46                                      stroke       0.338162   \n",
       "47          47                            optic neuropathy       0.486381   \n",
       "48          48                                     healthy       0.818323   \n",
       "49          49                               schizophrenia       0.502073   \n",
       "50          50                          endometrial cancer       0.533344   \n",
       "51          51                               breast cancer       0.516081   \n",
       "52          52                      venous thromboembolism       0.427185   \n",
       "53          53                                   psychosis       0.453765   \n",
       "54          54                               schizophrenia       0.491706   \n",
       "55          55                                          af       0.655439   \n",
       "57          57                                    epilepsy       0.486110   \n",
       "58          58  non - st - elevation myocardial infarction       0.388187   \n",
       "59          59                          psychotic disorder       0.486925   \n",
       "60          60                                   hypomania       0.504132   \n",
       "61          61    side effects from cytotoxic chemotherapy       0.575711   \n",
       "62          62                           protein excretion       0.694730   \n",
       "63          63                            molecular weight       0.846482   \n",
       "64          64               dopamine d2 receptor blockade       0.627349   \n",
       "65          65                                    striatum       0.706446   \n",
       "66          66                               basal ganglia       0.596933   \n",
       "67          67                              norepinephrine       0.730012   \n",
       "68          68                              hydrocortisone       0.730624   \n",
       "69          69                               hypercalcemia       0.481484   \n",
       "70          70                       adynamic bone disease       0.738927   \n",
       "71          71                               renal failure       0.440131   \n",
       "72          72                         parathyroid hormone       0.751272   \n",
       "73          73                                 hypokalemia       0.558369   \n",
       "74          74                 depletion of body potassium       0.712525   \n",
       "75          75                            optic neuropathy       0.489768   \n",
       "76          76                     glycine cleavage system       0.815186   \n",
       "77          77                       amino acid metabolism       0.735219   \n",
       "78          78                                       brain       0.662036   \n",
       "79          79                           body compartments       0.822363   \n",
       "80          80                                  ifosfamide       0.619994   \n",
       "81          81                                       mesna       0.797694   \n",
       "82          82                                    cystitis       0.551788   \n",
       "84          84                              antiarrhythmic       0.655789   \n",
       "85          85                                   aconitine       0.649020   \n",
       "86          86                                     ouabain       0.751513   \n",
       "87          87                                     m ( 3 )       0.706160   \n",
       "88          88                               nanoparticles       0.857605   \n",
       "89          89                          nephrotic syndrome       0.567810   \n",
       "90          90                                 reperfusion       0.565601   \n",
       "91          91                                   impotence       0.557581   \n",
       "92          92                                 paradoxical       0.661287   \n",
       "93          93                      pulmonary hypertension       0.440759   \n",
       "94          94                                  fluoxetine       0.740163   \n",
       "95          95                               adult rodents       0.723660   \n",
       "\n",
       "    positive_prob  true_ent  \n",
       "0        0.177654         0  \n",
       "2        0.277399         0  \n",
       "3        0.473244         1  \n",
       "4        0.487812         1  \n",
       "5        0.197972         0  \n",
       "6        0.495556         1  \n",
       "7        0.310076         0  \n",
       "8        0.141887         0  \n",
       "9        0.268790         0  \n",
       "10       0.350704         0  \n",
       "11       0.592387         1  \n",
       "12       0.327482         1  \n",
       "13       0.482262         1  \n",
       "14       0.355912         0  \n",
       "15       0.486799         1  \n",
       "16       0.441179         1  \n",
       "17       0.223411         0  \n",
       "18       0.402845         1  \n",
       "19       0.285456         0  \n",
       "20       0.160517         0  \n",
       "21       0.377235         0  \n",
       "22       0.241542         0  \n",
       "23       0.316571         0  \n",
       "24       0.303654         0  \n",
       "25       0.299581         0  \n",
       "26       0.391888         0  \n",
       "27       0.352697         0  \n",
       "28       0.472813         1  \n",
       "29       0.372738         1  \n",
       "30       0.288933         0  \n",
       "31       0.374304         0  \n",
       "32       0.388309         1  \n",
       "33       0.333905         0  \n",
       "34       0.409108         1  \n",
       "35       0.210097         0  \n",
       "36       0.279414         0  \n",
       "37       0.430089         1  \n",
       "38       0.330969         0  \n",
       "39       0.300971         0  \n",
       "40       0.524924         1  \n",
       "41       0.353231         1  \n",
       "42       0.513656         1  \n",
       "43       0.356959         1  \n",
       "44       0.245406         0  \n",
       "45       0.655305         1  \n",
       "46       0.661838         1  \n",
       "47       0.513619         1  \n",
       "48       0.181677         0  \n",
       "49       0.497927         1  \n",
       "50       0.466656         1  \n",
       "51       0.483919         1  \n",
       "52       0.572815         1  \n",
       "53       0.546235         1  \n",
       "54       0.508294         0  \n",
       "55       0.344561         1  \n",
       "57       0.513890         1  \n",
       "58       0.611813         0  \n",
       "59       0.513075         1  \n",
       "60       0.495868         1  \n",
       "61       0.424289         0  \n",
       "62       0.305270         1  \n",
       "63       0.153518         0  \n",
       "64       0.372651         0  \n",
       "65       0.293554         0  \n",
       "66       0.403067         0  \n",
       "67       0.269988         0  \n",
       "68       0.269376         0  \n",
       "69       0.518516         1  \n",
       "70       0.261073         1  \n",
       "71       0.559869         1  \n",
       "72       0.248728         0  \n",
       "73       0.441631         1  \n",
       "74       0.287475         0  \n",
       "75       0.510232         1  \n",
       "76       0.184814         0  \n",
       "77       0.264781         0  \n",
       "78       0.337964         0  \n",
       "79       0.177637         0  \n",
       "80       0.380006         0  \n",
       "81       0.202306         0  \n",
       "82       0.448212         0  \n",
       "84       0.344211         0  \n",
       "85       0.350980         0  \n",
       "86       0.248487         0  \n",
       "87       0.293840         0  \n",
       "88       0.142395         0  \n",
       "89       0.432190         1  \n",
       "90       0.434399         0  \n",
       "91       0.442419         0  \n",
       "92       0.338713         0  \n",
       "93       0.559241         1  \n",
       "94       0.259837         0  \n",
       "95       0.276340         0  "
      ]
     },
     "execution_count": 669,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(predicted_phrases)\n",
    "predicted_phrases"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 743,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_yes_no_probs(entity_list, predicted_sample):\n",
    "    predicted_text = predicted_sample['choices'][0]['text']\n",
    "    print('GPT3 Output:' + predicted_text)\n",
    "    entity_probs = []\n",
    "    predicted_lines = predicted_text.split('\\n')\n",
    "    \n",
    "    curr_token = 0\n",
    "    for i, phrase_to_pred in enumerate(entity_list):\n",
    "    \n",
    "        predicted_line = predicted_lines[i]\n",
    "        tokens = tokenizer.encode(predicted_line)\n",
    "        curr_token += len(tokens)\n",
    "\n",
    "        if i == 0:\n",
    "            phrase, prediction = phrase_to_pred, predicted_line\n",
    "        else:\n",
    "            phrase, prediction = predicted_line.split(':')\n",
    "        \n",
    "        try:\n",
    "            yes_no_dict = dict(predicted_sample['choices'][0]['logprobs']['top_logprobs'][curr_token-1])\n",
    "            prob = calc_prob(yes_no_dict)\n",
    "        except:\n",
    "            ipdb.set_trace()\n",
    "        entity_probs.append((phrase_to_pred.replace('\"',''), prob[0], prob[1]))\n",
    "        \n",
    "        curr_token += 1\n",
    "        \n",
    "    return entity_probs\n",
    "    \n",
    "def calc_prob(yes_no_dict):\n",
    "    entity_logits = []\n",
    "    for opt in ['No','Yes']:\n",
    "        entity_logits.append(yes_no_dict[opt])\n",
    "\n",
    "    return scipy.special.softmax(entity_logits)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 766,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"enzyme - mediated immunoassay methodology\"\n",
      "\n",
      "\"enzyme - mediated immunoassay methodology\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"mwm\"\n",
      "\n",
      "\"mwm\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"syncope\"\n",
      "\n",
      "\"syncope\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"edema\"\n",
      "\n",
      "\"edema\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"angiographies\"\n",
      "\n",
      "\"angiographies\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hyperthermia\"\n",
      "\n",
      "\"hyperthermia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"locomotor activity\"\n",
      "\n",
      "\"locomotor activity\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"cirazoline\"\n",
      "\n",
      "\"cirazoline\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"prazosin\"\n",
      "\n",
      "\"prazosin\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"shr\"\n",
      "\n",
      "\"shr\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"thromboembolism\"\n",
      "\n",
      "\"thromboembolism\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"fasciculation\"\n",
      "\n",
      "\"fasciculation\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"seizures\"\n",
      "\n",
      "\"seizures\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"lmwh administration\"\n",
      "\n",
      "\"lmwh administration\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hemolytic anemia\"\n",
      "\n",
      "\"hemolytic anemia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"interstitial nephritis\"\n",
      "\n",
      "\"interstitial nephritis\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"neuraxial morphine\"\n",
      "\n",
      "\"neuraxial morphine\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"aortic occlusion\"\n",
      "\n",
      "\"aortic occlusion\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"spinal motor neurons\"\n",
      "\n",
      "\"spinal motor neurons\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"nmda receptors\"\n",
      "\n",
      "\"nmda receptors\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"sedation\"\n",
      "\n",
      "\"sedation\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"dexmedetomidine\"\n",
      "\n",
      "\"dexmedetomidine\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"pentobarbital\"\n",
      "\n",
      "\"pentobarbital\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"recovery time\"\n",
      "\n",
      "\"recovery time\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"iop\"\n",
      "\n",
      "\"iop\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"iop lowering medication\"\n",
      "\n",
      "\"iop lowering medication\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"iop lowering surgeries\"\n",
      "\n",
      "\"iop lowering surgeries\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"aortic regurgitation\"\n",
      "\n",
      "\"aortic regurgitation\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"wilms tumor\"\n",
      "\n",
      "\"wilms tumor\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"left kidney\"\n",
      "\n",
      "\"left kidney\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"postoperative irradiation\"\n",
      "\n",
      "\"postoperative irradiation\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hepatomas\"\n",
      "\n",
      "\"hepatomas\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hyperplastic preneoplastic liver lesions\"\n",
      "\n",
      "\"hyperplastic preneoplastic liver lesions\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"aplastic anemia\"\n",
      "\n",
      "\"aplastic anemia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"topical administration\"\n",
      "\n",
      "\"topical administration\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"ophthalmic chloramphenicol\"\n",
      "\n",
      "\"ophthalmic chloramphenicol\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"dyskinesias\"\n",
      "\n",
      "\"dyskinesias\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"parkinsonian ' off ' signs\"\n",
      "\n",
      "\"parkinsonian ' off ' signs\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"levodopa responsiveness\"\n",
      "\n",
      "\"levodopa responsiveness\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"lymphoma\"\n",
      "\n",
      "\"lymphoma\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"mast cell tumour\"\n",
      "\n",
      "\"mast cell tumour\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"brain tumour\"\n",
      "\n",
      "\"brain tumour\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"histiocytic tumours\"\n",
      "\n",
      "\"histiocytic tumours\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"epit\"\n",
      "\n",
      "\"epit\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"coronary artery disease\"\n",
      "\n",
      "\"coronary artery disease\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"stroke\"\n",
      "\n",
      "\"stroke\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"optic neuropathy\"\n",
      "\n",
      "\"optic neuropathy\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"healthy\"\n",
      "\n",
      "\"healthy\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"schizophrenia\"\n",
      "\n",
      "\"schizophrenia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"endometrial cancer\"\n",
      "\n",
      "\"endometrial cancer\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"breast cancer\"\n",
      "\n",
      "\"breast cancer\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"venous thromboembolism\"\n",
      "\n",
      "\"venous thromboembolism\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"psychosis\"\n",
      "\n",
      "\"psychosis\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"schizophrenia\"\n",
      "\n",
      "\"schizophrenia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"af\"\n",
      "\n",
      "\"af\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"epilepsy\"\n",
      "\n",
      "\"epilepsy\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"non - st - elevation myocardial infarction\"\n",
      "\n",
      "\"non - st - elevation myocardial infarction\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"psychotic disorder\"\n",
      "\n",
      "\"psychotic disorder\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hypomania\"\n",
      "\n",
      "\"hypomania\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"side effects from cytotoxic chemotherapy\"\n",
      "\n",
      "\"side effects from cytotoxic chemotherapy\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"protein excretion\"\n",
      "\n",
      "\"protein excretion\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"molecular weight\"\n",
      "\n",
      "\"molecular weight\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"dopamine d2 receptor blockade\"\n",
      "\n",
      "\"dopamine d2 receptor blockade\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"striatum\"\n",
      "\n",
      "\"striatum\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"basal ganglia\"\n",
      "\n",
      "\"basal ganglia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"norepinephrine\"\n",
      "\n",
      "\"norepinephrine\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hydrocortisone\"\n",
      "\n",
      "\"hydrocortisone\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hypercalcemia\"\n",
      "\n",
      "\"hypercalcemia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"adynamic bone disease\"\n",
      "\n",
      "\"adynamic bone disease\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"renal failure\"\n",
      "\n",
      "\"renal failure\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"parathyroid hormone\"\n",
      "\n",
      "\"parathyroid hormone\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"hypokalemia\"\n",
      "\n",
      "\"hypokalemia\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"depletion of body potassium\"\n",
      "\n",
      "\"depletion of body potassium\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"optic neuropathy\"\n",
      "\n",
      "\"optic neuropathy\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"glycine cleavage system\"\n",
      "\n",
      "\"glycine cleavage system\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"amino acid metabolism\"\n",
      "\n",
      "\"amino acid metabolism\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"brain\"\n",
      "\n",
      "\"brain\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"body compartments\"\n",
      "\n",
      "\"body compartments\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"ifosfamide\"\n",
      "\n",
      "\"ifosfamide\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"mesna\"\n",
      "\n",
      "\"mesna\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"cystitis\"\n",
      "\n",
      "\"cystitis\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"antiarrhythmic\"\n",
      "\n",
      "\"antiarrhythmic\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"aconitine\"\n",
      "\n",
      "\"aconitine\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"ouabain\"\n",
      "\n",
      "\"ouabain\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"m ( 3 )\"\n",
      "\n",
      "\"m ( 3 )\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:No\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"nanoparticles\"\n",
      "\n",
      "\"nanoparticles\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"nephrotic syndrome\"\n",
      "\n",
      "\"nephrotic syndrome\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"reperfusion\"\n",
      "\n",
      "\"reperfusion\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"impotence\"\n",
      "\n",
      "\"impotence\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"paradoxical\"\n",
      "\n",
      "\"paradoxical\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"pulmonary hypertension\"\n",
      "\n",
      "\"pulmonary hypertension\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"fluoxetine\"\n",
      "\n",
      "\"fluoxetine\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n",
      "Prompt:Determine whether the following phrases are diseases or not:\n",
      "\"respiratory arrest\", \"myocardial infarction\", \"hypotension\", \"retinal toxicity\", \"diabetic autonomic neuropathy\", \"intracarotid drug delivery system\", \"follow - up period\", \"amphetamine\", \"regurgitation\", \"intracarotid injection\"\n",
      "\n",
      "\"amphetamine\": No\n",
      "\"diabetic autonomic neuropathy\": Yes\n",
      "\"retinal toxicity\": Yes\n",
      "\"intracarotid injection\": No\n",
      "\"myocardial infarction\": Yes\n",
      "\"hypotension\": Yes\n",
      "\"follow - up period\": No\n",
      "\"respiratory arrest\": Yes\n",
      "\"intracarotid drug delivery system\": No\n",
      "\"regurgitation\": No\n",
      "\n",
      "Determine whether the following phrases are diseases or not:\n",
      "\"adult rodents\"\n",
      "\n",
      "\"adult rodents\":\n",
      "Logit Bias: {5297: 10, 2949: 10, 1298: 10, 198: 10}\n",
      "\n",
      "\n",
      "GPT3 Output:Yes\n",
      "\n"
     ]
    }
   ],
   "source": [
    "i = 0\n",
    "num_phrases = 1\n",
    "\n",
    "predicted_new_probs = []\n",
    "\n",
    "while i < len(predicted_phrases):\n",
    "    phrases_to_pred = predicted_phrases['phrase'].values[i:i+num_phrases]\n",
    "    phrases_to_pred = ['\"{}\"'.format(p) for p in phrases_to_pred]\n",
    "    phrases_to_pred_str = ', '.join(phrases_to_pred)\n",
    "    \n",
    "    logit_biases = {}\n",
    "    tokens = ['Yes','No','\":']\n",
    "\n",
    "    for token in tokens:\n",
    "        token_id = tokenizer.encode(token)[0]\n",
    "        logit_biases[token_id] = 10\n",
    "\n",
    "    #Adding bias for newline (token id 198)\n",
    "    logit_biases[198] = 10 \n",
    "        \n",
    "    filter_prompt_n = filter_prompt + '\\n' + template_prompt.format(phrases_to_pred_str + '\\n\\n' + phrases_to_pred[0]+':')\n",
    "    print('Prompt:'+filter_prompt_n)\n",
    "    print('Logit Bias: {}'.format(logit_biases))\n",
    "    print('\\n')\n",
    "    \n",
    "    expected_output = 'No\\n'+''.join([p+':No\\n' for p in phrases_to_pred[1:]])\n",
    "    tokens = tokenizer.encode(expected_output)\n",
    "    for token in tokens:\n",
    "        logit_biases[token] = logit_bias\n",
    "        \n",
    "    expected_length = len(tokenizer.encode(expected_output))\n",
    "\n",
    "    filter_sample = openai.Completion.create(engine=engine,\n",
    "                                      prompt=filter_prompt_n,\n",
    "                                      max_tokens=expected_length,\n",
    "                                      temperature=0,\n",
    "                                      logprobs=2,\n",
    "                                      logit_bias = logit_biases,\n",
    "                                      stop=[\"<|endoftext|>\"])\n",
    "    \n",
    "    entity_probs = extract_yes_no_probs(phrases_to_pred, filter_sample)\n",
    "    \n",
    "    predicted_new_probs.extend(entity_probs)\n",
    "    i += num_phrases\n",
    "    \n",
    "predicted_new_probs_df = pd.DataFrame(predicted_new_probs,columns=['phrase','negative_prob','positive_prob'])\n",
    "predicted_new_probs_df['true_ent'] = predicted_phrases['true_ent'].values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 767,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 768,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(positive_prob    0.607337\n",
       " dtype: float64,\n",
       " positive_prob    0.550129\n",
       " dtype: float64)"
      ]
     },
     "execution_count": 768,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "predicted_new_probs_df[predicted_new_probs_df.true_ent == 1][['positive_prob']].mean(), predicted_new_probs_df[predicted_new_probs_df.true_ent == 0][['positive_prob']].mean()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 770,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[<AxesSubplot:title={'center':'positive_prob'}>]], dtype=object)"
      ]
     },
     "execution_count": 770,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "predicted_new_probs_df[predicted_new_probs_df.true_ent == 1][['positive_prob']].hist()\n",
    "predicted_new_probs_df[predicted_new_probs_df.true_ent == 0][['positive_prob']].hist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 942,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "positive_prob    0.169249\n",
       "dtype: float64"
      ]
     },
     "execution_count": 942,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "predicted_phrases[predicted_phrases.true_ent == 1][['positive_prob']].mean()- predicted_phrases[predicted_phrases.true_ent == 0][['positive_prob']].mean()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 927,
   "metadata": {},
   "outputs": [],
   "source": [
    "filter_prompt2 = \"\"\"Does the phrase \"regurgitation\" refer to a disease?\n",
    "No\n",
    "\n",
    "Does the phrase \"retinal toxicity\" refer to a disease?\n",
    "Yes\n",
    "\n",
    "Does the phrase \"hypotension\" refer to a disease?\n",
    "Yes\n",
    "\n",
    "Does the phrase \"intracarotid injection\" refer to a disease?\n",
    "No\n",
    "\n",
    "Does the phrase \"diabetic autonomic neuropathy\" refer to a disease?\n",
    "Yes\n",
    "\n",
    "Does the phrase \"amphetamine\" refer to a disease?\n",
    "No\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 930,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['enzyme - mediated immunoassay methodology', 'mwm', 'syncope',\n",
       "       'edema', 'angiographies', 'hyperthermia', 'locomotor activity',\n",
       "       'cirazoline', 'prazosin', 'shr', 'thromboembolism',\n",
       "       'fasciculation', 'seizures', 'lmwh administration',\n",
       "       'hemolytic anemia', 'interstitial nephritis', 'neuraxial morphine',\n",
       "       'aortic occlusion', 'spinal motor neurons', 'nmda receptors',\n",
       "       'sedation', 'dexmedetomidine', 'pentobarbital', 'recovery time',\n",
       "       'iop', 'iop lowering medication', 'iop lowering surgeries',\n",
       "       'aortic regurgitation', 'wilms tumor', 'left kidney',\n",
       "       'postoperative irradiation', 'hepatomas',\n",
       "       'hyperplastic preneoplastic liver lesions', 'aplastic anemia',\n",
       "       'topical administration', 'ophthalmic chloramphenicol',\n",
       "       'dyskinesias', \"parkinsonian ' off ' signs\",\n",
       "       'levodopa responsiveness', 'lymphoma', 'mast cell tumour',\n",
       "       'brain tumour', 'histiocytic tumours', 'epit',\n",
       "       'coronary artery disease', 'stroke', 'optic neuropathy', 'healthy',\n",
       "       'schizophrenia', 'endometrial cancer', 'breast cancer',\n",
       "       'venous thromboembolism', 'psychosis', 'schizophrenia', 'af',\n",
       "       'epilepsy', 'non - st - elevation myocardial infarction',\n",
       "       'psychotic disorder', 'hypomania',\n",
       "       'side effects from cytotoxic chemotherapy', 'protein excretion',\n",
       "       'molecular weight', 'dopamine d2 receptor blockade', 'striatum',\n",
       "       'basal ganglia', 'norepinephrine', 'hydrocortisone',\n",
       "       'hypercalcemia', 'adynamic bone disease', 'renal failure',\n",
       "       'parathyroid hormone', 'hypokalemia',\n",
       "       'depletion of body potassium', 'optic neuropathy',\n",
       "       'glycine cleavage system', 'amino acid metabolism', 'brain',\n",
       "       'body compartments', 'ifosfamide', 'mesna', 'cystitis',\n",
       "       'antiarrhythmic', 'aconitine', 'ouabain', 'm ( 3 )',\n",
       "       'nanoparticles', 'nephrotic syndrome', 'reperfusion', 'impotence',\n",
       "       'paradoxical', 'pulmonary hypertension', 'fluoxetine',\n",
       "       'adult rodents'], dtype=object)"
      ]
     },
     "execution_count": 930,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "predicted_phrases.phrase.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 931,
   "metadata": {},
   "outputs": [],
   "source": [
    "entity_probs = run_gpt3_ner_post_filtering(engine, filter_prompt2, template_prompt, predicted_phrases.phrase.values)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 936,
   "metadata": {},
   "outputs": [],
   "source": [
    "entity_probs_df = pd.DataFrame([(e[0],e[1][0],e[1][1]) for e in entity_probs.items()],columns=['phrase','n','p'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 937,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>phrase</th>\n",
       "      <th>n</th>\n",
       "      <th>p</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>enzyme - mediated immunoassay methodology</td>\n",
       "      <td>0.737625</td>\n",
       "      <td>0.262375</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>mwm</td>\n",
       "      <td>0.767854</td>\n",
       "      <td>0.232146</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>syncope</td>\n",
       "      <td>0.483890</td>\n",
       "      <td>0.516110</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>edema</td>\n",
       "      <td>0.365836</td>\n",
       "      <td>0.634164</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>angiographies</td>\n",
       "      <td>0.760444</td>\n",
       "      <td>0.239556</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>hyperthermia</td>\n",
       "      <td>0.426617</td>\n",
       "      <td>0.573383</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>locomotor activity</td>\n",
       "      <td>0.580042</td>\n",
       "      <td>0.419958</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>cirazoline</td>\n",
       "      <td>0.811176</td>\n",
       "      <td>0.188824</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>prazosin</td>\n",
       "      <td>0.709296</td>\n",
       "      <td>0.290704</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>shr</td>\n",
       "      <td>0.695700</td>\n",
       "      <td>0.304300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>thromboembolism</td>\n",
       "      <td>0.355864</td>\n",
       "      <td>0.644136</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>fasciculation</td>\n",
       "      <td>0.596519</td>\n",
       "      <td>0.403481</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>seizures</td>\n",
       "      <td>0.423755</td>\n",
       "      <td>0.576245</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>lmwh administration</td>\n",
       "      <td>0.637473</td>\n",
       "      <td>0.362527</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>hemolytic anemia</td>\n",
       "      <td>0.386974</td>\n",
       "      <td>0.613026</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>interstitial nephritis</td>\n",
       "      <td>0.391892</td>\n",
       "      <td>0.608108</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>neuraxial morphine</td>\n",
       "      <td>0.724805</td>\n",
       "      <td>0.275195</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>aortic occlusion</td>\n",
       "      <td>0.551236</td>\n",
       "      <td>0.448764</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>spinal motor neurons</td>\n",
       "      <td>0.620507</td>\n",
       "      <td>0.379493</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>nmda receptors</td>\n",
       "      <td>0.726244</td>\n",
       "      <td>0.273756</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>sedation</td>\n",
       "      <td>0.572347</td>\n",
       "      <td>0.427653</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>dexmedetomidine</td>\n",
       "      <td>0.692150</td>\n",
       "      <td>0.307850</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>pentobarbital</td>\n",
       "      <td>0.719923</td>\n",
       "      <td>0.280077</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>recovery time</td>\n",
       "      <td>0.570829</td>\n",
       "      <td>0.429171</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>iop</td>\n",
       "      <td>0.709010</td>\n",
       "      <td>0.290990</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>iop lowering medication</td>\n",
       "      <td>0.482910</td>\n",
       "      <td>0.517090</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>iop lowering surgeries</td>\n",
       "      <td>0.541421</td>\n",
       "      <td>0.458579</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>aortic regurgitation</td>\n",
       "      <td>0.461004</td>\n",
       "      <td>0.538996</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>wilms tumor</td>\n",
       "      <td>0.442384</td>\n",
       "      <td>0.557616</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>left kidney</td>\n",
       "      <td>0.614967</td>\n",
       "      <td>0.385033</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>postoperative irradiation</td>\n",
       "      <td>0.604706</td>\n",
       "      <td>0.395294</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>hepatomas</td>\n",
       "      <td>0.503013</td>\n",
       "      <td>0.496987</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>hyperplastic preneoplastic liver lesions</td>\n",
       "      <td>0.488797</td>\n",
       "      <td>0.511203</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>aplastic anemia</td>\n",
       "      <td>0.440571</td>\n",
       "      <td>0.559429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>topical administration</td>\n",
       "      <td>0.731735</td>\n",
       "      <td>0.268265</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>ophthalmic chloramphenicol</td>\n",
       "      <td>0.686287</td>\n",
       "      <td>0.313713</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>dyskinesias</td>\n",
       "      <td>0.355034</td>\n",
       "      <td>0.644966</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>parkinsonian ' off ' signs</td>\n",
       "      <td>0.536522</td>\n",
       "      <td>0.463478</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>levodopa responsiveness</td>\n",
       "      <td>0.530809</td>\n",
       "      <td>0.469191</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>lymphoma</td>\n",
       "      <td>0.317913</td>\n",
       "      <td>0.682087</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>mast cell tumour</td>\n",
       "      <td>0.496636</td>\n",
       "      <td>0.503364</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>brain tumour</td>\n",
       "      <td>0.408800</td>\n",
       "      <td>0.591200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>histiocytic tumours</td>\n",
       "      <td>0.433241</td>\n",
       "      <td>0.566759</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>epit</td>\n",
       "      <td>0.794102</td>\n",
       "      <td>0.205898</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>coronary artery disease</td>\n",
       "      <td>0.327275</td>\n",
       "      <td>0.672725</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>stroke</td>\n",
       "      <td>0.341040</td>\n",
       "      <td>0.658960</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>optic neuropathy</td>\n",
       "      <td>0.324674</td>\n",
       "      <td>0.675326</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>healthy</td>\n",
       "      <td>0.747779</td>\n",
       "      <td>0.252221</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>schizophrenia</td>\n",
       "      <td>0.373973</td>\n",
       "      <td>0.626027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>endometrial cancer</td>\n",
       "      <td>0.362266</td>\n",
       "      <td>0.637734</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>breast cancer</td>\n",
       "      <td>0.373840</td>\n",
       "      <td>0.626160</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>venous thromboembolism</td>\n",
       "      <td>0.338189</td>\n",
       "      <td>0.661811</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>psychosis</td>\n",
       "      <td>0.394082</td>\n",
       "      <td>0.605918</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>af</td>\n",
       "      <td>0.775564</td>\n",
       "      <td>0.224436</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>epilepsy</td>\n",
       "      <td>0.419521</td>\n",
       "      <td>0.580479</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>non - st - elevation myocardial infarction</td>\n",
       "      <td>0.455539</td>\n",
       "      <td>0.544461</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>psychotic disorder</td>\n",
       "      <td>0.356259</td>\n",
       "      <td>0.643741</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>hypomania</td>\n",
       "      <td>0.388173</td>\n",
       "      <td>0.611827</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>side effects from cytotoxic chemotherapy</td>\n",
       "      <td>0.477925</td>\n",
       "      <td>0.522075</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>protein excretion</td>\n",
       "      <td>0.600589</td>\n",
       "      <td>0.399411</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>molecular weight</td>\n",
       "      <td>0.738077</td>\n",
       "      <td>0.261923</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>dopamine d2 receptor blockade</td>\n",
       "      <td>0.564842</td>\n",
       "      <td>0.435158</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>striatum</td>\n",
       "      <td>0.692532</td>\n",
       "      <td>0.307468</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>basal ganglia</td>\n",
       "      <td>0.516176</td>\n",
       "      <td>0.483824</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>norepinephrine</td>\n",
       "      <td>0.748598</td>\n",
       "      <td>0.251402</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>hydrocortisone</td>\n",
       "      <td>0.735298</td>\n",
       "      <td>0.264702</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>hypercalcemia</td>\n",
       "      <td>0.313459</td>\n",
       "      <td>0.686541</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>adynamic bone disease</td>\n",
       "      <td>0.543253</td>\n",
       "      <td>0.456747</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>renal failure</td>\n",
       "      <td>0.382153</td>\n",
       "      <td>0.617847</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>parathyroid hormone</td>\n",
       "      <td>0.590034</td>\n",
       "      <td>0.409966</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>hypokalemia</td>\n",
       "      <td>0.388519</td>\n",
       "      <td>0.611481</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>depletion of body potassium</td>\n",
       "      <td>0.652868</td>\n",
       "      <td>0.347132</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>glycine cleavage system</td>\n",
       "      <td>0.673751</td>\n",
       "      <td>0.326249</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>amino acid metabolism</td>\n",
       "      <td>0.506982</td>\n",
       "      <td>0.493018</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>brain</td>\n",
       "      <td>0.704995</td>\n",
       "      <td>0.295005</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>body compartments</td>\n",
       "      <td>0.725759</td>\n",
       "      <td>0.274241</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>ifosfamide</td>\n",
       "      <td>0.617137</td>\n",
       "      <td>0.382863</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>mesna</td>\n",
       "      <td>0.803013</td>\n",
       "      <td>0.196987</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>cystitis</td>\n",
       "      <td>0.464399</td>\n",
       "      <td>0.535601</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>antiarrhythmic</td>\n",
       "      <td>0.606696</td>\n",
       "      <td>0.393304</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>aconitine</td>\n",
       "      <td>0.632517</td>\n",
       "      <td>0.367483</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>ouabain</td>\n",
       "      <td>0.712817</td>\n",
       "      <td>0.287183</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>m ( 3 )</td>\n",
       "      <td>0.747759</td>\n",
       "      <td>0.252241</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>nanoparticles</td>\n",
       "      <td>0.772096</td>\n",
       "      <td>0.227904</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>nephrotic syndrome</td>\n",
       "      <td>0.357963</td>\n",
       "      <td>0.642037</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>reperfusion</td>\n",
       "      <td>0.602794</td>\n",
       "      <td>0.397206</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>impotence</td>\n",
       "      <td>0.503258</td>\n",
       "      <td>0.496742</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>paradoxical</td>\n",
       "      <td>0.669593</td>\n",
       "      <td>0.330407</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>pulmonary hypertension</td>\n",
       "      <td>0.302724</td>\n",
       "      <td>0.697276</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>fluoxetine</td>\n",
       "      <td>0.732196</td>\n",
       "      <td>0.267804</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>adult rodents</td>\n",
       "      <td>0.704747</td>\n",
       "      <td>0.295253</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        phrase         n         p\n",
       "0    enzyme - mediated immunoassay methodology  0.737625  0.262375\n",
       "1                                          mwm  0.767854  0.232146\n",
       "2                                      syncope  0.483890  0.516110\n",
       "3                                        edema  0.365836  0.634164\n",
       "4                                angiographies  0.760444  0.239556\n",
       "5                                 hyperthermia  0.426617  0.573383\n",
       "6                           locomotor activity  0.580042  0.419958\n",
       "7                                   cirazoline  0.811176  0.188824\n",
       "8                                     prazosin  0.709296  0.290704\n",
       "9                                          shr  0.695700  0.304300\n",
       "10                             thromboembolism  0.355864  0.644136\n",
       "11                               fasciculation  0.596519  0.403481\n",
       "12                                    seizures  0.423755  0.576245\n",
       "13                         lmwh administration  0.637473  0.362527\n",
       "14                            hemolytic anemia  0.386974  0.613026\n",
       "15                      interstitial nephritis  0.391892  0.608108\n",
       "16                          neuraxial morphine  0.724805  0.275195\n",
       "17                            aortic occlusion  0.551236  0.448764\n",
       "18                        spinal motor neurons  0.620507  0.379493\n",
       "19                              nmda receptors  0.726244  0.273756\n",
       "20                                    sedation  0.572347  0.427653\n",
       "21                             dexmedetomidine  0.692150  0.307850\n",
       "22                               pentobarbital  0.719923  0.280077\n",
       "23                               recovery time  0.570829  0.429171\n",
       "24                                         iop  0.709010  0.290990\n",
       "25                     iop lowering medication  0.482910  0.517090\n",
       "26                      iop lowering surgeries  0.541421  0.458579\n",
       "27                        aortic regurgitation  0.461004  0.538996\n",
       "28                                 wilms tumor  0.442384  0.557616\n",
       "29                                 left kidney  0.614967  0.385033\n",
       "30                   postoperative irradiation  0.604706  0.395294\n",
       "31                                   hepatomas  0.503013  0.496987\n",
       "32    hyperplastic preneoplastic liver lesions  0.488797  0.511203\n",
       "33                             aplastic anemia  0.440571  0.559429\n",
       "34                      topical administration  0.731735  0.268265\n",
       "35                  ophthalmic chloramphenicol  0.686287  0.313713\n",
       "36                                 dyskinesias  0.355034  0.644966\n",
       "37                  parkinsonian ' off ' signs  0.536522  0.463478\n",
       "38                     levodopa responsiveness  0.530809  0.469191\n",
       "39                                    lymphoma  0.317913  0.682087\n",
       "40                            mast cell tumour  0.496636  0.503364\n",
       "41                                brain tumour  0.408800  0.591200\n",
       "42                         histiocytic tumours  0.433241  0.566759\n",
       "43                                        epit  0.794102  0.205898\n",
       "44                     coronary artery disease  0.327275  0.672725\n",
       "45                                      stroke  0.341040  0.658960\n",
       "46                            optic neuropathy  0.324674  0.675326\n",
       "47                                     healthy  0.747779  0.252221\n",
       "48                               schizophrenia  0.373973  0.626027\n",
       "49                          endometrial cancer  0.362266  0.637734\n",
       "50                               breast cancer  0.373840  0.626160\n",
       "51                      venous thromboembolism  0.338189  0.661811\n",
       "52                                   psychosis  0.394082  0.605918\n",
       "53                                          af  0.775564  0.224436\n",
       "54                                    epilepsy  0.419521  0.580479\n",
       "55  non - st - elevation myocardial infarction  0.455539  0.544461\n",
       "56                          psychotic disorder  0.356259  0.643741\n",
       "57                                   hypomania  0.388173  0.611827\n",
       "58    side effects from cytotoxic chemotherapy  0.477925  0.522075\n",
       "59                           protein excretion  0.600589  0.399411\n",
       "60                            molecular weight  0.738077  0.261923\n",
       "61               dopamine d2 receptor blockade  0.564842  0.435158\n",
       "62                                    striatum  0.692532  0.307468\n",
       "63                               basal ganglia  0.516176  0.483824\n",
       "64                              norepinephrine  0.748598  0.251402\n",
       "65                              hydrocortisone  0.735298  0.264702\n",
       "66                               hypercalcemia  0.313459  0.686541\n",
       "67                       adynamic bone disease  0.543253  0.456747\n",
       "68                               renal failure  0.382153  0.617847\n",
       "69                         parathyroid hormone  0.590034  0.409966\n",
       "70                                 hypokalemia  0.388519  0.611481\n",
       "71                 depletion of body potassium  0.652868  0.347132\n",
       "72                     glycine cleavage system  0.673751  0.326249\n",
       "73                       amino acid metabolism  0.506982  0.493018\n",
       "74                                       brain  0.704995  0.295005\n",
       "75                           body compartments  0.725759  0.274241\n",
       "76                                  ifosfamide  0.617137  0.382863\n",
       "77                                       mesna  0.803013  0.196987\n",
       "78                                    cystitis  0.464399  0.535601\n",
       "79                              antiarrhythmic  0.606696  0.393304\n",
       "80                                   aconitine  0.632517  0.367483\n",
       "81                                     ouabain  0.712817  0.287183\n",
       "82                                     m ( 3 )  0.747759  0.252241\n",
       "83                               nanoparticles  0.772096  0.227904\n",
       "84                          nephrotic syndrome  0.357963  0.642037\n",
       "85                                 reperfusion  0.602794  0.397206\n",
       "86                                   impotence  0.503258  0.496742\n",
       "87                                 paradoxical  0.669593  0.330407\n",
       "88                      pulmonary hypertension  0.302724  0.697276\n",
       "89                                  fluoxetine  0.732196  0.267804\n",
       "90                               adult rodents  0.704747  0.295253"
      ]
     },
     "execution_count": 937,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entity_probs_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 940,
   "metadata": {},
   "outputs": [],
   "source": [
    "entity_probs_df = predicted_phrases.merge(entity_probs_df,on='phrase',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 943,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "p    0.229289\n",
       "dtype: float64"
      ]
     },
     "execution_count": 943,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entity_probs_df[entity_probs_df.true_ent == 1][['p']].mean() - entity_probs_df[entity_probs_df.true_ent == 0][['p']].mean()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "EOF while scanning triple-quoted string literal (<ipython-input-1-e0e2b19ddc08>, line 10)",
     "output_type": "error",
     "traceback": [
      "\u001b[0;36m  File \u001b[0;32m\"<ipython-input-1-e0e2b19ddc08>\"\u001b[0;36m, line \u001b[0;32m10\u001b[0m\n\u001b[0;31m    stop=[\"<|endoftext|>\"])\u001b[0m\n\u001b[0m                           \n^\u001b[0m\n\u001b[0;31mSyntaxError\u001b[0m\u001b[0;31m:\u001b[0m EOF while scanning triple-quoted string literal\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "scispacy",
   "language": "python",
   "name": "scispacy"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
